Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Previous issues

Page Path
HOME > Browse articles > Previous issues
40 Previous issues
Filter
Filter
Article category
Keywords
More +
Authors
More +
Funded articles
More +
Volume 50(3); July 2018
Prev issue Next issue
Original Articles
Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer
Seung Ah Lee, Hak Min Lee, Hak Woo Lee, Ban Seok Yang, Jong Tae Park, Sung Gwe Ahn, Joon Jeong, Seung Il Kim
Cancer Res Treat. 2018;50(3):625-633.   Published online July 31, 2017
DOI: https://doi.org/10.4143/crt.2017.089
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although sentinel lymph node biopsy (SLNB) can accurately represent the axillary lymph node (ALN) status, the false-negative rate (FNR) of SLNB is the main concern in the patients who receive SLNB alone instead of ALN dissection (ALND).
Materials and Methods
We analyzed 1,886 patientswho underwent ALNDafter negative results of SLNB,retrospectively. A logistic regression analysis was used to identify risk factors associated with a falsenegative (FN) result. Cox regression model was used to estimate the hazard ratio of factors affecting disease-free survival (DFS).
Results
Tumor located in the upper outer portion of the breast, lymphovascular invasion, suspicious node in imaging assessment and less than three sentinel lymph nodes (SLNs) were significant independent risk factors for FN in SLNB conferring an adjusted odds ratio of 2.10 (95% confidence interval [CI], 1.30 to 3.39), 2.69 (95% CI, 1.47 to 4.91), 2.59 (95% CI, 1.62 to 4.14), and 2.39 (95% CI, 1.45 to 3.95), respectively. The prognostic factors affecting DFS were tumor size larger than 2 cm (hazard ratio [HR], 1.86; 95% CI, 1.17 to 2.96) and FN of SLNB (HR, 2.51; 95% CI, 1.42 to 4.42) in SLN-negative group (FN and true-negative), but in ALN-positive group (FN and true-positive), FN of SLNB (HR, 0.64; 95% CI, 0.33 to 1.25) did not affect DFS.
Conclusion
In patients with risk factors for a FN such as suspicious node in imaging assessment, upper outer breast cancer, less than three harvested nodes, we need attention to find another metastatic focus in non-SLNs during the operation. It may contribute to provide an exact prognosis and optimizing adjuvant treatments.

Citations

Citations to this article as recorded by  
  • Detection of presence or absence of metastasis in WSI patches of breast cancer using the dual-enhanced convolutional ensemble neural network
    Ruigang Ge, Guoyue Chen, Kazuki Saruta, Yuki Terata
    Machine Learning with Applications.2024; 17: 100579.     CrossRef
  • Ultrasound radiomics based on axillary lymph nodes images for predicting lymph node metastasis in breast cancer
    Yu-Long Tang, Bin Wang, Tao Ou-Yang, Wen-Zhi Lv, Shi-Chu Tang, An Wei, Xin-Wu Cui, Jiang-Sheng Huang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Future Directions in the Assessment of Axillary Lymph Nodes in Patients with Breast Cancer
    Filippo Pesapane, Luciano Mariano, Francesca Magnoni, Anna Rotili, Davide Pupo, Luca Nicosia, Anna Carla Bozzini, Silvia Penco, Antuono Latronico, Maria Pizzamiglio, Giovanni Corso, Enrico Cassano
    Medicina.2023; 59(9): 1544.     CrossRef
  • Axillary Lymph Node Dissection Can Be Omitted in Breast Cancer Patients With Mastectomy and False-Negative Frozen Section in Sentinel Lymph Node Biopsy
    Jing Si, Rong Guo, Huan Pan, Xiang Lu, Zhiqin Guo, Chao Han, Li Xue, Dan Xing, Wanxin Wu, Caiping Chen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients
    Zhu-Jun Loh, Kuo-Ting Lee, Ya-Ping Chen, Yao-Lung Kuo, Wei-Pang Chung, Ya-Ting Hsu, Chien-Chang Huang, Hui-Ping Hsu
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
    Sang-Won Kim, Won Kyung Cho, Doo Ho Choi, Haeyoung Kim, Oyeon Cho, Won Park, Mison Chun
    International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 992.     CrossRef
  • Validating the ACOSOG Z0011 Trial Result: A Population-Based Study Using the SEER Database
    Jiwoong Jung, Byoung Hyuck Kim, Jongjin Kim, Sohee Oh, Su-jin Kim, Chang-Sup Lim, In Sil Choi, Ki-Tae Hwang
    Cancers.2020; 12(4): 950.     CrossRef
  • Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort
    Jiwoong Jung, Wonshik Han, Eun Sook Lee, So-Youn Jung, Jai Hong Han, Dong-Young Noh, Yumi Kim, Hee Jun Choi, Jeong Eon Lee, Seok Jin Nam, Jong Won Lee, Hee Jeong Kim, Eunhae Um, Joo Heung Kim, Seho Park, Young Up Cho
    Breast Cancer Research and Treatment.2019; 175(1): 203.     CrossRef
  • Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer
    Yidong Zhou, Yan Li, Feng Mao, Jing Zhang, Qingli Zhu, Songjie Shen, Yan Lin, Xiaohui Zhang, He Liu, Mengsu Xiao, Yuxin Jiang, Qiang Sun
    BMC Cancer.2019;[Epub]     CrossRef
  • 12,123 View
  • 346 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy?
Bo Young Oh, Jung Wook Huh, Woo Yong Lee, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun
Cancer Res Treat. 2018;50(3):634-645.   Published online July 3, 2017
DOI: https://doi.org/10.4143/crt.2017.069
AbstractAbstract PDFPubReaderePub
Purpose
There are patients who do not undergo surgery, regardless of tumor response for neoadjuvant chemoradiotherapy (nCRT) in rectal cancer. However, there have been few reports focused on how oncologic outcomes are worse in these patients. We sought to investigate oncologic outcomes for these non-operated patients with rectal cancer after nCRT.
Materials and Methods
A total of 1,063 records of patients with rectal cancer who were treated with nCRT from January 2002 to December 2013 were retrospectively reviewed. We categorized patients into the non-operated group (n=77), transanal local excision (TLE) group (n=54), ortotal mesorectal excision (TME) group (n=932) and compared each group using propensity score matching.
Results
In the non-operated group, the most common reason for no surgery was patient refusal (n=64). Eleven patients were considered to have achieve clinical complete response (cCR), which was an independent prognostic factor of progression-free survival (p=0.045). In patients with disease progression in the non-operated group, the overall survival did not improved according to salvage treatments (p=0.451). The non-operated group showed worse survivals compared to the TLE or TME group before and after matching (p < 0.001). This finding was also noted in the analysis of survival only in patients with cCR.
Conclusion
In this study, non-operated patients did not secure oncologic safety regardless of cCR after nCRT. Our results suggest that a non-operative management must be carefully considered even if cCR is achieved.

Citations

Citations to this article as recorded by  
  • Long-term efficacy of transanal local excision versus total mesorectal excision after neoadjuvant treatment for rectal cancer: A meta-analysis
    Yihui Lei, Li Lin, Qiming Shao, Weiping Chen, Guoyan Liu, Antonio Brillantino
    PLOS ONE.2023; 18(11): e0294510.     CrossRef
  • Non-operative Management (NOM) of Rectal Cancer: Literature Review and Translation of Evidence into Practice
    Christopher J. Anker, Dmitriy Akselrod, Steven Ades, Nancy A. Bianchi, Nataniel H. Lester-Coll, Peter A. Cataldo
    Current Colorectal Cancer Reports.2021; 17(2): 23.     CrossRef
  • Prognostic Factors and Treatment of Recurrence after Local Excision of Rectal Cancer
    Moon Suk Choi, Jung Wook Huh, Jung Kyong Shin, Yoon Ah Park, Yong Beom Cho, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee
    Yonsei Medical Journal.2021; 62(12): 1107.     CrossRef
  • Treatment of stage I‐III rectal cancer: Who is refusing surgery?
    Adam C. Fields, Pamela W. Lu, James Yoo, Jennifer Irani, Joel E. Goldberg, Ronald Bleday, Nelya Melnitchouk
    Journal of Surgical Oncology.2020; 121(6): 990.     CrossRef
  • MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology
    Seong Ho Park, Seung Hyun Cho, Sang Hyun Choi, Jong Keon Jang, Min Ju Kim, Seung Ho Kim, Joon Seok Lim, Sung Kyoung Moon, Ji Hoon Park, Nieun Seo
    Korean Journal of Radiology.2020; 21(7): 812.     CrossRef
  • Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
    Wonkyo Shin, Joseph J. Noh, Sang-Soo Seo, Sokbom Kang, Chel-Hun Choi, Sang-Yoon Park, Byoung-Gie Kim, Myong Cheol Lim
    Yonsei Medical Journal.2020; 61(11): 935.     CrossRef
  • Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer: A Multicenter Comparative Cross‐Sectional Study with Rectal Preservation as Supported by Surgeon
    Kwang‐Seop Song, Sung Chan Park, Dae Kyung Sohn, Jae Hwan Oh, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Seung‐Yong Jeong, Kyu Joo Park, Heung‐Kwon Oh, Duck‐Woo Kim, Sung‐Bum Kang
    World Journal of Surgery.2019; 43(12): 3216.     CrossRef
  • 10,305 View
  • 246 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma
Eun-Jung Lee, Seung-Hyun Yang, Kyoung-Jin Kim, Hyejung Cha, Seo Jin Lee, Ji-Hye Kim, Junkyu Song, Kyung-Hee Chun, Jinsil Seong
Cancer Res Treat. 2018;50(3):646-657.   Published online July 17, 2017
DOI: https://doi.org/10.4143/crt.2016.550
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Early prediction of treatment outcomes represents an essential step towards increased treatment efficacy and survival in patients with hepatocellular carcinoma (HCC). In this study, we performed two-dimensional electrophoresis (2-DE) followed by protein profiling to identify biomarkers predictive of therapeutic outcomes in patients with HCC who received liver-directed therapy (LDTx) involving local radiotherapy (RT), and studied the underlying mechanisms of the identified proteins.
Materials and Methods
2-DE analysis was conducted by pooling sera from patients with a good or poor prognosis; serum proteomic profiles of the two groups were compared and analyzed using matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Identified proteins were confirmed via enzyme-linked immunosorbent assay. An invasion assay was performed after overexpression and knockdown of target protein in Huh7 cells.
Results
Levels of inter-alpha inhibitor H4 (ITIH4), fibrinogen gamma chain, keratin 9/1 complex, carbonic anhydrase I, and carbonmonoxyhemoglobin S were changed by more than 4-fold in response to LDTx. In particular, pre-LDTx ITIH4 expression was more than 5-fold higher in patients with a good prognosis, compared to patients with a poor prognosis. The migration ability of Huh7 cells was significantly suppressed and enhanced by ITIH4 overexpression and knockdown, respectively. The tumors of patients with HCC and a good prognosis expressed high levels of ITIH4, compared to those of patients with a poor prognosis.
Conclusion
Taken together, ITIH4 may be a potential therapeutic target that could inhibit cancer metastasis, as well as a prognostic marker for patients with HCC who are receiving LDTx.

Citations

Citations to this article as recorded by  
  • Mass spectrometry-based proteomics of cerebrospinal fluid in pediatric central nervous system malignancies: a systematic review with meta-analysis of individual patient data
    Christian Mirian, Maria Thastrup, René Mathiasen, Kjeld Schmiegelow, Jesper Velgaard Olsen, Ole Østergaard
    Fluids and Barriers of the CNS.2024;[Epub]     CrossRef
  • Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis
    Christina B. Schroeter, Christopher Nelke, Frauke Stascheit, Niklas Huntemann, Corinna Preusse, Vera Dobelmann, Lukas Theissen, Marc Pawlitzki, Saskia Räuber, Alice Willison, Anna Vogelsang, Adela Della Marina, Hans-Peter Hartung, Nico Melzer, Felix F. Ko
    Acta Neuropathologica.2024;[Epub]     CrossRef
  • The function of the inter-alpha-trypsin inhibitors in the development of disease
    Xin-feng Zhang, Xiao-li Zhang, Li Guo, Yun-ping Bai, Yan Tian, Hua-you Luo
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Characterization of the Limbal Epithelial Stem Cell Niche
    Isabel Y. Moreno, Arian Parsaie, Tarsis F. Gesteira, Vivien J. Coulson-Thomas
    Investigative Opthalmology & Visual Science.2023; 64(13): 48.     CrossRef
  • Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers
    Franziska Hauth, Hannah J. Roberts, Theodore S. Hong, Dan G. Duda
    International Journal of Molecular Sciences.2022; 23(4): 1926.     CrossRef
  • Regulatory network identified by pulmonary transcriptome and proteome profiling reveals extensive change of tumor-related genes in microRNA-21 knockout mice
    Ge Luan, Ming Wang, Jing Yuan, Xiangting Bu, Jing Song, Chengshuo Wang, Luo Zhang
    Journal of Cancer Research and Clinical Oncology.2022; 148(8): 1919.     CrossRef
  • Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles
    Hendrik Spreen, Matthias Behrens, Dennis Mulac, Hans-Ulrich Humpf, Klaus Langer
    European Journal of Pharmaceutics and Biopharmaceutics.2021; 163: 212.     CrossRef
  • Clinical Assay for the Early Detection of Colorectal Cancer Using Mass Spectrometric Wheat Germ Agglutinin Multiple Reaction Monitoring
    I-Jung Tsai, Emily Chia-Yu Su, I-Lin Tsai, Ching-Yu Lin
    Cancers.2021; 13(9): 2190.     CrossRef
  • Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways
    Yu Liu, Yan-Qing Li, Shi-Hao Huang, Yong-Long Li, Jia-Wei Xia, Jun-Shuang Jia, Fang Wei, Jia-Hong Wang, Guan-Qi Dai, Yu-Cai Wang, Xiao-Yan Li, Liu-Xin Han, Xiao-Ling Zhang, Xu-Dong Xiang, Wen-Tao Zhao, Dong Xiao, Xiao-Lin Lin
    Aging.2021; 13(17): 21155.     CrossRef
  • ITIH4 is a novel serum biomarker for early gastric cancer diagnosis
    Yingying Sun, Jie Jin, Hongyan Jing, Yingying Lu, Qingqing Zhu, Changjuan Shu, Qinghua Zhang, Dadao Jing
    Clinica Chimica Acta.2021; 523: 365.     CrossRef
  • The Alterations in Methylene Blue/Light-Treated Frozen Plasma Proteins Revealed by Proteomics
    Tiange Wu, Xiaoning Wang, Kai Ren, Xiaochen Huang, Jiankai Liu
    Transfusion Medicine and Hemotherapy.2021; 48(5): 298.     CrossRef
  • The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma
    Lucas Trevisan França de Lima, Daniel Broszczak, Xi Zhang, Kim Bridle, Darrell Crawford, Chamindie Punyadeera
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2020; 1874(2): 188451.     CrossRef
  • Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data
    Lazaro Hiram Betancourt, Krzysztof Pawłowski, Jonatan Eriksson, A. Marcell Szasz, Shamik Mitra, Indira Pla, Charlotte Welinder, Henrik Ekedahl, Per Broberg, Roger Appelqvist, Maria Yakovleva, Yutaka Sugihara, Kenichi Miharada, Christian Ingvar, Lotta Lund
    Scientific Reports.2019;[Epub]     CrossRef
  • Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
    Xiao Jiang, Xiao-Yan Bai, Bowen Li, Yanan Li, Kangkai Xia, Miao Wang, Shujing Li, Huijian Wu
    Disease Markers.2019; 2019: 1.     CrossRef
  • 11,132 View
  • 243 Download
  • 17 Web of Science
  • 14 Crossref
Close layer
BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database
Ki-Tae Hwang, Kwangsoo Kim, Ji Hyun Chang, Sohee Oh, Young A Kim, Jong Yoon Lee, Se Hee Jung, In Sil Choi
Cancer Res Treat. 2018;50(3):658-669.   Published online July 4, 2017
DOI: https://doi.org/10.4143/crt.2017.134
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We investigated B-cell lymphoma 2 (BCL2) regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database.
Materials and Methods
We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA-seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data.
Results
The luminal A and luminal B subtypes showed upregulated expression of RPPA and mRNAseq and hypomethylation compared to the human epidermal growth factor receptor 2 (HER2) and triple-negative subtypes (all p < 0.001). No mutations were found in any subjects. High mRNA-seq and high RPPA were strongly associated with positive estrogen receptor, positive progesterone receptor (all p < 0.001), and negative HER2 (p < 0.001 and p=0.002, respectively). Correlation analysis revealed a strong positive correlation between protein and mRNA levels and a strong negative correlation between methylation and protein and mRNA levels (all p < 0.001). The high BCL2 group showed superior overall survival compared to the low BCL2 group (p=0.006).
Conclusion
The regulation of BCL2 was mainly associated with methylation across the molecular subtypes of breast cancer, and luminal A and luminal B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation. Although copy number alteration may have played a minor role, mutation status was not related to BCL2 regulation. Upregulation of BCL2 was associated with superior prognosis than downregulation of BCL2.

Citations

Citations to this article as recorded by  
  • AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen
    Maiquidieli Dal Berto, Laura Martin Manfroi, Aniúsca Vieira dos Santos, Giovana Tavares dos Santos, Gabriela Krüger da Costa, Camila Macedo Boaro, Péttala Rigon, Rafael José Vargas Alves, Claudia Giuliano Bica
    Advances in Cancer Biology - Metastasis.2023; 8: 100108.     CrossRef
  • Clinicopathological features and prognosis of patients with HER2-low breast cancer
    Xin Yang, Yao Li, Xu lu, Xiaotian Ren, Bin Hua
    BMC Cancer.2023;[Epub]     CrossRef
  • Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature
    Guang‐Li Zhu, Kai‐Bin Yang, Cheng Xu, Rui‐Jia Feng, Wen‐Fei Li, Jun Ma
    Cancer Medicine.2022; 11(23): 4673.     CrossRef
  • Significance of Bcl-2 expression in breast cancer
    Nitika Kumari, Natarajan Suresh, Josephine A.
    Biomedicine.2022; 42(4): 775.     CrossRef
  • Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers
    Yingying Xu, Yonghao Liang, Guanghao Yin
    Clinical and Translational Oncology.2022; 25(4): 1024.     CrossRef
  • Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
    Lorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, Sofia Asioli, Giordano Nicoletti, Veronica Giusti, Francesca Ruzzi, Marianna L. Ianzano, Laura Scalambra, Roberta Laranga, Tania Balboni, Maddalena Arigoni, Martina Olivero, Raffaele A. Calogero, Car
    Scientific Reports.2021;[Epub]     CrossRef
  • Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
    Ki-Tae Hwang, Young A. Kim, Jongjin Kim, Hyeon Jeong Oh, Jeong Hwan Park, In Sil Choi, Jin Hyun Park, Sohee Oh, Ajung Chu, Jong Yoon Lee, Kyu Ri Hwang
    Scientific Reports.2021;[Epub]     CrossRef
  • p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study
    Alessandra Fabi, Marcella Mottolese, Anna Di Benedetto, Francesca Sperati, Cristiana Ercolani, Simonetta Buglioni, Cecilia Nisticò, Gianluigi Ferretti, Patrizia Vici, Letizia Perracchio, Paola Malaguti, Michelangelo Russillo, Claudio Botti, Edoardo Pescar
    Clinical Breast Cancer.2020; 20(6): e761.     CrossRef
  • Methylation of the NT5E Gene Is Associated with Poor Prognostic Factors in Breast Cancer
    Young Ju Jeong, Hoon Kyu Oh, Hye Ryeon Choi, Sung Hwan Park
    Diagnostics.2020; 10(11): 939.     CrossRef
  • Differential responses of epithelial cells from urinary and biliary tract to eggs of Schistosoma haematobium and S. mansoni
    Rafael Nacif-Pimenta, Alessandra da Silva Orfanó, Ilana A. Mosley, Shannon E. Karinshak, Kenji Ishida, Victoria H. Mann, Paulo Marcos Zech Coelho, José M. Correia da Costa, Michael H. Hsieh, Paul J. Brindley, Gabriel Rinaldi
    Scientific Reports.2019;[Epub]     CrossRef
  • A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer
    Hariprasad Thangavel, Carmine De Angelis, Suhas Vasaikar, Raksha Bhat, Mohit Kumar Jolly, Chandandeep Nagi, Chad J. Creighton, Fengju Chen, Lacey E. Dobrolecki, Jason T. George, Tanya Kumar, Noor Mazin Abdulkareem, Sufeng Mao, Agostina Nardone, Mothaffar
    Journal of Clinical Medicine.2019; 8(11): 1772.     CrossRef
  • BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer
    Athina Kladi-Skandali, Diamantis C. Sideris, Andreas Scorilas
    Clinical Chemistry and Laboratory Medicine (CCLM).2018; 57(2): 276.     CrossRef
  • 15,590 View
  • 328 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
Hyun Jee Kim, Chan-Young Ock, Tae Min Kim, Sung Hee Lee, Ju-Yeun Lee, Sun hoi Jung, Yoon Sook Cho, Miso Kim, Bhumsuk Keam, Dong-Wan Kim, Il Han Kim, Dae Seog Heo
Cancer Res Treat. 2018;50(3):670-680.   Published online July 3, 2017
DOI: https://doi.org/10.4143/crt.2017.051
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL).
Materials and Methods
A total of 41 NTCL patients who received IMEP plus native E. coli L-ASP or PEG-ASP at Seoul National University Hospital were included in this study between January 2013 and March 2016. IMEP/ASP treatment consisted of ifosfamide, methotrexate, etoposide, plus native E. coli L-ASP (6,000 IU/m2 on days 1, 3, 5, 7, 9, and 11) or PEG-ASP (2,500 IU/m2 on day 1) every 3 weeks. ASP-related toxicities, toxicity patterns, length of hospital stay, and clinical outcomes were compared between the different treatment groups.
Results
The frequency of ASP-related toxicities was similar between the IMEP plus native E. coli L-ASP group and the PEG-ASP group apart from hypofibrinogenemia (native E. coli L-ASP vs. PEG-ASP group, 86.4% vs. 36.8%; p=0.001). Although post-treatment transaminase and albumin levels were significantly high and low, respectively, hepatotoxicity gradients before and after treatment did not differ significantly between the groups. Since PEG-ASP was given at an outpatient clinic in some patients, length of hospital stay was significantly shorter in the IMEP plus PEG-ASP group (median, 4.0 vs. 6.0 days; p=0.002). A favorable tendency of clinical outcomes was observed in NTCL patients treated with IMEP plus PEG-ASP (complete remission rate, 73.7% vs. 45.5%; p=0.067).
Conclusion
IMEP plus PEG-ASP showed similar ASP-related toxicities, shorter length of hospital stay, and a trend towards improved clinical outcomes compared with IMEP plus native E. coli L-ASP in NTCL.

Citations

Citations to this article as recorded by  
  • From the midfacial destructive drama to the unfolding EBV story: a short history of EBV-positive NK-cell and T-cell lymphoproliferative diseases
    Chi Sing Ng
    Pathology.2024; 56(6): 773.     CrossRef
  • Treatment of extranodal NK/T-cell lymphoma: From past to future
    Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T‐cell lymphoma: A French retrospective study
    Sammara Chaubard, Amira Marouf, David Lavergne, François Lemonnier, Julien Rossignol, Aline Clavert, Rémy Gressin, Guillaume Cartron, Agathe Waultier‐Rascalou, Jacques Vargaftig, Gilles Salles, Emmanuel Bachy, Hervé Ghesquières, Olivier Tournilhac, Adrien
    British Journal of Haematology.2023; 201(4): 673.     CrossRef
  • Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System
    Salvatore Crisafulli, Paola Maria Cutroneo, Nicoletta Luxi, Andrea Fontana, Carmen Ferrajolo, Pasquale Marchione, Laura Sottosanti, Giovanna Zanoni, Ugo Moretti, Silvia Franzè, Paola Minghetti, Gianluca Trifirò
    Drug Safety.2023; 46(4): 343.     CrossRef
  • Incidence and Related Factors of L-asparaginase-induced Hypersensitivity Reactions Requiring Treatment Changes in Pediatric Patients with Acute Lymphoblastic Leukemia
    Eun Eui Noh, Yujin Lee, Sukmin Hong, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Ju-Yeun Lee
    Journal of Korean Society of Health-System Pharmacists.2023; 40(2): 171.     CrossRef
  • DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma
    Lei Zhang, Chenxing Shangguan, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Yonggang Shi, Jingjing Wu, Xudong Zhang, Hui Yu, Feifei Nan, Jiaqin Yan, Yu Chang, Zhiyuan Zhou, Xiaolong Wu, Xiaoyan Feng, Xiyang Liu, Hongwei Xue, Liqun Zou, Yi Lu,
    Leukemia Research.2022; 118: 106881.     CrossRef
  • DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
    Xin Wang, Junxia Hu, Meng Dong, Mengjie Ding, Linan Zhu, Jingjing Wu, Zhenchang Sun, Xin Li, Lei Zhang, Ling Li, Xinhua Wang, Xiaorui Fu, Guannan Wang, Qingjiang Chen, Mingzhi Zhang, Xudong Zhang
    Clinical and Translational Science.2021; 14(1): 405.     CrossRef
  • Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge
    Yiwei Liu, Colton A. Smith, John C. Panetta, Wenjian Yang, Lauren E. Thompson, Jacob P. Counts, Alejandro R. Molinelli, Deqing Pei, Nancy M. Kornegay, Kristine R. Crews, Hope Swanson, Cheng Cheng, Seth E. Karol, William E. Evans, Hiroto Inaba, Ching-Hon P
    Journal of Clinical Oncology.2019; 37(23): 2051.     CrossRef
  • Multiple drugs

    Reactions Weekly.2018; 1717(1): 197.     CrossRef
  • PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity
    Wen Zheng, Yuhuan Gao, Xiaoyan Ke, Weijing Zhang, Liping Su, Hanyun Ren, Ningjing Lin, Yan Xie, Meifeng Tu, Weiping Liu, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Xiaopei Wang, Yuqin Song, Jun Zhu
    BMC Cancer.2018;[Epub]     CrossRef
  • 11,758 View
  • 389 Download
  • 8 Web of Science
  • 10 Crossref
Close layer
Patient’s Cognitive Function and Attitudes towards Family Involvement in Cancer Treatment Decision Making: A Patient-Family Caregiver Dyadic Analysis
Dong Wook Shin, Juhee Cho, Debra L. Roter, So Young Kim, Jong Hyock Park, Hyung Kook Yang, Hyun Woo Lee, Sun-Seog Kweon, Yune Sik Kang, Keeho Park
Cancer Res Treat. 2018;50(3):681-690.   Published online July 4, 2017
DOI: https://doi.org/10.4143/crt.2017.201
AbstractAbstract PDFPubReaderePub
Purpose
Older patient populations commonly have cognitive impairment, which might impact decisional capacity. We examined patients and family caregivers preferences for family involvement in treatment decision making assuming different level of cognitive impairment, and sought to explore the factors associated with the preferences and the degree to which patients and family members agree on preferences.
Materials and Methods
A total of 358 elderly cancer patient and caregiver dyads were recruited from the 11 cancer centers in Korea andwere asked to express their preferences forfamily involvement in treatment decision making using hypothetical scenarios with three different levels of cognitive status (intact, mild impairment, and severe impairment).
Results
Both patients and family caregivers preferred greater family dominance in treatment decision makingwith the increasing the level of cognitive impairment (39.7%, 60.9%, and 86.6% for patients and 45.0%, 66.2%, and 89.7% for caregivers in each scenarios). Patient and family caregiver concordance in decisional control preference was small for all three scenarios (weighted κ=0.32, κ=0.26, and κ=0.36, respectively). Higher patient education was associated with preference for patient dominance in treatment decision in conditions of both mild and severe cognitive impairment. The association of higher patient education and patient-caregiver preference concordance was positive with intact cognition, while it was negative with severe cognitive impairment.
Conclusion
Decision control preferences were affected by hypothesized cognitive status of the patients. Findings from our study would be helpful to develop effective strategy for optimizing family involvement in cancer treatment decision in the context of deteriorating cognitive function of the patients.

Citations

Citations to this article as recorded by  
  • Comorbid Dementia and Cancer Therapy Decision-Making: A Scoping Review
    Sean N. Halpin, Gabriel Alain, Aaron Seaman, Erin E. Stevens, Hui Zhao, Mackenzie E. Fowler, Qiuyang Zhang, Tamara Cadet, Minzhi Ye, Jessica L. Krok-Schoen
    Journal of Applied Gerontology.2024; 43(8): 1132.     CrossRef
  • Assessing the association between quantity and quality of family caregiver participation in decision-making clinical encounters on patient activation in the metastatic breast cancer setting
    Nicole L. Henderson, Tanvi Padalkar, Garrett Bourne, Emma K. Hendrix, Courtney P. Williams, J. Nicholas Odom, Kristen Triebel, Gabrielle B. Rocque
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Fatalism and metaphor in Confucianism: A qualitative study of barriers to genetic testing among first‐degree relatives of hereditary cancer patients from China
    Chaonan Jiang, Li Liu, Ye Wang, Liangzheng Wu, Wenxia Zhang, Xiaodan Wu
    Psycho-Oncology.2023; 32(2): 275.     CrossRef
  • The Role of Nurse on the Treatment Decision Support for Older People with Cancer: A Systematic Review
    Hiroko Komatsu, Yasuhiro Komatsu
    Healthcare.2023; 11(4): 546.     CrossRef
  • A prospective cohort study of decision‐making role preferences of patients with advanced cancer and their family caregivers
    Semra Ozdemir, Sean Ng, Isha Chaudhry, Chetna Malhotra, Eric Andrew Finkelstein
    Cancer.2023; 129(9): 1443.     CrossRef
  • Cancer literacy among Jordanian colorectal cancer survivors and informal carers: Qualitative explorations
    Samar J. Melhem, Shereen Nabhani-Gebara, Reem Kayyali
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Preferred and actual involvement of caregivers in oncologic treatment decision-making: A systematic review
    Laura M.L. Tielemans, Kirsten D. van Heugten, Marije E. Hamaker, Inez C. van Walree
    Journal of Geriatric Oncology.2023; 14(6): 101525.     CrossRef
  • Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent Lymphoma
    Chia Jie Tan, Melinda Si Yun Tan, Chandramouli Nagarajan, Wee Joo Chng, Yen-Lin Chee, Melissa Ooi, Lawrence Cheng Kiat Ng, Yunxin Chen, Joanne Su Yin Yoong, Xin Yi Wong, Wei-Ying Jen
    JCO Oncology Practice.2023; 19(12): 1168.     CrossRef
  • The Association Between Mild Cognitive Impairment Diagnosis and Patient Treatment Preferences: a Survey of Older Adults
    Deborah A. Levine, Andrzej T. Galecki, Brenda L. Plassman, Angela Fagerlin, Lauren P. Wallner, Kenneth M. Langa, Rachael T. Whitney, Brahmajee K. Nallamothu, Lewis B. Morgenstern, Bailey K. Reale, Emilie M. Blair, Bruno Giordani, Kathleen Anne Welsh-Bohme
    Journal of General Internal Medicine.2022; 37(8): 1925.     CrossRef
  • Patient activation and treatment decision-making in the context of cancer: examining the contribution of informal caregivers’ involvement
    Chiara Acquati, Judith H. Hibbard, Ellen Miller-Sonet, Anao Zhang, Elena Ionescu
    Journal of Cancer Survivorship.2022; 16(5): 929.     CrossRef
  • Factors influencing family involvement in treatment decision-making for older patients with cancer: A scoping review
    Bea L. Dijkman, Marie Louise Luttik, Hanneke Van der Wal-Huisman, Wolter Paans, Barbara L. van Leeuwen
    Journal of Geriatric Oncology.2022; 13(4): 391.     CrossRef
  • The role of caregivers in the clinical pathway of patients newly diagnosed with breast and prostate cancer: A study protocol
    Clizia Cincidda, Serena Oliveri, Virginia Sanchini, Gabriella Pravettoni
    Frontiers in Psychology.2022;[Epub]     CrossRef
  • Treatment decision-making for older adults with cancer: A qualitative study
    Ni Gong, Qianqian Du, Hongyu Lou, Yiheng Zhang, Hengying Fang, Xueying Zhang, Xiaoyu Wu, Ya Meng, Meifen Zhang
    Nursing Ethics.2021; 28(2): 242.     CrossRef
  • Family Caregiving Situations and Engagement in Advance Care Planning
    Kyeongmo Kim, Michin Hong, Thomas Buckley
    Journal of Palliative Medicine.2020; 23(1): 125.     CrossRef
  • What We Talk about When We Talk about Caregiving: The Distribution of Roles in Cancer Patient Caregiving in a Family-Oriented Culture
    Ansuk Jeong, Dongwook Shin, Jong Hyock Park, Keeho Park
    Cancer Research and Treatment.2019; 51(1): 141.     CrossRef
  • Experience with age discrimination and attitudes toward ageism in older patients with cancer and their caregivers: A nationwide Korean survey
    Dong Wook Shin, Keeho Park, Ansuk Jeong, Hyung Kook Yang, So Young Kim, Mihee Cho, Jong Hyock Park
    Journal of Geriatric Oncology.2019; 10(3): 459.     CrossRef
  • How family caregivers of persons with advanced cancer assist with upstream healthcare decision-making: A qualitative study
    J. Nicholas Dionne-Odom, Deborah Ejem, Rachel Wells, Amber E. Barnato, Richard A. Taylor, Gabrielle B. Rocque, Yasemin E. Turkman, Matthew Kenny, Nataliya V. Ivankova, Marie A. Bakitas, Michelle Y. Martin, Mojtaba Vaismoradi
    PLOS ONE.2019; 14(3): e0212967.     CrossRef
  • 10,582 View
  • 231 Download
  • 17 Web of Science
  • 17 Crossref
Close layer
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
Cancer Res Treat. 2018;50(3):691-700.   Published online July 6, 2017
DOI: https://doi.org/10.4143/crt.2017.280
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials.
Materials and Methods
This analysis evaluated previously treated and untreated patients in two randomized, openlabel phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and “as-treated” populations for efficacy and safety endpoints, respectively.
Results
In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade)with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity.
Conclusion
These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.

Citations

Citations to this article as recorded by  
  • Inhalable iron redox cycling powered nanoreactor for amplified ferroptosis-apoptosis synergetic therapy of lung cancer
    Linjing Wu, Wenhao Wang, Mengqin Guo, Fangqin Fu, Wenhua Wang, Tszching Sung, Meihong Zhang, Ziqiao Zhong, Chuanbin Wu, Xin Pan, Zhengwei Huang
    Nano Research.2024; 17(6): 5435.     CrossRef
  • Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
    Akhil Kapoor, Vanita Noronha, Vijay Patil, Nandini Menon, Ravindra Nandhana, Amit Kumar, Abhishek Mahajan, Amit Janu, Rajiv Kumar, Kumar Prabhash
    South Asian Journal of Cancer.2023; 12(02): 179.     CrossRef
  • Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
    Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon, Virote Sriuranpong, K. Govind Babu, Khalid Amin, Yingbo Wang, Paramita Sen, Khemaies Slimane, Sarayut Geater
    Cancer Research and Treatment.2023; 55(1): 83.     CrossRef
  • Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
    Xiangming Zhang, Kai Ni, Huijun Chen
    OncoTargets and Therapy.2023; Volume 16: 87.     CrossRef
  • A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
    Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang
    Cancer Medicine.2023; 12(15): 15983.     CrossRef
  • Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review
    Fabien Moinard-Butot, Simon Nannini, Cathie Fischbach, Safa Abdallahoui, Martin Demarchi, Thierry Petit, Laura Bender, Roland Schott
    Cancers.2023; 15(20): 4940.     CrossRef
  • Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy
    Ziyu Zhao, Wenhao Wang, Guanlin Wang, Zhengwei Huang, Liping Zhou, Li Lin, Yueling Ou, Wanzhen Huang, Xuejuan Zhang, Chuanbin Wu, Liang Tao, Qin Wang
    Journal of Nanobiotechnology.2023;[Epub]     CrossRef
  • Performance of Japanese patients in registrational studies
    Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
    Japanese Journal of Clinical Oncology.2022; 52(1): 53.     CrossRef
  • Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
    Laird B Cameron, Nadia Hitchen, Elias Chandran, Tessa Morris, Renée Manser, Benjamin J Solomon, Vanessa Jordan
    Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
  • Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
    Kai Chen, Yingnan Si, Jia-Shiung Guan, Zhuoxin Zhou, Seulhee Kim, Taehyun Kim, Liang Shan, Christopher D. Willey, Lufang Zhou, Xiaoguang Liu
    Biomedicines.2022; 10(1): 130.     CrossRef
  • The application of radiomics in predicting gene mutations in cancer
    Yana Qi, Tingting Zhao, Mingyong Han
    European Radiology.2022; 32(6): 4014.     CrossRef
  • Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
    Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D. Ross Camidge, Karin Berghoff, Soetkin Vlassak, Paul K. Paik
    Clinical Lung Cancer.2022; 23(3): 195.     CrossRef
  • Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)
    Wen Zhou, Lu-Da Yan, Zhi-Qiong Yu, Na Li, Yong-Hua Yang, Meng Wang, Yuan-Yuan Chen, Meng-Xia Mao, Xiao-Chun Peng, Jun Cai
    Oncology Letters.2022;[Epub]     CrossRef
  • Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
    Myung J. Ahn, Hye R. Kim, James C.H. Yang, Ji-Yu Han, Jacky Yu-Chung. Li, Maximilian J. Hochmair, Gee-Chen Chang, Angelo Delmonte, Ki H. Lee, Rosario G. Campelo, Cesare Gridelli, Alexander I. Spira, Raffaele Califano, Frank Griesinger, Sharmistha Ghosh, E
    Clinical Lung Cancer.2022; 23(8): 720.     CrossRef
  • Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
    Dan Han, Kewei Zhao, Qin Yang, Liling Zhang, Shihong Fei
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
    Mei-ting Chen, Xiao-hong Fu, He Huang, Zhao Wang, Xiao-jie Fang, Yu-Yi Yao, Quan-Guang Ren, Ze-geng Chen, Tong-yu Lin
    Leukemia & Lymphoma.2021; 62(3): 571.     CrossRef
  • Breakthrough in targeted therapy for non-small cell lung cancer
    Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
    Biomedicine & Pharmacotherapy.2021; 133: 111079.     CrossRef
  • Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
    Daniel S.W. Tan, Sarayut Geater, Chong-Jen Yu, Chun-Ming Tsai, Te-Chun Hsia, Jun Chen, Meng-Chih Lin, You Lu, Virote Sriuranpong, Cheng-Ta Yang, Paramita Sen, Fabrice Branle, Michael Shi, Yi-Long Wu
    JTO Clinical and Research Reports.2021; 2(3): 100131.     CrossRef
  • Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
    Wenbin Li, Jing Zhang, Zhijie Wang, Lin Li, Jie Ma, Xiaoyang Zhou, Jie Wang, Zhiyong Liang, Jianming Ying
    Journal of the National Cancer Center.2021; 1(4): 123.     CrossRef
  • Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study
    Fenge Jiang, Congcong Wang, Ping Yang, Ping Sun, Jiannan Liu
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • Genetic Analysis of Pediatric Pancreatoblastoma
    Zhengzheng Wang, Xiaoting Li, Qingjun Li, Jinxue Zhou
    Pancreas.2021; 50(10): 1445.     CrossRef
  • Treatment of advanced non-small-cell lung cancer
    Kumar Prabhash, Amish Vora, Sewanti Limaye, Tarini Prasad Sahoo, Ullas Batra, Shekhar Patil, Vijay M. Patil, Vanita Noronha, Bharat Bhosale, Nirmal Vivek Raut, Narayanankutty Warrier, Bharat Vaswani, Govind Babu, Adwaita Gore, Nitesh Rohatgi, Shailesh Bon
    Cancer Research, Statistics, and Treatment.2021; 4(2): 279.     CrossRef
  • Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
    Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi
    The Lancet Respiratory Medicine.2020; 8(1): 45.     CrossRef
  • Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
    Lan Song, Zhenchen Zhu, Li Mao, Xiuli Li, Wei Han, Huayang Du, Huanwen Wu, Wei Song, Zhengyu Jin
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Renal complication of crizotinib: Crizotinib-associated complex renal cyst
    Warissara Jutidamrongphan, Pimporn Puttawibul
    The ASEAN Journal of Radiology.2020; : 44.     CrossRef
  • A Unique Case of a High-Grade Neuroepithelial Tumor With EML4-ALK Fusion in a Five-Month-Old
    Oliver D Mrowczynski, Russell Payne, Cunfeng Pu, Robert Greiner, Elias Rizk
    Cureus.2020;[Epub]     CrossRef
  • Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement
    Daniel S. Grosser, Haiying Zhang
    Baylor University Medical Center Proceedings.2019; 32(2): 206.     CrossRef
  • ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib
    Ye Qiu, Bixun Li, Yihong Zhang, Xiaoyun Guo, Chunzhi Xiang, Congshui Wang, Yang Lu, Shuang Ren, Juan Zhao
    Medicine.2019; 98(11): e14826.     CrossRef
  • Emerging therapies for non-small cell lung cancer
    Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
    Journal of Hematology & Oncology.2019;[Epub]     CrossRef
  • De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
    Jing-Wen Li, Shu-Hui Cao, Jian-Lin Xu, Hua Zhong
    Cancer Biology & Therapy.2019; 20(9): 1183.     CrossRef
  • Incidence and risk of fatigue in cancer patients treated with MET inhibitors
    Hongxuan Tong, Yutian Zhu, Yihua Liu
    Medicine.2019; 98(22): e15522.     CrossRef
  • Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
    Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo, Yingliang Wu
    RSC Advances.2019; 9(31): 17921.     CrossRef
  • Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
    Shih‐Hao Huang, Allen Chung‐Cheng Huang, Chin‐Chou Wang, Wen‐Chen Chang, Chien‐Ying Liu, Stelios Pavlidis, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
    Thoracic Cancer.2019; 10(12): 2274.     CrossRef
  • Erastin/sorafenib induces cisplatin‑resistant non‑small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway
    Yu Li, Hengyi Yan, Xiaoman Xu, Hongbo Liu, Cen Wu, Li Zhao
    Oncology Letters.2019;[Epub]     CrossRef
  • Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1
    Yan Yang, Caiyu Jiang, Yang Yang, Lu Guo, Jiang Huang, Xingren Liu, Chi Wu, Jun Zou
    Biochemical and Biophysical Research Communications.2018; 497(4): 1003.     CrossRef
  • Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices
    Claudio Martín, Andrés F. Cardona, Zyanya Lucia Zatarain-Barrón, Alejandro Ruiz-Patiño, Omar Castillo, George Oblitas, Luis Corrales, Lorena Lupinacci, María Angelina Pérez, Leonardo Rojas, Lisde González, Luis Chirinos, Carlos Ortíz, Mauricio Lema, Carlo
    Oncology.2018; 94(5): 297.     CrossRef
  • CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
    Stella Baliou, Maria Adamaki, Anthony Kyriakopoulos, Demetrios Spandidos, Michalis Panagiotidis, Ioannis Christodoulou, Vassilis Zoumpourlis
    International Journal of Oncology.2018;[Epub]     CrossRef
  • 15,780 View
  • 704 Download
  • 42 Web of Science
  • 37 Crossref
Close layer
Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study
Qiu-Yan Chen, Qing-Nan Tang, Lin-Quan Tang, Wen-Hui Chen, Shan-Shan Guo, Li-Ting Liu, Chao-Feng Li, Yang Li, Yu-Jing Liang, Xue-Song Sun, Ling Guo, Hao-Yuan Mo, Rui Sun, Dong-Hua Luo, Yu-Ying Fan, Yan He, Ming-Yuan Chen, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Hai-Qiang Mai
Cancer Res Treat. 2018;50(3):701-711.   Published online July 14, 2017
DOI: https://doi.org/10.4143/crt.2017.180
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The measuring Epstein-Barr virus (EBV) DNA is an important predictor of nasopharyngeal carcinoma (NPC). This study evaluated the predictive value of pretreatment serum amyloid A (SAA) and C-reactive protein (CRP) comparing with EBV DNA in patients with NPC.
Materials and Methods
In an observational study of 419 non-metastatic NPC patients, we prospectively evaluated the prognostic effects of pretreatment SAA, CRP, and EBV DNA on survival. The primary endpoint was progress-free survival (PFS).
Results
The median level of SAA and CRP was 4.28 mg/L and 1.88 mg/L, respectively. For the highSAA group (> 4.28 mg/L) versus the low-SAA (≤ 4.28 mg/L) group and the high-CRP group (> 1.88 mg/L) versus the low-CRP (≤ 1.88 mg/L) group, the 5-year PFS was 64.5% versus 73.1% (p=0.013) and 65.2% versus 73.3% (p=0.064), respectively. EBV DNA detection showed a superior predictive result, the 5-year PFS in the EBV DNA ≥ 1,500 copies/mL group was obviously different than the EBV DNA < 1,500 copies/mL group (62.2% versus 77.8%, p < 0.001). Multifactorial Cox regression analysis confirmed that in the PFS, the independent prognostic factors were including EBV DNA (hazard ratio [HR], 1.788; p=0.009), tumour stage (HR, 1.903; p=0.021), and node stage (HR, 1.498; p=0.049), but the SAA and CRP were not included in the independent prognostic factors.
Conclusion
The results of SAA and CRP had a certain relationship with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP were poor. However, the predictive ability of SAA and CRP was lower than that of EBV DNA.

Citations

Citations to this article as recorded by  
  • Development and application of a serious adverse events risk model for concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
    Jiahui Li, Qianwen Liu, Huiying Qin
    Medicine.2024; 103(34): e39377.     CrossRef
  • Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA
    Youliang Weng, Sunqin Cai, Chao Li, Yun Xu, Yuhui Pan, Zongwei Huang, Ying Li, Zijie Wu, Yu Chen, Sufang Qiu
    Scientific Reports.2024;[Epub]     CrossRef
  • Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study
    Ying Lu, Haixin Huang, Hui Yang, Xiaohua Hu, Meilian Liu, Changjie Huang, Xianbin Feng, Xishan Chen, Zhou Jiang
    Journal of Cancer Research and Clinical Oncology.2023; 149(8): 4327.     CrossRef
  • Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma
    Ying Lu, Zhou Jiang, Huan Lin, Hui Yang, Xishan Chen, Haixin Huang
    Future Oncology.2022; 18(22): 2441.     CrossRef
  • Long‐term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma
    Wanxia Li, Jing Chen, Bijun Liang, Zonghua Li, Junzheng Li, Xiaofei Yuan, Shuting Wu, Fangfang Zeng, Xinyu Peng, Yanfei Li, Juan Lu, Feipeng Zhao, Xiong Liu
    Cancer Medicine.2021; 10(3): 883.     CrossRef
  • A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
    Anne W.M. Lee, Victor H.F. Lee, Wai-Tong Ng, Primož Strojan, Nabil F. Saba, Alessandra Rinaldo, Stefan M. Willems, Juan P. Rodrigo, Arlene A. Forastiere, Alfio Ferlito
    European Journal of Cancer.2021; 153: 109.     CrossRef
  • Prognostic value of Epstein–Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases
    Hongling Qu, Yuli Huang, Shufen Zhao, Yuanqing Zhou, Weibiao Lv
    European Archives of Oto-Rhino-Laryngology.2020; 277(1): 9.     CrossRef
  • The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S‐D) grade in patients with nasopharyngeal carcinoma
    Jianpei Li, Changchun Lai, Songguo Peng, Hao Chen, Lei Zhou, Yufeng Chen, Shulin Chen
    Clinical and Translational Medicine.2020;[Epub]     CrossRef
  • Utility of a Simple Scoring System in Differentiating Bacterial Infections in Cases of Fever of Unknown Origin
    Teng Xu, Li Wang, Shi Wu, Fenfen Zhou, Haihui Huang
    Clinical Infectious Diseases.2020; 71(Supplement): S409.     CrossRef
  • The prognostic value of serum amyloid A in solid tumors: a meta-analysis
    Hai-yingjie Lin, Guo-qiang Tan, Yan Liu, Shao-qiang Lin
    Cancer Cell International.2019;[Epub]     CrossRef
  • Molecular Prognostic Value of Circulating Epstein–Barr Viral DNA in Nasopharyngeal Carcinoma: A Meta-Analysis of 27,235 Cases in the Endemic Area of Southeast Asia
    Xulin Xie, Yupei Ren, Kun Wang, Bin Yi
    Genetic Testing and Molecular Biomarkers.2019; 23(7): 448.     CrossRef
  • Rapid detection of quantum dot immune chromatography nasopharyngeal carcinoma EBNA1 antibody
    Jian He, Jing Xu, Ping Wu, Lingfeng Liao, Huatao Quan, Jing Kang, Yongquan Tian, Yaoyun Tang
    Oncology Letters.2018;[Epub]     CrossRef
  • 9,179 View
  • 268 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
Which Patients with Isolated Para-aortic Lymph Node Metastasis Will Truly Benefit from Extended Lymph Node Dissection for Colon Cancer?
Sung Uk Bae, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Nam Kyu Kim
Cancer Res Treat. 2018;50(3):712-719.   Published online July 14, 2017
DOI: https://doi.org/10.4143/crt.2017.100
AbstractAbstract PDFPubReaderePub
Purpose
The prognosis of patientswith colon cancer and para-aortic lymph node metastasis (PALNM) is poor. We analyzed the prognostic factors of extramesenteric lymphadenectomy for colon cancer patients with isolated PALNM.
Materials and Methods
We retrospectively reviewed 49 patients with PALNM who underwent curative resection between October 1988 and December 2009.
Results
In univariate analyses, the 5-year overall survival (OS) and disease-free survival (DFS) rates were higher in patients with ≤ 7 positive para-aortic lymph node (PALN) (36.5% and 27.5%) than in those with > 7 PALN (14.3% and 14.3%; p=0.010 and p=0.027, respectively), and preoperative carcinoembryonic antigen (CEA) level > 5 was also correlated with a lower 5-year OS and DFS rate of 21.5% and 11.7% compared with those with CEA ≤ 5 (46.3% and 41.4%; p=0.122 and 0.039, respectively). Multivariate analysis found that the number of positive PALN (hazard ratio [HR], 3.291; 95% confidence interval [CI], 1.309 to 8.275; p=0.011) was an independent prognostic factor for OS and the number of positive PALN (HR, 2.484; 95% CI, 0.993 to 6.211; p=0.052) and preoperative CEA level (HR, 1.953; 95% CI, 0.940 to 4.057; p=0.073) were marginally independent prognostic factors for DFS. According to our prognostic model, the 5-year OS and DFS rate increased to 59.3% and 53.3%, respectively, in patients with ≤ 7 positive PALN and CEA level ≤ 5.
Conclusion
PALN dissection might be beneficial in carefully selected patients with a low CEA level and less extensive PALNM.

Citations

Citations to this article as recorded by  
  • Prognostic factors of para-aortic lymph node metastasis from colorectal cancer in highly selected patients undergoing para-aortic lymph node dissection
    Shin Emoto, Yosuke Fukunaga, Manabu Takamatsu, Hiroshi Kawachi, Shuhei Sano, Tetsuro Tominaga, Toshiki Mukai, Tomohiro Yamaguchi, Toshiya Nagasaki, Takashi Akiyoshi, Tsuyoshi Konishi, Satoshi Nagayama, Masashi Ueno
    Surgery Today.2024; 54(4): 356.     CrossRef
  • Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence
    Rémi Grange, Pascal Rousset, Nicolas Williet, Mathias Guesnon, Laurent Milot, Guillaume Passot, Jean-Marc Phelip, Bertrand Le Roy, Olivier Glehen, Vahan Kepenekian
    Annals of Surgical Oncology.2024; 31(4): 2378.     CrossRef
  • Para-aortic Lymph Node Dissection for Colorectal Cancer: Predicting Pathologic Lymph Node Positivity and Optimizing Outcomes
    Neal Bhutiani, Kentaro Ochiai, Muhammad O. Awiwi, Miguel A. Rodriguez-Bigas, Abhineet Uppal, Oliver Peacock, Craig Messick, Michael G. White, John M. Skibber, Brian K. Bednarski, Y. Nancy You, George J. Chang, Harmeet Kaur, Tsuyoshi Konishi
    Annals of Surgical Oncology.2024; 31(9): 5962.     CrossRef
  • Surgery for Infrarenal Retroperitoneal Node Metastases from Colon Cancer
    Anne-Sophie Dulac, Pietro Genova, Olivier Benoit, Cindy Neuzillet, Mostapha El Hajjam, Jean-François Emile, Frédérique Peschaud, Renato Micelli Lupinacci
    Journal of Gastrointestinal Cancer.2024; 55(3): 1306.     CrossRef
  • Long-term Outcome After Surgical Resection of Para-aortic Lymph Node Metastasis of Colorectal Cancer: A Multicenter Retrospective Study
    Sono Ito, Yusuke Kinugasa, Shinichi Yamauchi, Hiroyuki Sato, Akihiro Hirakawa, Soichiro Ishihara, Akio Shiomi, Yukihide Kanemitsu, Takeshi Suto, Hiroki Takahashi, Michio Itabashi, Manabu Shiozawa, Masaya Hiyoshi, Takaya Kobatake, Koji Komori, Hiroyuki Egi
    Diseases of the Colon & Rectum.2024; 67(11): 1423.     CrossRef
  • Long-Term Outcome After Resection of Hepatic and Pulmonary Metastases in Multivisceral Colorectal Cancer
    Christopher Berlin, Geoffroy Andrieux, Magdalena Menzel, Gabriel J. Stöger, Andreas Gengenbach, Luisa Schäfer, Hans C. Hillebrecht, Rebecca Kesselring, Uyen-Thao Le, Stefan Fichtner-Feigl, Philipp A. Holzner
    Cancers.2024; 16(22): 3741.     CrossRef
  • Survival outcomes after synchronous para‐aortic lymph node metastasis in colorectal cancer: A systematic review
    Conor Aylward, Jawed Noori, Jack Tyrrell, Niall O'sullivan, Dara O. Kavanagh, John O. Larkin, Brian J. Mehigan, Paul H. McCormick, Michael E. Kelly
    Journal of Surgical Oncology.2023; 127(4): 645.     CrossRef
  • Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review
    Michael G. Fadel, Mosab Ahmed, Gianluca Pellino, Shahnawaz Rasheed, Paris Tekkis, David Nicol, Christos Kontovounisios, Erik Mayer
    Cancers.2023; 15(2): 455.     CrossRef
  • The management of clinically suspicious para‐aortic lymph node metastasis in colorectal cancer: A systematic review
    Michelle Zhiyun Chen, Yeng Kwang Tay, Swetha Prabhakaran, Joseph C Kong
    Asia-Pacific Journal of Clinical Oncology.2023; 19(6): 596.     CrossRef
  • Survival benefits of para-aortic lymphadenectomy in colorectal cancer with clinically suspected para-aortic lymph node metastasis: a meta-analysis and systematic review
    Rong-Chang Wang, Jian-Qi Wang, Xiao-Yu Zhou, Chu-lin Zhong, Jin-Xu Chen, Jing-Song Chen
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases
    Frédéric Schell, Amaniel Kefleyesus, Nazim Benzerdjeb, Guillaume Passot, Pascal Rousset, Alhadeedi Omar, Laurent Villeneuve, Julien Péron, Olivier Glehen, Vahan Kepenekian
    Annals of Surgical Oncology.2023; 30(7): 4444.     CrossRef
  • Lymph nodes primary staging of colorectal cancer in 18F-FDG PET/MRI: a systematic review and meta-analysis
    Qingwei Ren, Yanyan Chen, Xuejun Shao, Lanzhong Guo, Xinxin Xu
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Oncologic Outcomes after Surgical Resection for Para-aortic Lymph Node Metastasis in Colorectal Cancer
    Takayuki Okuno, Masaya Hiyoshi, Yuusuke Kyoden, Junji Yamamoto
    Nippon Daicho Komonbyo Gakkai Zasshi.2023; 76(7): 460.     CrossRef
  • Multicenter study of prognostic factors in paraaortic lymph node dissection for metastatic colorectal cancer
    Jun Woo Bong, Sanghee Kang, Pyoungjae Park
    Annals of Surgical Treatment and Research.2023; 105(5): 271.     CrossRef
  • Outcomes of metachronous para-aortic lymphadenectomy in colorectal cancer: a systematic review of the literature
    Oluwatobi O. Onafowokan, Jennifer Redfern, Agastya Patel, Thomas Satyadas, Minas Baltatzis
    Langenbeck's Archives of Surgery.2023;[Epub]     CrossRef
  • Predictive factors of survival of colorectal cancer patients after para-aortic lymph node metastasis
    Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Shigenobu Emoto, Shinya Abe, Hirofumi Sonoda, Koji Murono, Junko Kishikawa, Yuzo Nagai, Yuichiro Yokoyama, Hiroyuki Anzai, Soichiro Ishihara
    International Journal of Clinical Oncology.2022; 27(3): 520.     CrossRef
  • Long-Term Outcomes of Surgical Resection of Pathologically Confirmed Isolated Para-Aortic Lymph Node Metastases in Colorectal Cancer: A Systematic Review
    Maurizio Zizzo, Maria Pia Federica Dorma, Magda Zanelli, Francesca Sanguedolce, Maria Chiara Bassi, Andrea Palicelli, Stefano Ascani, Alessandro Giunta
    Cancers.2022; 14(3): 661.     CrossRef
  • Effect of radical lymphadenectomy in colorectal cancer with para-aortic lymph node metastasis: a systematic review and meta-analysis
    Pengyue Zhao, Xingpeng Yang, Yang Yan, Jiaqi Yang, Songyan Li, Xiaohui Du
    BMC Surgery.2022;[Epub]     CrossRef
  • Prognostic significance of enlarged paraaortic lymph nodes detected during left-sided colorectal cancer surgery: a single-center retrospective cohort study
    Jaram Lee, Hyeong-min Park, Soo Young Lee, Chang Hyun Kim, Hyeong Rok Kim
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • Risk factors for local recurrence and long term survival after minimally invasive intersphincteric resection for very low rectal cancer: Multivariate analysis in 161 patients
    G.N. Piozzi, H. Park, T.H. Lee, J.S. Kim, H.B. Choi, S.J. Baek, J.M. Kwak, J. Kim, S.H. Kim
    European Journal of Surgical Oncology.2021; 47(8): 2069.     CrossRef
  • Effect of lymphadenectomy in colorectal cancer with isolated synchronous para‐aortic lymph node metastasis
    Sung Chul Lee, Hee Cheol Kim, Woo Yong Lee, Seong Hyeon Yun, Yong Beom Cho, Jung Wook Huh, Yoon Ah Park, Jung Kyong Shin
    Colorectal Disease.2021; 23(10): 2584.     CrossRef
  • Robotic Intersphincteric Resection for Low Rectal Cancer: Technical Controversies and a Systematic Review on the Perioperative, Oncological, and Functional Outcomes
    Guglielmo Niccolò Piozzi, Seon Hahn Kim
    Annals of Coloproctology.2021; 37(6): 351.     CrossRef
  • Is 18F-FDG PET/CT an Accurate Way to Detect Lymph Node Metastasis in Colorectal Cancer: A Systematic Review and Meta-Analysis
    Hamid Dahmarde, Fateme Parooie, Morteza Salarzaei
    Contrast Media & Molecular Imaging.2020; 2020: 1.     CrossRef
  • Oncologic outcomes after resection of para-aortic lymph node metastasis in left-sided colon and rectal cancer
    Junichi Sakamoto, Heita Ozawa, Hiroki Nakanishi, Shin Fujita, Norikatsu Miyoshi
    PLOS ONE.2020; 15(11): e0241815.     CrossRef
  • Long-term outcome and prognostic factors for patients with para-aortic lymph node dissection in left-sided colorectal cancer
    Kota Sahara, Jun Watanabe, Atsushi Ishibe, Yusuke Suwa, Hirokazu Suwa, Mitsuyoshi Ota, Chikara Kunisaki, Itaru Endo
    International Journal of Colorectal Disease.2019; 34(6): 1121.     CrossRef
  • 16,064 View
  • 329 Download
  • 25 Web of Science
  • 25 Crossref
Close layer
The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
Shin Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Cancer Res Treat. 2018;50(3):720-728.   Published online July 14, 2017
DOI: https://doi.org/10.4143/crt.2017.169
AbstractAbstract PDFPubReaderePub
Purpose
The aims of this study were to investigate trends of aggressive treatment of non-small cell lung cancer (NSCLC) patients at the end-of-life (EOL) during the recent 5 years and examine the relationship between hospice consultation (HC) and aggressive care.
Materials and Methods
The medical records of 789 patients with stage IIIB-IV NSCLC at Seoul National University Hospital (SNUH) who received palliative chemotherapy and died from 2010 to 2014 were retrospectively reviewed. Indicators of aggressive treatment were evaluated, and the association of HC with these indicators was analyzed.
Results
During the last 5 years, the frequency of HC increased from 26.7% to 43.6%. The time interval from last chemotherapy to death increased, and the proportion of patients who received palliative chemotherapy, visited an emergency room, were admitted to intensive care unit, during the last month of life, and died in SNUH significantly decreased over time. Referral to HC was significantly associated with lower intensive care unit admission rates, lower out-of-hospital death rates, and less use of the chemotherapy within 1 month prior to death. Overall survival did not differ by HC.
Conclusion
The pattern of cancer care nearthe EOL has become less aggressivewhen HCwas provided. The positive association of HCwith better EOL care suggests that providing HC at the optimal time might help to avoid futile aggressive treatment.

Citations

Citations to this article as recorded by  
  • Hospice delivery models and survival differences in the terminally ill: a large cohort study
    Wei-Shu Lai, I-Ting Liu, Jui-Hung Tsai, Pei-Fang Su, Pin-Hsuan Chiu, Ying-Tzu Huang, Ge-Lin Chiu, Yu-Yeh Chen, Peng-Chan Lin
    BMJ Supportive & Palliative Care.2024; 14(e1): e1134.     CrossRef
  • Use of high‐flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life
    Jung Sun Kim, Jeongmi Shin, Nam Hee Kim, Sun Young Lee, Shin Hye Yoo, Bhumsuk Keam, Dae Seog Heo
    Cancer Medicine.2023; 12(13): 14612.     CrossRef
  • Antibiotic prescription patterns during last days of hospitalized patients with advanced cancer: the role of palliative care consultation
    Jeong-Han Kim, Shin Hye Yoo, Bhumsuk Keam, Dae Seog Heo
    Journal of Antimicrobial Chemotherapy.2023; 78(7): 1694.     CrossRef
  • Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
    Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, Su-Jin Koh
    Supportive Care in Cancer.2022; 30(9): 7431.     CrossRef
  • Perceptions on the current content and pedagogical approaches used in end-of-life care education among undergraduate nursing students: a qualitative, descriptive study
    Wenjing Cao, Chunyan Li, Qianqian Zhang, Huiru Tong
    BMC Medical Education.2022;[Epub]     CrossRef
  • Increased in-hospital mortality and emergent cases in patients with stage IV cancer
    Elleana J. Majdinasab, Yana Puckett, Kevin Y. Pei
    Supportive Care in Cancer.2021; 29(6): 3201.     CrossRef
  • Changes of End of Life Practices for Cancer Patients and Their Association with Hospice Palliative Care Referral over 2009-2014: A Single Institution Study
    Hyun Jung Jho, Eun Jung Nam, Il Won Shin, Sun Young Kim
    Cancer Research and Treatment.2020; 52(2): 419.     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Do advance directive attitudes and perceived susceptibility and end-of-life life-sustaining treatment preferences between patients with heart failure and cancer differ?
    JinShil Kim, Jiin Choi, Mi-Seung Shin, Miyeong Kim, EunJu Seo, Minjeong An, Jae Lan Shim, Seongkum Heo, Hans-Peter Brunner-La Rocca
    PLOS ONE.2020; 15(9): e0238567.     CrossRef
  • Duration of palliative care before death in international routine practice: a systematic review and meta-analysis
    Roberta I. Jordan, Matthew J. Allsop, Yousuf ElMokhallalati, Catriona E. Jackson, Helen L. Edwards, Emma J. Chapman, Luc Deliens, Michael I. Bennett
    BMC Medicine.2020;[Epub]     CrossRef
  • Relationship Between Preferences for Advance Directive Treatments and Decisional Conflicts Among Low-Income, Home-Based Cancer Management Recipients in Korea
    Miyeong Kim, Seongkum Heo, Jung-Yi Hur, JaeLan Shim, JinShil Kim
    Journal of Transcultural Nursing.2019; 30(6): 587.     CrossRef
  • Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study
    Amanda J.W. Gibson, Haocheng Li, Adrijana D’Silva, Anifat A. Elegbede, Roxana A. Tudor, Shannon Otsuka, D. Gwyn Bebb, Winson Y. Cheung
    Lung Cancer.2019; 134: 141.     CrossRef
  • Interventions to reduce aggressive care at end of life among patients with cancer: a systematic review
    Nauzley C Abedini, Rachel K Hechtman, Achintya D Singh, Rafina Khateeb, Jason Mann, Whitney Townsend, Vineet Chopra
    The Lancet Oncology.2019; 20(11): e627.     CrossRef
  • Demographic and Socioeconomic Factors for Renouncing Further Active Therapy for Patients with Brain Metastasis of Non-Small Cell Lung Cancer
    Gyuseo Jung, Seok-Hyun Kim, Tae Gyu Kim, Young Zoon Kim
    Brain Tumor Research and Treatment.2019; 7(2): 112.     CrossRef
  • 9,501 View
  • 261 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea
Chang-Mo Oh, Hyunsoon Cho, Young-Joo Won, Hyun-Joo Kong, Yun Ho Roh, Ki-Heon Jeong, Kyu-Won Jung
Cancer Res Treat. 2018;50(3):729-737.   Published online July 14, 2017
DOI: https://doi.org/10.4143/crt.2017.166
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This descriptive study was aimed to examine trends in the incidence of melanoma and nonmelanoma in South Korea.
Materials and Methods
The nationwide incidence data for melanoma and non-melanoma skin cancer was obtained from the Korea Central Cancer Registry. Age-standardized rates were calculated and analyzed, using a Joinpoint regression model.
Results
The incidence of basal cell carcinoma has increased dramatically both in men (average annual percentage change [AAPC], 8.0 [95% confidence interval (CI), 6.0 to 10.1]) and women (AAPC, 9.0 [95% CI, 7.5 to 10.4]). Squamous cell carcinoma has also steadily increased both in men (AAPC, 3.3 [95% CI, 2.6 to 4.0]) and women (AAPC, 6.8 [95% CI, 5.3 to 8.4]). Cutaneous melanoma increased continuously from 1999 to 2014 inwomen (AAPC, 3.5 [95% CI, 2.4 to 4.6]), whilst rapidly increasing in men until 2005 (APC, 7.9 [95% CI, 2.4 to 13.7]) after which no increase has been observed (APC, ‒0.2 [95% CI, ‒2.3 to 2.0]).
Conclusion
The incidence rates of melanoma and non-melanoma skin cancer have increased over the past years, with the exception of melanoma in men. Further studies are required to investigate the reasons for the increased incidence of these skin cancers in South Korea.

Citations

Citations to this article as recorded by  
  • Clinical and histopathological features of lentigo maligna and lentigo maligna melanoma: a retrospective analysis in Korea
    Chanyong Park, Dong Hyo Kim, Keunyoung Hur, Je-Ho Mun
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Incidence and survival rates of primary cutaneous malignancies in Korea, 1999–2019: A nationwide population‐based study
    Soon‐Hyo Kwon, Sangmin Choi, Joung Soo Kim, Sang Seok Kim, Mihn‐Sook Jue, Soo Hong Seo, Jihye Park, Mi Ryung Roh, Je‐Ho Mun, Jun Young Kim, Jee Woong Choi, Ji Won Byun, Sanghyun Park, Min Sung Kim, Seok‐Jong Lee
    The Journal of Dermatology.2024; 51(4): 532.     CrossRef
  • Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea
    Jin-Hee Kwon, Heyjin Kim, Jin Kyung Lee, Young Jun Hong, Hye Jin Kang, Yoon Jung Jang
    Cancers.2024; 16(13): 2346.     CrossRef
  • Incidence of cancer in chronic inflammatory demyelinating polyneuropathy: a nationwide cohort study in South Korea
    Kyomin Choi, Sohee Jung, Gucheol Jung, Dayoung Kim, Jeeyoung Oh
    Frontiers in Neurology.2024;[Epub]     CrossRef
  • Somatic mutations in facial skin from countries of contrasting skin cancer risk
    Charlotte King, Joanna C. Fowler, Irina Abnizova, Roshan K. Sood, Michael W. J. Hall, Ildikó Szeverényi, Muly Tham, Jingxiang Huang, Stephanie Ming Young, Benjamin A. Hall, E. Birgitte Lane, Philip H. Jones
    Nature Genetics.2023; 55(9): 1440.     CrossRef
  • Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study
    Zhen Li, Yuan Fang, Hui Chen, Tongchao Zhang, Xiaolin Yin, Jinyu Man, Xiaorong Yang, Ming Lu
    Neoplasia.2022; 24(1): 12.     CrossRef
  • Skin Cancer in People of Color: A Systematic Review
    George A. Zakhem, Akshay N. Pulavarty, Jenna C. Lester, Mary L. Stevenson
    American Journal of Clinical Dermatology.2022; 23(2): 137.     CrossRef
  • Acculturation, Sun Tanning Behavior, and Tanning Attitudes Among Asian College Students in the Northeastern USA
    Jennifer M. Bowers, Jada G. Hamilton, Yelena P. Wu, Anne Moyer, Jennifer L. Hay
    International Journal of Behavioral Medicine.2022; 29(1): 25.     CrossRef
  • Segmentation of skin lesions image based on U-Net + +
    Chen Zhao, Renjun Shuai, Li Ma, Wenjia Liu, Menglin Wu
    Multimedia Tools and Applications.2022; 81(6): 8691.     CrossRef
  • Identification of genetic mutations of cutaneous squamous cell carcinoma using whole exome sequencing in non-Caucasian population
    Soo Young Lee, Minho Lee, Dong Soo Yu, Young Bok Lee
    Journal of Dermatological Science.2022; 106(2): 70.     CrossRef
  • Incidence and Prevalence of Skin Cancers in South Korea from 2008 to 2016: A Nation-Wide Population Based Study
    Kyungduck Park, Jung Min Bae, Kee Yang Chung, Sook Jung Yun, Soo Hong Seo, Hyo Hyun Ahn, Dong-Youn Lee, Heesu Kim, Uri Sohn, Byung Cheol Park
    Annals of Dermatology.2022; 34(2): 105.     CrossRef
  • Basal cell carcinoma of the scalp shows distinct features from the face in Asians
    Minsu Kim, Jee-Woo Kim, Jung-Won Shin, Jung-Im Na, Chang-Hun Huh
    Scientific Reports.2022;[Epub]     CrossRef
  • Incidence and Survival Rates of Cutaneous Melanoma in South Korea Using Nationwide Health Insurance Claims Data
    TaeHo Kim, Siyeong Yoon, Dong-Eun Shin, Sang Cheol Lee, Jisu Oh, So-Young Lee, Do Kyung Kim, Segi Kim, Bosung Jung, Minsup Kim, Soonchul Lee
    Cancer Research and Treatment.2022; 54(3): 937.     CrossRef
  • Đặc điểm mô bệnh học và mối liên quan với biểu hiện lâm sàng trên bệnh nhân ung thư da tại Bệnh viện Trung ương Huế và Bệnh viện Đại học Y Dược Huế
    My Nguyen
    Journal of Clinical Medicine- Hue Central Hospital.2022;[Epub]     CrossRef
  • Use of hydrochlorothiazide and risk of nonmelanoma skin cancer in Koreans: a retrospective cohort study using administrative healthcare data
    J. C. Kim, Y. C. Kim, J. W. Choi
    Clinical and Experimental Dermatology.2021; 46(4): 680.     CrossRef
  • A retrospective case series of 10 patients with malignant melanomas arising from small- and medium-sized congenital melanocytic nevi in South Koreans
    Jun Young Kim, Seok Min Kim, Kyung Duck Park, Yong Hyun Jang, Weon Ju Lee, Seok-Jong Lee
    Indian Journal of Dermatology, Venereology and Leprology.2021; 87: 293.     CrossRef
  • A Case of Metastatic Melanoma in the Liver Mimicking Hepatocellular Carcinoma
    Jae-Kyoung So, Ji-Yun Hong, Min-Woo Chung, Sung-Bum Cho
    Journal of Liver Cancer.2021; 21(1): 92.     CrossRef
  • Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy
    Jun Xu, Jianguo Zhao, Jianfang Wang, Caiping Sun, Xiaoling Zhu
    Medicine.2021; 100(14): e25318.     CrossRef
  • Evaluation of skin cancer resection guide using hyper-realistic in-vitro phantom fabricated by 3D printing
    Junhyeok Ock, Taehun Kim, Sangwook Lee, Tae Seong Yang, Minji kim, Wooshik Jeong, Jongwoo Choi, Namkug Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?
    Chang‐Mo Oh, Jiwon Lim, Yuh Seog Jung, Yeol Kim, Kyu‐Won Jung, Seri Hong, Young‐Joo Won
    Cancer Medicine.2021; 10(12): 4087.     CrossRef
  • Occupational radiation exposure and cancer incidence in a cohort of diagnostic medical radiation workers in South Korea
    Won Jin Lee, Seulki Ko, Ye Jin Bang, Seung-Ah Choe, Yeongchull Choi, Dale L Preston
    Occupational and Environmental Medicine.2021; 78(12): 876.     CrossRef
  • Association between Skin Cancer and Systemic and Ocular Comorbidities in South Korea
    Sul Hee Lee, Jun-Soo Ro, Kee Yang Chung, Sang Hoon Lee, Young Lip Park, Jung Eun Kim, Si Hyung Lee
    Journal of Clinical Medicine.2021; 10(11): 2451.     CrossRef
  • Segmentation of dermoscopy images based on deformable 3D convolution and ResU-NeXt + +
    Chen Zhao, Renjun Shuai, Li Ma, Wenjia Liu, Menglin Wu
    Medical & Biological Engineering & Computing.2021; 59(9): 1815.     CrossRef
  • Dynamic thermal imaging for pigmented basal cell carcinoma and seborrheic keratosis
    Yoo Sang Baek, Anna Kim, Ji Yun Seo, Jiehyun Jeon, Chil Hwan Oh, Jaeyoung Kim
    International Journal of Hyperthermia.2021; 38(1): 1462.     CrossRef
  • Testing Multi-Theory Model (MTM) in Explaining Sunscreen Use among Florida Residents: An Integrative Approach for Sun Protection
    Manoj Sharma, Matthew Asare, Erin Largo-Wight, Julie Merten, Mike Binder, Ram Lakhan, Kavita Batra
    Healthcare.2021; 9(10): 1343.     CrossRef
  • Coexisting and Second Primary Cancers in Patients with Uveal Melanoma: A 10-Year Nationwide Database Analysis
    Yong Joon Kim, Myeongjee Lee, Eun Hwa Kim, Inkyung Jung, Christopher Seungkyu Lee
    Journal of Clinical Medicine.2021; 10(20): 4744.     CrossRef
  • A case of modified advancement flap for an auricular skin defect
    Geun Woo Park, Gyo Han Bae, Tae Young Jung, Woong Jae Noh
    Journal of Cosmetic Medicine.2021; 5(2): 82.     CrossRef
  • Hyperspectral imaging and robust statistics in non-melanoma skin cancer analysis
    Lloyd A. Courtenay, Diego González-Aguilera, Susana Lagüela, Susana del Pozo, Camilo Ruiz-Mendez, Inés Barbero-García, Concepción Román-Curto, Javier Cañueto, Carlos Santos-Durán, María Esther Cardeñoso-Álvarez, Mónica Roncero-Riesco, David Hernandez-Lope
    Biomedical Optics Express.2021; 12(8): 5107.     CrossRef
  • Efficacy and clinical significance of omitting blue dye injection during sentinel lymph node biopsy before Mohs micrographic surgery for malignant melanoma of the lower extremities
    T.H. Kim, H.J. Kim, J.W. Seo, K.H. Song
    British Journal of Dermatology.2020; 182(2): 427.     CrossRef
  • A rare case of abdominal adenoid basal cell carcinoma in a patient with a history of radiation therapy
    Ji Hun Kim, Sun Eung Kim, Young Woo Cheon
    Archives of Plastic Surgery.2020; 47(01): 78.     CrossRef
  • The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population‐based matched cohort study in Korea
    H.S. Kim, H.J. Kim, E.S. Hong, K.B. Kim, J.D. Lee, T.U. Kang, H.S. Ahn
    British Journal of Dermatology.2020; 182(4): 907.     CrossRef
  • Dual vascular free transverse rectus abdominis myocutaneous flap for hemifacial reconstruction in a vessel-depleted neck
    Su-Hyun Lee, Hi-Jin You, Yun-Hwan Lee, Deok-Woo Kim
    Archives of Plastic Surgery.2020; 47(01): 88.     CrossRef
  • Primary amelanotic melanoma of the mandibular gingiva
    Byeong Jun Kim, Hyeong Seop Kim, Yong Joon Chang, Kee Hwan Kwon, Seong Jin Cho
    Archives of Craniofacial Surgery.2020; 21(2): 132.     CrossRef
  • A retrospective study of changes in skin cancer characteristics over 11 years
    Young Ji Park, Gyu Hyeon Kwon, Jun Oh Kim, Nam Kyun Kim, Woo Sang Ryu, Kyung Suk Lee
    Archives of Craniofacial Surgery.2020; 21(2): 87.     CrossRef
  • Environmental effects of stratospheric ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2019
    G. H. Bernhard, R. E. Neale, P. W. Barnes, P. J. Neale, R. G. Zepp, S. R. Wilson, A. L. Andrady, A. F. Bais, R. L. McKenzie, P. J. Aucamp, P. J. Young, J. B. Liley, R. M. Lucas, S. Yazar, L. E. Rhodes, S. N. Byrne, L. M. Hollestein, C. M. Olsen, A. R. You
    Photochemical & Photobiological Sciences.2020; 19(5): 542.     CrossRef
  • Parkinson’s disease and skin cancer risk: a nationwide population‐based cohort study in Korea
    H.J. Ryu, J.‐H. Park, M. Choi, J.‐H. Jung, K. Han, D.‐Y. Kwon, D.‐H. Kim, Y.‐G. Park
    Journal of the European Academy of Dermatology and Venereology.2020; 34(12): 2775.     CrossRef
  • A case of melanoma-associated retinopathy with autoantibodies against TRPM1
    Min Seok Kim, Hye Kyoung Hong, You Jin Ko, Kyu Hyung Park, Shinji Ueno, Satoshi Okado, Se Joon Woo, Kwangsic Joo
    Documenta Ophthalmologica.2020; 141(3): 313.     CrossRef
  • Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea
    Eunjung Park, Young Lee, Mihn-Sook Jue
    The Korean Journal of Internal Medicine.2020; 35(4): 917.     CrossRef
  • Association between Use of Hydrochlorothiazide and Nonmelanoma Skin Cancer: Common Data Model Cohort Study in Asian Population
    Seung Min Lee, Kwangsoo Kim, Jihoon Yoon, Sue K. Park, Sungji Moon, Sang Eun Lee, JiSeon Oh, Sooyoung Yoo, Kwang-Il Kim, Hyung-Jin Yoon, Hae-Young Lee
    Journal of Clinical Medicine.2020; 9(9): 2910.     CrossRef
  • Assessment of deep neural networks for the diagnosis of benign and malignant skin neoplasms in comparison with dermatologists: A retrospective validation study
    Seung Seog Han, Ik Jun Moon, Seong Hwan Kim, Jung-Im Na, Myoung Shin Kim, Gyeong Hun Park, Ilwoo Park, Keewon Kim, Woohyung Lim, Ju Hee Lee, Sung Eun Chang, Harald Kittler
    PLOS Medicine.2020; 17(11): e1003381.     CrossRef
  • Usefulness of full-thickness skin grafting from the infraclavicular area for facial reconstruction
    Jae Kyoung Kang, Jae Seong Lee, Byung Min Yun, Myoung Soo Shin
    Archives of Craniofacial Surgery.2020; 21(6): 357.     CrossRef
  • Aggressive cutaneous squamous cell carcinoma of the scalp
    Sangwoo Suk, Hyun Woo Shin, Kun Chul Yoon, Junekyu Kim
    Archives of Craniofacial Surgery.2020; 21(6): 363.     CrossRef
  • Occupational differences in standardized mortality ratios for non-melanotic skin cancer and melanoma in exposed areas among individuals with Fitzpatrick skin types III and IV
    Jaeyong Shin, Kee Yang Chung, Eun-Cheol Park, Kyoung Ae Nam, Jin-Ha Yoon
    Journal of Occupational Health.2019; 61(3): 235.     CrossRef
  • Human health in relation to exposure to solar ultraviolet radiation under changing stratospheric ozone and climate
    R. M. Lucas, S. Yazar, A. R. Young, M. Norval, F. R. de Gruijl, Y. Takizawa, L. E. Rhodes, C. A. Sinclair, R. E. Neale
    Photochemical & Photobiological Sciences.2019; 18(3): 641.     CrossRef
  • Local recurrence and metastasis in patients with malignant melanomas after surgery: A single-center analysis of 202 patients in South Korea
    Soo Ick Cho, Jaewon Lee, Gwanghyun Jo, Sang Wha Kim, Kyung Won Minn, Ki Yong Hong, Seong Jin Jo, Kwang Hyun Cho, Byung Jun Kim, Je-Ho Mun, Aamir Ahmad
    PLOS ONE.2019; 14(3): e0213475.     CrossRef
  • Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
    Jiyoung Rhee, Jaemin Jo, Sang-Hoon Han, Jung-Mi Kwon
    Annals of Dermatology.2019; 31(2): 201.     CrossRef
  • Analysis of Judicial Precedents Cases Regarding Skin Cancer from 1997 to 2017 in Republic of Korea
    Su Hwan Shin, Won Lee, So Yoon Kim, Gwanghyun Jo, Je-Ho Mun, Soo Ick Cho
    Annals of Dermatology.2019; 31(3): 300.     CrossRef
  • Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
    Jiyun Lee, Su Jin Lee, Kyung Kim, Seung Tae Kim, Kee-Taek Jang, Jeeyun Lee
    BMC Cancer.2019;[Epub]     CrossRef
  • BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis
    Kyueng-Whan Min, Ji-Young Choe, Mi Jung Kwon, Hye Kyung Lee, Ho Suk Kang, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Yun Joong Kim, Nan Young Kim, Ho Young Kim
    Pathology - Research and Practice.2019; 215(12): 152671.     CrossRef
  • Melanoma Growth Analysis in Blood Serum and Tissue Using Xenograft Model with Response to Cold Atmospheric Plasma Activated Medium
    Manish Adhikari, Bhawana Adhikari, Neha Kaushik, Su-Jae Lee, Nagendra Kumar Kaushik, Eun Ha Choi
    Applied Sciences.2019; 9(20): 4227.     CrossRef
  • Sex‑biased differences in the correlation between epithelial‑to‑mesenchymal transition‑associated genes in cancer cell lines
    Sun Kim, Seungeun Lee, Eunhye Lee, Hyesol Lim, Ji Shin, Joohee Jung, Sang Kim, Aree Moon
    Oncology Letters.2019;[Epub]     CrossRef
  • Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years
    Andréia C. de Melo, Alberto J.A. Wainstein, Antonio C. Buzaid, Luiz C.S. Thuler
    Melanoma Research.2018; 28(6): 629.     CrossRef
  • 14,736 View
  • 445 Download
  • 47 Web of Science
  • 52 Crossref
Close layer
Risky Lifestyle Behaviors among Gastric Cancer Survivors Compared with Matched Non-cancer Controls: Results from Baseline Result of Community Based Cohort Study
Minkyung Kim, Kui Son Choi, Mina Suh, Jae Kwan Jun, Kumban Walter Chuck, Boyoung Park
Cancer Res Treat. 2018;50(3):738-747.   Published online July 24, 2017
DOI: https://doi.org/10.4143/crt.2017.129
AbstractAbstract PDFPubReaderePub
Purpose
This study investigated the prevalence of smoking, drinking, and physical inactivity and the associated factors of these behaviors in gastric cancer survivors.
Materials and Methods
The baseline data from the nationwide cohort study was used. Four hundred thirty-seven gastric cancer survivors who survived ≥ 2 years from diagnosis and reported completion of treatment were matched with 4,370 controls according to age, sex, education, and household income.
Results
The prevalence rates of current smoking and drinking among gastric cancer survivors were 8.7% and 38.3%, which were significantly lower than those among matched controls (p ≤ 0.001), but the prevalence rates of physical inactivity were not significantly different (55.8% vs. 59.9%, p=0.248). In gastric cancer survivors, ≥ 5 years since cancer diagnosis and current drinking contributed to more current smoking; otherwise, age increment and femalewere associatedwith lower current smoking. Thosewith household income ≥ $2,000 and current smokers were more likely to drink and female showed less drinking. Female, currently employed state, and self-rated health status were associated with more physical inactivity.
Conclusion
Although gastric cancer survivors showed better health behaviors than controls, suggesting that the diagnosis of cancer may motivate individuals towards healthy behaviors, their current prevalence rates of smoking and drinking were still high, and more than 50% of them were physically inactive. Tailored interventions to improve their health behaviors considering associated factors for the gastric cancer survivors are necessary.

Citations

Citations to this article as recorded by  
  • Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities
    Era Cobani, Mohammed Najeeb Al Hallak, Anthony F. Shields, Jordan Maier, Thomas E. Kelly, Niren Naidoo, Miguel Tobon, Steve Kim, Eliza W. Beal
    Journal of Gastrointestinal Cancer.2024; 55(2): 519.     CrossRef
  • Characterizing risky alcohol use, cigarette smoking, e-cigarette use, and physical inactivity among cancer survivors in the USA—a cross-sectional study
    Jiyeong Kim, Theresa H. Keegan
    Journal of Cancer Survivorship.2023; 17(6): 1799.     CrossRef
  • Risk of Metabolic Syndrome and Fatty Liver Diseases in Gastric Cancer Survivors: A Propensity Score-Matched Analysis
    Sang Jo Han, Su Jung Baik, Young Hoon Yoon, Jie Hyun Kim, Hye Sun Lee, Soyoung Jeon, Hyojin Park
    The Korean Journal of Gastroenterology.2023; 81(4): 154.     CrossRef
  • Factors related to Cancer Preventive Behavior among Patients with Early Gastric Cancer who Underwent Endoscopic Submucosal Dissection
    Sunghye Choo, Sanghee Kim, Yong Chan Lee, Eunsung Kim
    Asian Oncology Nursing.2023; 23(2): 47.     CrossRef
  • MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A
    Haithm Mousa, Menglang Yuan, Xinsheng Zhang, Xiaomeng Li, Abdullah Shopit, Marwan Almoiliqy, Mohammed Alshwmi, Aisha Al-Dherasi, Yue Xu, Yunfei Zuo
    Cancer Cell International.2020;[Epub]     CrossRef
  • Assessment of Diet Quality and Adherence to Dietary Guidelines in Gastrointestinal Cancer Survivors: A Cross-Sectional Study
    Sara Moazzen, Francisco O. Cortés-Ibañez, Barbara L. van Leeuwen, Behrooz Z. Alizadeh, Geertruida H. de Bock
    Nutrients.2020; 12(8): 2232.     CrossRef
  • miR-300/FA2H affects gastric cancer cell proliferation and apoptosis
    Bo Hong, Jie Li, Chunxiao Huang, Tao Huang, Mengpei Zhang, Lijiang Huang
    Open Medicine.2020; 15(1): 882.     CrossRef
  • Association between Dietary Habits and Self-rated Health According to Sasang Constitution
    Kyoungsik Jeong, Hoseok Kim, Siwoo Lee, Younghwa Baek
    Journal of Physiology & Pathology in Korean Medicine.2020; 34(1): 53.     CrossRef
  • Factors Associated with Health Behaviors in Thyroid Cancer Survivors
    Junghyun Yoon, Boyoung Park
    Journal of Cancer Prevention.2020; 25(3): 173.     CrossRef
  • Discovery of potential therapeutic targets for non-small cell lung cancer using high-throughput metabolomics analysis based on liquid chromatography coupled with tandem mass spectrometry
    Hong-dan Xu, Wen Luo, Yuanlong Lin, Jiawen Zhang, Lijuan Zhang, Wei Zhang, Shu-ming Huang
    RSC Advances.2019; 9(19): 10905.     CrossRef
  • Compliance with Multiple Health Behaviour Recommendations: A Cross-Sectional Comparison between Female Cancer Survivors and Those with no Cancer History
    Daniel N Tollosa, Meredith Tavener, Alexis Hure, Erica L James
    International Journal of Environmental Research and Public Health.2019; 16(8): 1345.     CrossRef
  • El consumo de alcohol en los supervivientes al cáncer: estado de la cuestión y propuestas para el desarrollo de intervenciones psicológicas
    Francisco García-Torres, Francisco J. Alós, Rosario Castillo-Mayén
    Psicooncología.1970; 15(1): 65.     CrossRef
  • 8,410 View
  • 180 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
Lung Cancer Screening with Low-Dose CT in Female Never Smokers: Retrospective Cohort Study with Long-term National Data Follow-up
Hyae Young Kim, Kyu-Won Jung, Kun Young Lim, Soo-Hyun Lee, Jae Kwan Jun, Jeongseon Kim, Bin Hwangbo, Jin Soo Lee
Cancer Res Treat. 2018;50(3):748-756.   Published online July 17, 2017
DOI: https://doi.org/10.4143/crt.2017.312
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Because of growing concerns about lung cancer in female never smokers, chest low-dose computed tomography (LDCT) screening is often performed although it has never shown clinical benefits. We examinewhether or not female never smokers really need annual LDCT screening when the initial LDCT showed negative findings.
Materials and Methods
This retrospective cohort study included 4,365 female never smokers aged 40 to 79 years who performed initial LDCT from Aug 2002 to Dec 2007. Lung cancer diagnosis was identified from the Korea Central Cancer Registry Database registered until December 31, 2013. We calculated the incidence, cumulative probability, and standardized incidence ratio (SIR) of lung cancer by Lung Imaging Reporting and Data System (Lung-RADS) categories showed on initial LDCT.
Results
After median follow-up of 9.69 years, 22 (0.5%) had lung cancer. Lung cancer incidence for Lung-RADS category 4 was 1,848.4 (95% confidence interval [CI], 1,132.4 to 3,017.2) per 100,000 person-years and 16.4 (95% CI, 7.4 to 36.4) for categories 1, 2, and 3 combined. The cumulative probability of lung cancer for category 4 was 10.6% at 5 years and 14.8% at 10 years while they were 0.07% and 0.17% when categories 1, 2, and 3 were combined. The SIR for subjects with category 4 was 43.80 (95% CI, 25.03 to 71.14), which was much higher than 0.47 (95% CI, 0.17 to 1.02) for categories 1, 2, and 3 combined.
Conclusion
Considering the low risk of lung cancer development in female never smokers, it seems unnecessary to repeat annual LDCT screening for at least 5 years or even longer unless the initial LDCT showed Lung-RADS category 4 findings.

Citations

Citations to this article as recorded by  
  • Lung cancer screening for never smokers: current evidence and future directions
    Kay Choong See
    Singapore Medical Journal.2024;[Epub]     CrossRef
  • Cooking oil fume exposure and Lung-RADS distribution among school cafeteria workers of South Korea
    Minjun Kim, Yangho Kim, A Ram Kim, Woon Jung Kwon, Soyeoun Lim, Woojin Kim, Cheolin Yoo
    Annals of Occupational and Environmental Medicine.2024;[Epub]     CrossRef
  • Distribution of Solid Lung Nodules Presence and Size by Age and Sex in a Northern European Nonsmoking Population
    Jiali Cai, Marleen Vonder, Gert Jan Pelgrim, Mieneke Rook, Gerdien Kramer, Harry J.M. Groen, Geertruida H. de Bock, Rozemarijn Vliegenthart, Albert de Roos
    Radiology.2024;[Epub]     CrossRef
  • Toward More Effective Lung Cancer Risk Stratification to Empower Screening Programs for the Asian Nonsmoking Population
    Fu-Zong Wu, Yeun-Chung Chang
    Journal of the American College of Radiology.2023; 20(2): 156.     CrossRef
  • ACR Appropriateness Criteria® Lung Cancer Screening: 2022 Update
    Kim L. Sandler, Travis S. Henry, Arya Amini, Saeed Elojeimy, Aine Marie Kelly, Christopher T. Kuzniewski, Elizabeth Lee, Maria D. Martin, Michael F. Morris, Neeraja B. Peterson, Constantine A. Raptis, Gerard A. Silvestri, Arlene Sirajuddin, Betty C. Tong,
    Journal of the American College of Radiology.2023; 20(5): S94.     CrossRef
  • Performance of Lung-RADS in different target populations: a systematic review and meta-analysis
    Yifei Mao, Jiali Cai, Marjolein A. Heuvelmans, Rozemarijn Vliegenthart, Harry J. M. Groen, Matthijs Oudkerk, Marleen Vonder, Monique D. Dorrius, Geertruida H. de Bock
    European Radiology.2023; 34(3): 1877.     CrossRef
  • Preoperative computed tomography-guided patent blue localization for pulmonary nodules
    Po-Chih Chang, Shah-Hwa Chou, Che-Yu Chuang, I-Hsiao Yang, Yu-Wei Liu, Ming-Cheng Shi, Reu-Sheng Sheu, Ting-Wei Chang
    Formosan Journal of Surgery.2022; 55(3): 102.     CrossRef
  • Lung cancer screening in never-smokers: facts and remaining issues
    Maurizio V. Infante, Giuseppe Cardillo
    European Respiratory Journal.2020; 56(5): 2002949.     CrossRef
  • Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers
    Yeon Wook Kim, Hye-Rin Kang, Byoung Soo Kwon, Sung Yoon Lim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
    European Respiratory Journal.2020; 56(5): 2000177.     CrossRef
  • Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model
    Li-Hsin Chien, Chung-Hsing Chen, Tzu-Yu Chen, Gee-Chen Chang, Ying-Huang Tsai, Chin-Fu Hsiao, Kuan-Yu Chen, Wu-Chou Su, Wen-Chang Wang, Ming-Shyan Huang, Yuh-Min Chen, Chih-Yi Chen, Sheng-Kai Liang, Chung-Yu Chen, Chih-Liang Wang, Mei-Hsuan Lee, Ren-Hua C
    Cancer Epidemiology, Biomarkers & Prevention.2020; 29(2): 452.     CrossRef
  • Role of Low-Dose Computerized Tomography in Lung Cancer Screening among Never-Smokers
    Hye-Rin Kang, Jun Yeun Cho, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
    Journal of Thoracic Oncology.2019; 14(3): 436.     CrossRef
  • Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018
    Haval Balata, Kwun M. Fong, Lizza E. Hendriks, Stephen Lam, Jamie S. Ostroff, Nir Peled, Ning Wu, Charu Aggarwal
    Journal of Thoracic Oncology.2019; 14(9): 1513.     CrossRef
  • 14,376 View
  • 356 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013
Dohun Kim, So Young Kim, Beomseok Suh, Jong Hyock Park
Cancer Res Treat. 2018;50(3):757-767.   Published online September 4, 2017
DOI: https://doi.org/10.4143/crt.2017.050
AbstractAbstract PDFPubReaderePub
Purpose
Our study aimed to report the annual changes in lung cancer statistics and analyze trends in sociodemographic, medical, and financial factors from 2003 to 2013 in the national database from the Korean National Health Insurance (KNHI).
Materials and Methods
Among 7,489 patients with code C34 in KNHI database, only lung cancer patients newly diagnosed after 2003 were included in the study population, for a total of 4,582 patients. Descriptive statistics were used to characterize treatment patterns and medical costs according to sociodemographic factors.
Results
Approximately 70% of subjects were male, and the mean age was 67 years. Around 46% of patients were over 70 years old, and 12% were over 80 years old. The medical costs were highest for patients younger than 60 and lowest for those over 80 years old. Surgery was more common in younger patients, while “no treatment” increased greatly with age. In trend analysis, the proportions of aging (p for trend < 0.001), female (p for trend=0.003), metropolitan/urban (p for trend=0.041), and lowest or highest-income patients (p for trend=0.004) increased over time, along with the prevalence of surgery as the primary treatment (p for trend < 0.001). There was also a trend with regard to change in medical costs (p for trend < 0.001), in that those of surgery and radiotherapy increased.
Conclusion
Surgery as a curative treatment has increased over the past decade. However, the elderly, suburban/rural residents, and low-income patients were more likely to be untreated. Therefore, active measures are required for these increasingly vulnerable groups.

Citations

Citations to this article as recorded by  
  • Effect of Perioperative Factors on Short-Term Outcomes in Patients with Non-Small Cell Lung Cancer Over 60 Years of Age
    Wenzhi Zhu, Jiaonan Yang, Xiaoyi Wang, Xinqiang Ji, Hongyu Tan
    International Journal of General Medicine.2024; Volume 17: 5453.     CrossRef
  • Trend of lung cancer surgery, hospital selection, and survival between 2005 and 2016 in South Korea
    Dohun Kim, Gil‐Won Kang, Hoyeon Jang, Jun Yeun Cho, Bumhee Yang, Hee Chul Yang, Jinwook Hwang
    Thoracic Cancer.2022; 13(2): 210.     CrossRef
  • Current Status of Lung Cancer and Surgery Based on Studies Using a Nationwide Database
    Dohun Kim, Jung-Won Lee
    Journal of Chest Surgery.2022; 55(1): 1.     CrossRef
  • Association of institutional transition of cancer care with mortality in elderly patients with lung cancer: a retrospective cohort study using national claim data
    Kyu-Tae Han, Jongwha Chang, Dong-Woo Choi, Seungju Kim, Dong Jun Kim, Yoon-Jung Chang, Sun Jung Kim
    BMC Cancer.2022;[Epub]     CrossRef
  • Is time-to-treatment associated with higher mortality in Korean elderly lung cancer patients?
    Kyu-Tae Han, Woorim Kim, Areum Song, Yeong Jun Ju, Dong-Woo Choi, Seungju Kim
    Health Policy.2021; 125(8): 1047.     CrossRef
  • Estimating the disease burden of lung cancer attributable to residential radon exposure in Korea during 2006–2015: A socio-economic approach
    Juhwan Noh, Heeseon Jang, Jaelim Cho, Dae Ryong Kang, Tae Hyun Kim, Dong Chun Shin, Changsoo Kim
    Science of The Total Environment.2020; 749: 141573.     CrossRef
  • 21,767 View
  • 209 Download
  • 8 Web of Science
  • 6 Crossref
Close layer
Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer
Claudia Marchetti, Francesca De Felice, Anna Di Pinto, Alessia Romito, Angela Musella, Innocenza Palaia, Marco Monti, Vincenzo Tombolin, Ludovico Muzii, PierLuigi Benedetti Panici
Cancer Res Treat. 2018;50(3):768-776.   Published online July 19, 2017
DOI: https://doi.org/10.4143/crt.2017.141
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to develop nomograms for predicting the probability of overall survival (OS) and progression-free survival (PFS) in locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical surgery.
Materials and Methods
Nomograms to predict the 5-year OS rates and the 2-year PFS rates were constructed. Calibration plots were constructed, and concordance indices were calculated. Evaluated variableswere body mass index, age, tumor size, tumor histology, grading, lymphovascular space invasion, positive parametria, and positive lymph nodes.
Results
In total 245 patients with locally advanced cervical cancer who underwent neoadjuvant chemotherapy and radical surgery were included for the construction of the nomogram. The 5-year OS and PFS were 72.6% and 66%, respectively. Tumor size, grading, and parametria status affected the rate of OS, whereas tumor size and positive parametria were the main independent PFS prognostic factors.
Conclusion
We constructed a nomogram based on clinicopathological features in order to predict 2-year PFS and 5-year OS in locally advanced cervical cancer primarily treated with neoadjuvant chemotherapy followed by radical surgery. This tool might be particularly helpful for assisting in the follow-up of cervical cancer patients who have not undergone concurrent chemoradiotherapy.

Citations

Citations to this article as recorded by  
  • Plasma-based proteomic and metabolomic characterization of lung and lymph node metastases in cervical cancer patients
    Yue Feng, Zijian Sun, Huan Zhang, Zhao Wang, Lichao Wang, Hui Ye, Xiaojing Zhang, Zhuomin Yin, Juan Ni, Jingkui Tian, Hanmei Lou, Xiaojuan Lv, Wei Zhu
    Journal of Pharmaceutical and Biomedical Analysis.2025; 253: 116521.     CrossRef
  • Dose prediction for cervical cancer in radiotherapy based on the beam channel generative adversarial network
    Hui Xie, Tao Tan, Hua Zhang, Qing Li
    Heliyon.2024; 10(18): e37472.     CrossRef
  • Systematic review and meta-analysis of prediction models used in cervical cancer
    Ashish Kumar Jha, Sneha Mithun, Umeshkumar B. Sherkhane, Vinay Jaiswar, Biche Osong, Nilendu Purandare, Sadhana Kannan, Kumar Prabhash, Sudeep Gupta, Ben Vanneste, Venkatesh Rangarajan, Andre Dekker, Leonard Wee
    Artificial Intelligence in Medicine.2023; 139: 102549.     CrossRef
  • Development and validation of radiomic signature for predicting overall survival in advanced-stage cervical cancer
    Ashish Kumar Jha, Sneha Mithun, Umeshkumar B. Sherkhane, Vinay Jaiswar, Sneha Shah, Nilendu Purandare, Kumar Prabhash, Amita Maheshwari, Sudeep Gupta, Leonard Wee, V. Rangarajan, Andre Dekker
    Frontiers in Nuclear Medicine.2023;[Epub]     CrossRef
  • Advanced cervical stump cancer after laparoscopic subtotal hysterectomy: a case report of imaging, laparoscopic staging and treatment approach
    Dimitrios Andrikos, Argyrios Andrikos, Antoine Naem, Olga Ebertz, Rajesh Devassy, Rudy Leon De Wilde, Michael Khamou, Harald Krentel
    BMC Women's Health.2023;[Epub]     CrossRef
  • Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
    Linlin Liu, Xianbo Deng, Shuang Guo, Shouhua Yang
    Diagnostic Pathology.2023;[Epub]     CrossRef
  • Influence of the Clinical Nursing Pathway on Nursing Outcomes and Complications of Cervical Carcinoma Patients Undergoing Chemotherapy via PICC
    Hongxia Tang, Li Gao, Yahui Li, Zhiqian Zhang
    Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
  • Current and future direction in treatment of HPV-related cervical disease
    Niloofar Khairkhah, Azam Bolhassani, Reza Najafipour
    Journal of Molecular Medicine.2022; 100(6): 829.     CrossRef
  • Machine Learning of Dose-Volume Histogram Parameters Predicting Overall Survival in Patients with Cervical Cancer Treated with Definitive Radiotherapy
    Zhiyuan Xu, Li Yang, Qin Liu, Hao Yu, Longhua Chen, Claudia Marchetti
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis
    Lin Qi, Ning Li, Aimin Lin, Xiuli Wang, Jianglin Cong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Jing Liu, Guyu Tang, Qin Zhou, Weilu Kuang
    Radiation Oncology.2022;[Epub]     CrossRef
  • The comparative study for survival outcome of locally advanced cervical cancer treated by neoadjuvant arterial interventional chemotherapy or intravenous chemotherapy followed by surgery or concurrent chemoradiation
    Yi Sun, Gailing Li, Panpan Hai, Yuan Cao, Pin Han, Yuchen Liu, Jing Wen, Yuanpei Wang, Xiaoran Cheng, Fang Ren
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Pembrolizumab for advanced cervical cancer: safety and efficacy
    Francesca De Felice, Elena Giudice, Giulia Bolomini, Maria Grazia Distefano, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
    Expert Review of Anticancer Therapy.2021; 21(2): 221.     CrossRef
  • Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer
    Yifan Feng, Ye Wang, Yangqin Xie, Shuwei Wu, Yuyang Li, Min Li
    BMC Cancer.2021;[Epub]     CrossRef
  • Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2)
    Setareh Akhavan, Abbas Alibakhshi, Mahdieh Parsapoor, Abbas Alipour, Elahe Rezayof
    BMC Cancer.2021;[Epub]     CrossRef
  • Macleayins A From Macleaya Promotes Cell Apoptosis Through Wnt/β-Catenin Signaling Pathway and Inhibits Proliferation, Migration, and Invasion in Cervical Cancer HeLa Cells
    Chunmei Sai, Wei Qin, Junyu Meng, Li-Na Gao, Lufen Huang, Zhen Zhang, Huannan Wang, Haixia Chen, Chaohua Yan
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Nomogram Predicting Overall Survival in Patients with FIGO II to III Squamous Cell Cervical Carcinoma Under Radical Radiotherapy: A Retrospective Analysis Based on 2018 FIGO Staging
    Lele Zang, Qin Chen, Xiaozhen Zhang, Xiaohong Zhong, Jian Chen, Yi Fang, An Lin, Min Wang
    Cancer Management and Research.2021; Volume 13: 9391.     CrossRef
  • Prediction of early response to concurrent chemoradiotherapy in cervical cancer: Value of multi-parameter MRI combined with clinical prognostic factors
    Xiaomin Zheng, Weiqian Guo, Jiangning Dong, Liting Qian
    Magnetic Resonance Imaging.2020; 72: 159.     CrossRef
  • Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study
    Guilan Xie, Ruiqi Wang, Li Shang, Cuifang Qi, Liren Yang, Liyan Huang, Wenfang Yang, Mei Chun Chung
    BMC Cancer.2020;[Epub]     CrossRef
  • SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines
    Xing Chen, Dongsheng Xiong, Liya Ye, Huichun Yang, Shuangshuang Mei, Jinhong Wu, Shanshan Chen, Ruoran Mi
    Cancer Chemotherapy and Pharmacology.2019; 83(4): 603.     CrossRef
  • Systemic therapy in cervical cancer: 30 years in review
    Michalis Liontos, Anastasios Kyriazoglou, Ioannis Dimitriadis, Meletios-Athanasios Dimopoulos, Aristotelis Bamias
    Critical Reviews in Oncology/Hematology.2019; 137: 9.     CrossRef
  • Adjuvant chemoradiotherapy versus radiotherapy in cervical cancer patients with intermediate-risk factors: A systematic review and meta-analysis
    Meng Li, Mengyang Hu, Yuanjian Wang, Xingsheng Yang
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2019; 238: 1.     CrossRef
  • Neoadjuvant chemotherapy followed by radical hysterectomy for stage IB2-to-IIB cervical cancer: a retrospective cohort study
    Lei Li, Ming Wu, Shuiqing Ma, Xianjie Tan, Sen Zhong
    International Journal of Clinical Oncology.2019; 24(11): 1440.     CrossRef
  • Immune check-point in cervical cancer
    F. De Felice, C. Marchetti, I. Palaia, R. Ostuni, L. Muzii, V. Tombolini, P. Benedetti Panici
    Critical Reviews in Oncology/Hematology.2018; 129: 40.     CrossRef
  • 9,486 View
  • 396 Download
  • 30 Web of Science
  • 24 Crossref
Close layer
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
Cheng Xu, Shi-Ping Yang, Yuan Zhang, Ling-Long Tang, Guan-Qun Zhou, Xu Liu, Yan-Ping Mao, Rui Guo, Wen-Fei Li, Lei Chen, Ai-Hua Lin, Ying Sun, Jun Ma
Cancer Res Treat. 2018;50(3):777-790.   Published online July 24, 2017
DOI: https://doi.org/10.4143/crt.2017.255
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLRmin). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLRmin on OS/DFS.
Results
Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLRmin (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLRmin ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect.
Conclusion
Occurrence of neutropenia, number of myelosuppression events, and high post-NLRmin during PF/TP IC-1 have prognostic value for poor survival in LANPC.

Citations

Citations to this article as recorded by  
  • Prospective clinical study of the efficacy and safety of different doses of PEG recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventing leukopenia/neutropenia caused by concurrent chemoradiotherapy for cervical cancer
    Tingting Yu, Yiwei Zhang, Jiawen Li, Zhuo Li, Rui Tong
    Holistic Integrative Oncology.2024;[Epub]     CrossRef
  • Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma
    Lu‐Lu Zhang, Xi Chen, Ying‐Ying Huang, Chi‐Xiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jia‐Yu Zhou, Hao‐Yang Huang, Xiang Guo, Xing Lv
    Cancer Medicine.2023; 12(13): 14084.     CrossRef
  • Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)
    Jun Wang, Baosheng Li
    Precision Radiation Oncology.2023; 7(3): 150.     CrossRef
  • Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition)
    Jun Wang, Baosheng Li
    Precision Radiation Oncology.2021; 5(1): 4.     CrossRef
  • Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma
    Yuanji Xu, Zijie Wu, Wangzhong Ye, Youping Xiao, Wei Zheng, Qinyan Chen, Penggang Bai, Zhizhong Lin, Chuanben Chen
    BMC Cancer.2021;[Epub]     CrossRef
  • Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
    Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
    IEEE Access.2021; 9: 98701.     CrossRef
  • Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma
    Dan Ou, Xiaoshen Wang, Mingyao Wu, Fen Xue, Yujiao Li, Chaosu Hu, Xiayun He
    Strahlentherapie und Onkologie.2020; 196(3): 252.     CrossRef
  • Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound
    Wei Wang, Dong Luo, Junlin Chen, Jinyun Chen, Yi Xia, Wenzhi Chen, Yan Wang
    Bioscience Reports.2020;[Epub]     CrossRef
  • 11,947 View
  • 239 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis
Jun Ho Ji, Young Saing Kim, Inkeun Park, Soon Il Lee, Rock Bum Kim, Joon Oh Park, Sung Yong Oh, In Gyu Hwang, Joung-Soon Jang, Haa-Na Song, Jung-Hun Kang
Cancer Res Treat. 2018;50(3):791-800.   Published online August 23, 2017
DOI: https://doi.org/10.4143/crt.2017.044
AbstractAbstract PDFPubReaderePub
Purpose
Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients.
Materials and Methods
Advanced BTC patientswith a good performance status (Eastern CooperativeOncologyGroup [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis.
Results
In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 ≤ 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA ≤ 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052).
Conclusion
Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.

Citations

Citations to this article as recorded by  
  • National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
    Faisal Saud Dar, Zaigham Abbas, Irfan Ahmed, Muhammad Atique, Usman Iqbal Aujla, Muhammad Azeemuddin, Zeba Aziz, Abu Bakar Hafeez Bhatti, Tariq Ali Bangash, Amna Subhan Butt, Osama Tariq Butt, Abdul Wahab Dogar, Javed Iqbal Farooqi, Faisal Hanif, Jahanzai
    World Journal of Gastroenterology.2024; 30(9): 1018.     CrossRef
  • Treatment patterns and survival in older adults with unresected nonmetastatic biliary tract cancers
    Ali Belkouz, Elise de Savornin Lohman, Jyothi R. Thumma, Bas Groot Koerkamp, Philip R. de Reuver, Martijn G.H. van Oijen, Cornelis J.A. Punt, Hari Nathan, Heinz-Josef Klümpen
    Journal of Geriatric Oncology.2023; 14(3): 101447.     CrossRef
  • Main causes of death in advanced biliary tract cancer
    Kana Kimura‐Seto, Yasushi Kojima, Shiori Komori, Yuya Hisada, Yuki Otake, Yuka Yanai, Akiko Saito, Naoki Akazawa, Yasuo Tanaka, Chizu Yokoi, Mikio Yanase, Junichi Akiyama, Natsuyo Yamamoto, Kazuhiko Yamada
    Cancer Medicine.2023; 12(9): 10889.     CrossRef
  • A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
    Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
    Targeted Oncology.2023; 18(6): 837.     CrossRef
  • Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018
    Van Nghiem, Sarah Wood, Rekha Ramachandran, Grant Williams, Darryl Outlaw, Ravikumar Paluri, Young-il Kim, Olumide Gbolahan
    Cancer Control.2023;[Epub]     CrossRef
  • Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
    Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, Roberto Acosta-Dighero, Josefina Salazar, Marilina Santero, Adriana-G Meade, María Jesús Quintana, Gerardo Rodríguez-Grijalva, Anna Selva, Ivan Solà, Gerard Urrútia, Xavier Bonfill Cosp
    Clinical Epidemiology.2023; Volume 15: 1069.     CrossRef
  • 8,153 View
  • 213 Download
  • 8 Web of Science
  • 6 Crossref
Close layer
Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
Seho Park, Ja Seung Koo, Gun Min Kim, Joohyuk Sohn, Seung Il Kim, Young Up Cho, Byeong-Woo Park, Vivian Youngjean Park, Jung Hyun Yoon, Hee Jung Moon, Min Jung Kim, Eun-Kyung Kim
Cancer Res Treat. 2018;50(3):801-812.   Published online August 17, 2017
DOI: https://doi.org/10.4143/crt.2017.210
AbstractAbstract PDFPubReaderePub
Purpose
Sentinel lymph node biopsy (SLNB) can be performed when node-positive disease is converted to node-negative status after neoadjuvant chemotherapy (NCT). Tattooing nodes might improve accuracy but supportive data are limited. This study aimed to investigate the feasibility of charcoal tattooing metastatic axillary lymph node (ALN) at presentation followed by SLNB after NCT in breast cancers.
Materials and Methods
Twenty patientswith cytology-proven node metastases prospectively underwent charcoal tattooing at diagnosis. SLNB using dual tracers and axillary surgery after NCT were then performed. The detection rate of tattooed node and diagnostic performance of SLNB were analyzed.
Results
All patients underwent charcoal tattooingwithout significant morbidity. Sentinel and tattooed nodes could be detected during surgery after NCT. Nodal pathologic complete response was achieved in 10 patients. Overall sensitivity, false-negative rate (FNR), negative predictive value, and accuracy of hot/blue SLNB were 80.0%, 20.0%, 83.3%, and 90.0%, respectively. Retrieving more nodes and favorable nodal response were associated with improved performance. The best accuracy was observed when excised tattooed node was calculated together (FNR, 0.0%). Cold/non-blue tattooed nodes of five patients were removed during non-sentinel axillary surgery but clinicopathological parameters did not differ compared to patients with hot/blue tattooed node detected during SLNB, suggesting the importance of the tattooing procedure itself to improve performance.
Conclusion
Charcoal tattooing of cytology-confirmed metastatic ALN at presentation is technically feasible and does not limit SLNB after NCT. The tattooing procedure without additional preoperative localization is advantageous for improving the diagnostic performance of SLNB in this setting.

Citations

Citations to this article as recorded by  
  • Radiographic identification of a positive clipped axillary lymph node in a mastectomy specimen following neoadjuvant chemotherapy
    Andrew Seto, Cynthia Lin, Samantha Norden, Jamie Stratton, Moira O'Riordan, Helen Pass
    Radiology Case Reports.2024; 19(1): 435.     CrossRef
  • Peut-on surseoir au curage axillaire en cas de carcinome mammaire invasif avec envahissement ganglionnaire ?
    Susie Brousse, Clémentine Lafond, Martin Schmitt, Sophie Guillermet, Sébastien Molière, Carole Mathelin
    Gynécologie Obstétrique Fertilité & Sénologie .2024; 52(3): 132.     CrossRef
  • The Role of Level III Dissection in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy—A Prospective Study
    Rexeena V. Bhargavan, Nisha Prasannan, K.M. Jagathnath Krishna, Paul Augustine, Kurian Cherian
    South Asian Journal of Cancer.2024; 13(03): 170.     CrossRef
  • Melanin-Based Nanoparticles for Lymph Node Tattooing: Experimental, Histopathological and Ultrastructural Study
    Marta Baselga, Antonio Güemes, Cristina Yus, Teresa Alejo, Víctor Sebastián, Dolores Arribas, Gracia Mendoza, Eva Monleón, Manuel Arruebo
    Nanomaterials.2024; 14(13): 1149.     CrossRef
  • Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy
    Yuka Endo, Haruru Kotani, Nobuko Tamura, Kiyo Tanaka, Chiho Kudo, Masataka Sawaki, Masaya Hattori, Akiyo Yoshimura, Ayumi Kataoka, Kazuki Nozawa, Yuri Ozaki, Ayaka Isogai, Rie Komaki, Akira Nakakami, Nari Kureyama, Maho Kusudo, Waki Hosoda, Hidetaka Kawab
    Breast Cancer.2024; 31(6): 1130.     CrossRef
  • Oncological outcomes of selective axillary dissection with 4% carbon marking
    LUCAS ROSKAMP BUDEL, CLEVERTON CÉSAR SPAUTZ, MARIA HELENA LOUVEIRA, TERESA CRISTINA SANTOS CAVALCANTI, ALESSANDRA CORDEIRO FORNAZARI, PLINIO GASPERIN JUNIOR, LEONARDO NISSEN, VINICIUS MILANI BUDEL
    Revista do Colégio Brasileiro de Cirurgiões.2024;[Epub]     CrossRef
  • Desfechos oncológicos da dissecção axilar seletiva utilizando carvão a 4% como marcador
    LUCAS ROSKAMP BUDEL, CLEVERTON CÉSAR SPAUTZ, MARIA HELENA LOUVEIRA, TERESA CRISTINA SANTOS CAVALCANTI, ALESSANDRA CORDEIRO FORNAZARI, PLINIO GASPERIN JUNIOR, LEONARDO NISSEN, VINICIUS MILANI BUDEL
    Revista do Colégio Brasileiro de Cirurgiões.2024;[Epub]     CrossRef
  • Preclinical evaluation of polymer encapsulated carbon-based nano and microparticles for sentinel lymph node tattooing
    Marta Baselga, Antonio Güemes, Manuel Arruebo, Cristina Yus, Teresa Alejo, Víctor Sebastián, Gema Martínez, Dolores Arribas, Gracia Mendoza, Concepción Junquera, Eva Monleón
    Scientific Reports.2024;[Epub]     CrossRef
  • Biopsia del ganglio centinela y disección axilar dirigida en mujeres con cáncer de mama y axila positiva en el momento del diagnóstico: caminando hacia el futuro
    Paula Moral Rubio, Silvia Delgado García, Hortensia Ballester Galiana, Jose Ponce Lorenzo, Tina Martín Bayón, Gloria Peiró
    Revista de Senología y Patología Mamaria.2023; 36(1): 100402.     CrossRef
  • Estadificación ganglionar tras terapia sistémica primaria en mujeres con cáncer de mama y afectación ganglionar al diagnóstico
    Eva Acea-Figueira, Alejandra García-Novoa, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Paz Santiago Freijanes, Joaquín Mosquera Oses, Benigno Acea-Nebril
    Cirugía Española.2023; 101(6): 417.     CrossRef
  • Lymph node staging after primary systemic therapy in women with breast cancer and lymph node involvement at diagnosis
    Eva Acea-Figueira, Alejandra García-Novoa, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Paz Santiago Freijanes, Joaquín Mosquera Oses, Benigno Acea-Nebril
    Cirugía Española (English Edition).2023; 101(6): 417.     CrossRef
  • Carbon tattooing of axillary lymph nodes in breast cancer patients before neoadjuvant chemotherapy: A retrospective analysis
    Mauro Porpiglia, Fulvio Borella, Pierluigi Chieppa, Carola Brino, Ada Ala, Vincenzo Marra, Isabella Castellano, Chiara Benedetto
    Tumori Journal.2023; 109(3): 301.     CrossRef
  • Concomitant Use of Biopsy Clips and Wire Localization in Invasive Breast Cancer is Associated With Successful Clip Retrieval
    Jennifer H. Chen, Joe K. Canner, Kelly Myers, Melissa Camp
    Clinical Breast Cancer.2023; 23(3): e163.     CrossRef
  • Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study
    Xin Yang, Yao Li, Xiao-tian Ren, Lei Fan, Bin Hua
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data
    Shi-Qian Lin, Nguyen-Phong Vo, Yu-Chun Yen, Ka-Wai Tam
    Annals of Surgical Oncology.2022; 29(5): 3038.     CrossRef
  • Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers
    Jiqiao Yang, Tao He, Yunhao Wu, Zhoukai Fu, Qing Lv, Shan Lu, Xiaodong Wang, Hongjiang Li, Jing Wang, Jie Chen
    Breast Cancer Research and Treatment.2022; 192(3): 573.     CrossRef
  • Axillary Management: How Has Neoadjuvant Chemotherapy Changed Our Surgical Approach?
    Mara A. Piltin, Judy C. Boughey
    Current Breast Cancer Reports.2022; 14(1): 1.     CrossRef
  • Gezielte Entfernung axillärer Lymphknoten nach Kohlenstoffmarkierung bei Patientinnen mit primär systemisch behandeltem Mammakarzinom
    Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
    Senologie - Zeitschrift für Mammadiagnostik und -therapie.2022; 19(01): 49.     CrossRef
  • Gezielte Entfernung axillärer Lymphknoten nach Kohlenstoffmarkierung bei Patientinnen mit primär systemisch behandeltem Mammakarzinom
    Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
    TumorDiagnostik & Therapie.2022; 43(03): 197.     CrossRef
  • False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy
    Jana de Boniface, Jan Frisell, Thorsten Kühn, Ingrid Wiklander-Bråkenhielm, Karin Dembrower, Per Nyman, Athanasios Zouzos, Bernd Gerber, Toralf Reimer, Steffi Hartmann
    Breast Cancer Research and Treatment.2022; 193(3): 589.     CrossRef
  • Diagnostic accuracy of de‐escalated surgical procedure in axilla for node‐positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta‐analysis
    Yu‐xin Song, Zheng Xu, Ming‐xing Liang, Zhen Liu, Jun‐chen Hou, Xiu Chen, Di Xu, Yin‐jiao Fei, Jin‐hai Tang
    Cancer Medicine.2022; 11(22): 4085.     CrossRef
  • Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy
    Faina Nakhlis, Leah Portnow, Eva Gombos, Ayse Ece Cali Daylan, Jose Pablo Leone, Olga Kantor, Edward T. Richardson, Alice Ho, Samantha Armstrong Dunn, Nisha Ohri
    Current Problems in Surgery.2022; 59(9): 101191.     CrossRef
  • Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study
    Alejandra García-Novoa, Benigno Acea-Nebril, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Carmen Cereijo Garea, José Ramón Varela, Paz Santiago Freijanes, Silvia Antolín Novoa, Lourdes Calvo Martínez, Inma Díaz, Sofia Rodríguez Martíne
    Annals of Surgical Oncology.2021; 28(2): 958.     CrossRef
  • A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients
    Amit Goyal, Shama Puri, Andrea Marshall, Kalliope Valassiadou, Moin M. Hoosein, Amtul R. Carmichael, Gabriella Erdelyi, Nisha Sharma, Janet Dunn, Joanne York
    Breast Cancer Research and Treatment.2021; 185(2): 433.     CrossRef
  • Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial
    S Hartmann, T Kühn, J de Boniface, A Stachs, A Winckelmann, J Frisell, I Wiklander-Bråkenhielm, J Stubert, B Gerber, T Reimer
    British Journal of Surgery.2021; 108(3): 302.     CrossRef
  • Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review
    Vivian Man, Ava Kwong
    Breast Cancer Research and Treatment.2021; 186(3): 607.     CrossRef
  • Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?
    Marina Alarcón, Elvira Buch, Ana Julve, Marta Hernandorena, Marcos Tajahuerce, Héctor Rodríguez, Begoña Bermejo, Judith Ramírez, Octavio Burgués, Sandra Díaz, Gara M. Alcalá, Joaquín Ortega
    The Surgeon.2021; 19(6): 344.     CrossRef
  • The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis
    Parinita K. Swarnkar, Salim Tayeh, Michael J. Michell, Kefah Mokbel
    Cancers.2021; 13(7): 1539.     CrossRef
  • New horizons in imaging and surgical assessment of breast cancer lymph node metastasis
    Firouzeh Arjmandi, Ann Mootz, Deborah Farr, Sangeetha Reddy, Basak Dogan
    Breast Cancer Research and Treatment.2021; 187(2): 311.     CrossRef
  • Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
    Yurina Maeshima, Takehiko Sakai, Akiko Ogiya, Yoko Takahashi, Yumi Miyagi, Yumi Kokubu, Tomo Osako, Yoshinori Ito, Shunji Takahashi, Shinji Ohno, Takayuki Ueno
    Scientific Reports.2021;[Epub]     CrossRef
  • Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy
    Gunay Gurleyik, Sibel Aydin Aksu, Fügen Aker, Kubra Kaytaz Tekyol, Eda Tanrikulu, Emin Gurleyik
    Annals of Surgical Treatment and Research.2021; 100(6): 305.     CrossRef
  • Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer
    Vijayashree Murthy, Jessica Young, Yoshihisa Tokumaru, Marie Quinn, Stephen B. Edge, Kazuaki Takabe
    Cancers.2021; 13(16): 4167.     CrossRef
  • Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer
    Marlen Pajcini, Irene Wapnir, Jacqueline Tsai, Joanne Edquilang, Wendy DeMartini, Debra Ikeda
    Journal of Breast Imaging.2021; 3(5): 583.     CrossRef
  • Targeted Removal of Axillary Lymph Nodes After Carbon Marking in Patients with Breast Cancer Treated with Primary Chemotherapy
    Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
    Geburtshilfe und Frauenheilkunde.2021; 81(10): 1121.     CrossRef
  • Axillary Imaging Following a New Invasive Breast Cancer Diagnosis—A Radiologist’s Dilemma
    Vandana Dialani, Basak Dogan, Katerina Dodelzon, Brian N Dontchos, Neha Modi, Lars Grimm
    Journal of Breast Imaging.2021; 3(6): 645.     CrossRef
  • Selective Extirpation of Tattooed Lymph Node in Combination with Sentinel Lymph Node Biopsy in the Management of Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy
    Lukas Dostalek, Andrej Cerny, Petra Saskova, David Pavlista
    Breast Care.2021; 16(6): 623.     CrossRef
  • False Negativity of Targeted Axillary Dissection in Breast Cancer
    George Kirkilesis, Anastasia Constantinidou, Michalis Kontos
    Breast Care.2021; 16(5): 532.     CrossRef
  • Synchronous early‑stage breast cancer and axillary follicular lymphoma diagnosed by core needle biopsy: A case report
    Ryotaro Eto, Rikiya Nakamura, Naohito Yamamoto, Toshiko Miyaki, Shoko Hayama, Itaru Sonoda, Makiko Itami, Hideki Tsujimura, Hideyuki Hashimoto, Masayuki Otsuka
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019
    Nina Ditsch, Isabel T. Rubio, Maria L. Gasparri, Jana de Boniface, Thorsten Kuehn
    Current Opinion in Obstetrics & Gynecology.2020; 32(1): 91.     CrossRef
  • Targeted axillary dissection after neoadjuvant systemic therapy in patients with node‐positive breast cancer
    Kavitha Kanesalingam, Nina Sriram, Ghaith Heilat, E ‐Ern Ng, Farid Meybodi, Elisabeth Elder, Meagan Brennan, James French
    ANZ Journal of Surgery.2020; 90(3): 332.     CrossRef
  • Initial results of a novel technique of clipped node localization in breast cancer patients postneoadjuvant chemotherapy: Skin Mark clipped Axillary nodes Removal Technique (SMART trial)
    Geok Hoon Lim, Sze Yiun Teo, Mihir Gudi, Ruey Pyng Ng, Jinnie Pang, Yia Swam Tan, Yien Sien Lee, John C. Allen, Lester Chee Hao Leong
    Cancer Medicine.2020; 9(6): 1978.     CrossRef
  • Targeted axillary dissection of carbon‐tattooed metastatic lymph nodes in combination with post–neo‐adjuvant sentinel lymph node biopsy using 1% methylene blue in breast cancer patients
    Emad Khallaf, Rasha Wessam, Mohamed Abdoon
    The Breast Journal.2020; 26(5): 1061.     CrossRef
  • Marking axillary nodes with 4% carbon microparticle suspension before neoadjuvant chemotherapy improves sentinel node identification rate and axillary staging
    Cleverton Cesar Spautz, Eduardo Schunemann Junior, Lucas Roskamp Budel, Tereza Cristina Santos Cavalcanti, Maria Helena Louveira, Plinio Gasperin Junior, Leonardo Paese Nissen, Bernardo Passos Sobreiro, Maíra Teixeira Dória, Cicero Andrade Urban, Vinicius
    Journal of Surgical Oncology.2020; 122(2): 164.     CrossRef
  • Targeted Axillary Dissection for Patients Who Convert to Clinically Node Negative After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
    Kandice Ludwig, Amanda L. Kong
    Current Breast Cancer Reports.2020; 12(4): 391.     CrossRef

  • Clinical Practice Status of Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer Patients in China: A Multicenter Study


    Juliang Zhang, Ting Wang, Changjiao Yan, Meiling Huang, Zhimin Fan, Rui Ling
    Clinical Epidemiology.2020; Volume 12: 917.     CrossRef
  • Feasibility of preoperative tattooing of percutaneously biopsied axillary lymph node: an experimental pilot study
    Abida K. Sattar, Basim Ali, Imrana Masroor, Shaista Afzal, Mohammad Usman Tariq, Romana Idrees, Maseeh Uzzaman, Wardah Khalid
    Pilot and Feasibility Studies.2020;[Epub]     CrossRef
  • Effectiveness of preoperative ultrasound-guided charcoal tattooing for localization of metastatic melanoma
    Ji Hyun Lee, Hyun Su Kim, Young Cheol Yoon, Min Je Kim, Min Jae Cha, Jung-Han Kim
    Ultrasonography.2020; 39(4): 376.     CrossRef
  • To Evaluate the Accuracy of Axillary Staging Using Ultrasound and Ultrasound-Guided Fine-Needle Aspiration Cytology (USG-FNAC) in Early Breast Cancer Patients—a Prospective Study
    Rashpal Singh, S. V. S. Deo, Ekta Dhamija, Sandeep Mathur, Sanjay Thulkar
    Indian Journal of Surgical Oncology.2020; 11(4): 726.     CrossRef
  • Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques
    Alison Laws, Michelle C. Specht
    Current Breast Cancer Reports.2020; 12(4): 317.     CrossRef
  • Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer
    Janine M. Simons, Thiemo J. A. van Nijnatten, Carmen C. van der Pol, Ernest J. T. Luiten, Linetta B. Koppert, Marjolein L. Smidt
    Annals of Surgery.2019; 269(3): 432.     CrossRef
  • Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment
    Ioannis Natsiopoulos, Stavros Intzes, Triantafyllos Liappis, Konstantinos Zarampoukas, Thomas Zarampoukas, Vasiliki Zacharopoulou, Konstantinos Papazisis
    Clinical Breast Cancer.2019; 19(3): 208.     CrossRef
  • Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node
    Rupa Patel, Wendy MacKerricher, Jacqueline Tsai, Nicole Choy, Jafi Lipson, Debra Ikeda, Sunita Pal, Wendy De Martini, Kimberly H. Allison, Irene L. Wapnir
    Annals of Surgical Oncology.2019; 26(8): 2452.     CrossRef
  • Node positive breast cancer: Concordance between baseline PET/CT and sentinel node assessment after neoadjuvant therapy
    Oscar Leopoldo Christin, Jonathan Kuten, Einat Even-Sapir, Joseph Klausner, Tehillah S. Menes
    Surgical Oncology.2019; 30: 1.     CrossRef
  • Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques
    Jennifer M. Racz, Abigail S. Caudle
    Annals of Surgical Oncology.2019; 26(10): 3040.     CrossRef
  • Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer
    J M Simons, M L M A van Pelt, A W K S Marinelli, M E Straver, A M Zeillemaker, L M Pereira Arias-Bouda, T J A van Nijnatten, L B Koppert, K K Hunt, M L Smidt, E J T Luiten, C C van der Pol
    British Journal of Surgery.2019; 106(12): 1632.     CrossRef
  • Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study
    Won Hwa Kim, Hye Jung Kim, See Hyung Kim, Jin Hyang Jung, Ho Yong Park, Jeeyeon Lee, Wan Wook Kim, Ji Young Park, Yee Soo Chae, Soo Jung Lee
    BMC Cancer.2019;[Epub]     CrossRef
  • Conservative Management of Positive Axilla After Neoadjuvant Systemic Therapy—The Need for, and Review of, Techniques Used for Lymph Node Localization
    Matthew Green, Foteini Neamonitou, Raghavan Vidya
    Clinical Breast Cancer.2018; 18(5): e739.     CrossRef
  • Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
    Judy C. Boughey, Michael D. Alvarado, Rachael B. Lancaster, W. Fraser Symmans, Rita Mukhtar, Jasmine M. Wong, Cheryl A. Ewing, David A. Potter, Todd M. Tuttle, Tina J. Hieken, Jodi M. Carter, James W. Jakub, Henry G. Kaplan, Claire L. Buchanan, Nora T. Ja
    npj Breast Cancer.2018;[Epub]     CrossRef
  • 12,268 View
  • 360 Download
  • 57 Web of Science
  • 58 Crossref
Close layer
Human Papillomavirus Genotype-Specific Persistence and Potential Risk Factors among Korean Women: Results from a 2-Year Follow-up Study
Cecile Ingabire, Min Kyung Lim, Young-Joo Won, Jin-Kyoung Oh
Cancer Res Treat. 2018;50(3):813-822.   Published online August 17, 2017
DOI: https://doi.org/10.4143/crt.2017.340
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
High-risk human papillomavirus (HPV) infection progression should be considered a critical factor for preventing cervical cancer, although most infections are transient and rarely persist. This study aimed to examine the specific types of HPV infections, their change patterns, and the potential risk factors among Korean women.
Materials and Methods
We included 4,588 women who visited hospitals in Busan and Suwon for cervical cancer screening, and 1,224 of thesewomen attended a 2-yearfollow-up. Infection statuswas evaluated using HPV DNA testing (Hybrid Capture 2) and genotyping testing (Linear Array). Data regarding the potential risk factors for HPV infection were collected by trained nurses using structured questionnaires.
Results
Among the 1,224 women (mean age, 47 years), 105 women (8.6%) were HPV-positive at baseline. HPV infections had been cleared among 92 women (87.6%) within 2 years. Only 13 infections (12.4%) were remained, and the 10 cases of them are high-risk HPV types including genotype 33, 45, 16, 35, and 52. Among women who were negative at baseline, the HPV incidence was 4.8%. The HPV incidence was marginally associated with having multiple sexual partners (odds ratio, 2.0; 95% confidence interval, 1.0 to 3.9), although it was not significantly associated with HPV persistence.
Conclusion
Most HPV infections (88%) among Korean women were cleared within 2 years, with only a small number of persistent infections. The persistent HPV genotypes were different in our study, compared to those from previous studies. Having multiple sexual partners was associated with acquiring a HPV infection, but not with persistence.

Citations

Citations to this article as recorded by  
  • Investigation of Human Papillomavirus (HPV) Frequency and Genotype Analysis in Cervical Samples
    Yeliz Çetinkol, Selahattin Ünlü, Melahat Gürbüz, Cengiz Demir
    Journal of Biotechnology and Strategic Health Research.2024; 8(1): 50.     CrossRef
  • Global pattern of persistent human papillomavirus infection in female genital tract: An update system review and meta-analysis
    Ming Zhao, Peipei Kang, Liling Zhu, Dan Zhou, Meimei Cui, Min Zhang, Jingjing Jia, Limei Luo
    iScience.2024; 27(10): 110991.     CrossRef
  • Analysis of Human Papilloma Virus Infection and Genotype in 336 Patients
    秋培 谭
    Hans Journal of Biomedicine.2023; 13(02): 184.     CrossRef
  • Characteristic of persistent human papillomavirus infection in women worldwide: a meta–analysis
    Ming Zhao, Dan Zhou, Min Zhang, Peipei Kang, Meimei Cui, Liling Zhu, Limei Luo
    PeerJ.2023; 11: e16247.     CrossRef
  • Factors associated with persistence and clearance of HPV16/18 among rural Chinese women: a cohort study in Wufeng, Hubei province
    Shuqi Pan, Wenshuang Wei, Xueying Du, Zhi Li, Jiyu Tuo, Min Zhang, Qing Liu
    Women & Health.2022; 62(4): 276.     CrossRef
  • Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women?
    Miriam Dellino, Eliano Cascardi, Antonio Simone Laganà, Giovanni Di Vagno, Antonio Malvasi, Rosanna Zaccaro, Katia Maggipinto, Gerardo Cazzato, Salvatore Scacco, Raffaele Tinelli, Alessandro De Luca, Marina Vinciguerra, Vera Loizzi, Antonella Daniele, Ett
    Infectious Agents and Cancer.2022;[Epub]     CrossRef
  • Alternative New Mono-scaled Quantitative Benefit–Risk Assessment of Human Papillomavirus Vaccine in Japan
    Tomoko Matsumoto, Naoki Matsumaru, Paul Scuffham, Pieter Neels, Katsura Tsukamoto
    Therapeutic Innovation & Regulatory Science.2021; 55(1): 48.     CrossRef
  • Next‐generation sequencing for typing human papillomaviruses and predicting multi‐infections and their clinical symptoms
    Sang‐Yeon Kim, Kyung‐A Hwang, Ji‐Hoon Ann, Ji‐Hye Kim, Jae‐Hwan Nam
    Microbiology and Immunology.2021; 65(7): 273.     CrossRef
  • Association of age and viral factors with high-risk HPV persistence: A retrospective follow-up study
    Wending Li, Yifan Meng, Yi Wang, Xiaodong Cheng, Chen Wang, Songshu Xiao, Xiaofei Zhang, Zaixing Deng, Mengjun Hu, Pingrong Shen, Shengfeng Xu, Chenglin Fu, Wen Jiang, Bing Wu, Kezhen Li, Gang Chen, Juncheng Wei, Ling Xi, Junbo Hu, Ding Ma, Min Xue, Xing
    Gynecologic Oncology.2019; 154(2): 345.     CrossRef
  • Prevalence of HPV Among HIV-Negative Women of Child-Bearing Age in Lomé, Togo
    Yawo Tufa Nyasenu, Fifonsi A Gbeasor-Komlanvi, Sabi Abdul-Raouf Issa, Amivi Ehlan, Martin Kouame Tchankoni, Brice M Yambiyo, Mireille Prince-David, Mounerou Salou, Didier K Ekouevi, Anoumou Dagnra
    Future Virology.2019; 14(12): 783.     CrossRef
  • 9,954 View
  • 221 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
Hyery Kim, Heewon Seo, Yoomi Park, Byung-Joo Min, Myung-Eui Seo, Kyung Duk Park, Hee Young Shin, Ju Han Kim, Hyoung Jin Kang
Cancer Res Treat. 2018;50(3):823-834.   Published online September 4, 2017
DOI: https://doi.org/10.4143/crt.2017.351
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mercaptopurine (MP) is one of the main chemotherapeutics for acute lymphoblastic leukemia (ALL). To improve treatment outcomes, constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. We performed two-stage analyses to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients.
Materials and Methods
Targeted sequencing of 40 patients who exhibited definite MP intolerance was conducted using a novel panel of 211 pharmacogenetic-related genes, and subsequent analysis was performed with 185 patients.
Results
Using bioinformatics tools and genetic data, four functionally interesting variants were selected (ABCC4, APEX1, CYP1A1, and CYP4F2). Including four variants, 23 variants in 12 genes potentially linked to MP adverse reactions were selected as final candidates for subsequent analysis in 185 patients. Ultimately, a variant allele in APEX1 rs2307486was found to be strongly associated with MP-induced neutropenia that occurred within 28 days of initiating MP (odds ratio, 3.44; p=0.02). Moreover, the cumulative incidence of MP-related neutropenia was significantly higher in patients with APEX1 rs2307486 variants, as GG genotypes were associated with the highest cumulative incidence (p < 0.01). NUDT15 rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01).
Conclusion
We have identified that APEX1 rs2307486 variants conferred an increased risk of MP-related early onset neutropenia. APEX1 and NUDT15 both contribute to cell protection from DNA damage or misincorporation, so alleles that impair the function of either gene may affect MP sensitivities, thereby inducing MP-related neutropenia.

Citations

Citations to this article as recorded by  
  • Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response
    Ashwin Kamath, Suresh Kumar Srinivasamurthy, Mukta N. Chowta, Sheetal D. Ullal, Youssef Daali, Uppugunduri S. Chakradhara Rao
    Pharmaceuticals.2022; 15(8): 990.     CrossRef
  • The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia
    Jae Min Lee, Ye Jee Shim, Do-Hoon Kim, Nani Jung, Jung-Sook Ha
    Children.2021; 8(3): 224.     CrossRef
  • Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT
    Hyery Kim, Seungwon You, Yoomi Park, Jung Yoon Choi, Youngeun Ma, Kyung Tak Hong, Kyung-Nam Koh, Sunmin Yun, Kye Hwa Lee, Hee Young Shin, Suehyun Lee, Keon Hee Yoo, Ho Joon Im, Hyoung Jin Kang, Ju Han Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China
    Gangling Pu, Yali Wang, Shaoqin Duan, Jingpei Chen, Chunhui Yang, Tingting Cui, Chunlian Fang, Yan Zhou, Han Zhang, Xin Tian
    Pediatrics International.2021; 63(7): 790.     CrossRef
  • A Dual Face of APE1 in the Maintenance of Genetic Stability in Monocytes: An Overview of the Current Status and Future Perspectives
    Gabriela Betlej, Ewelina Bator, Antoni Pyrkosz, Aleksandra Kwiatkowska
    Genes.2020; 11(6): 643.     CrossRef
  • Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT
    Yoomi Park, Hyery Kim, Heewon Seo, Jung Yoon Choi, Youngeun Ma, Sunmin Yun, Byung-Joo Min, Myung-Eui Seo, Keon Hee Yoo, Hyoung Jin Kang, Ho Joon Im, Ju Han Kim
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology
    Emma C. Bernsen, Melanie M. Hagleitner, Theodorus W. Kouwenberg, Lidwien M. Hanff
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens: a single-center analysis
    Ho Jung Choi, Juhee Shin, Sunghan Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
    BLOOD RESEARCH.2020; 55(4): 262.     CrossRef
  • NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia
    Eun Sang Yi, Young Bae Choi, Rihwa Choi, Na Hee Lee, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Soo-Youn Lee, Hong Hoe Koo
    Cancer Research and Treatment.2018; 50(3): 872.     CrossRef
  • 23,744 View
  • 333 Download
  • 12 Web of Science
  • 9 Crossref
Close layer
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Res Treat. 2018;50(3):835-842.   Published online August 29, 2017
DOI: https://doi.org/10.4143/crt.2017.303
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity againstwild type of epidermal growth factorreceptor(EGFR) family kinases including EGFR, HER2, and HER4 and EGFR-mutant cells in vitro. Two phase I studies were conducted to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity against advanced solid tumors.
Materials and Methods
Standard 3+3 dose escalation scheme using two different dosing schedules were studied: once daily, 14-day on, and 7-day off (intermittent schedule); and once daily continuous dosing with food effect. Additional patients were enrolled in an expansion cohort.
Results
A total of 75 patients were enrolled in the two studies. The most common drug-related treatment-emergent adverse eventswere diarrhea,rash, stomatitis, pruritus, and anorexia. Doselimiting toxicities were grade 3 diarrhea in the intermittent schedule and grade 3 anorexia and diarrhea in the continuous dosing schedule. The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule. Eight (16%) and 24 (47%) of 51 evaluable patients in the intermittent schedule achieved partial response (PR) and stable disease (SD), respectively. Four (21%) and six (32%) of 19 evaluable patients in continuous dosing schedule achieved PR and SD, respectively. Patients with PR (n=7) or SD ≥ 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer).
Conclusion
Poziotinib was safe and well tolerated in patients with advanced solid tumors. It showed an encouraging activity against EGFR-mutant and HER2-amplified cancers.

Citations

Citations to this article as recorded by  
  • Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
    Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, Masato Chiba, Masaki Shimoji, Masaoki Ito, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani, Tetsuya Mitsudomi
    Journal of Thoracic Oncology.2024; 19(1): 71.     CrossRef
  • Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu-Yun Leu, Gajanan Bhat, Adam Brufsky
    Breast Cancer Research and Treatment.2024; 205(1): 29.     CrossRef
  • HER2-targeted therapies beyond breast cancer — an update
    Jeesun Yoon, Do-Youn Oh
    Nature Reviews Clinical Oncology.2024; 21(9): 675.     CrossRef
  • Emerging Targeted Therapies for HER2-Positive Breast Cancer
    María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci
    Cancers.2023; 15(7): 1987.     CrossRef
  • Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
    Shuanghu Wang, Mengming Xia, Yu Wang, Zebei Lu, Peiwu Geng, Dapeng Dai, Yunfang Zhou, Qingjun Wu
    Thoracic Cancer.2023; 14(14): 1276.     CrossRef
  • Neratinib for HER2-positive breast cancer with an overlooked option
    Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang
    Molecular Medicine.2023;[Epub]     CrossRef
  • Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
    Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Kenichi Suda, Kazuko Sakai, Hidenori Sato, Tetsuya Mitsudomi
    JTO Clinical and Research Reports.2023; 4(9): 100554.     CrossRef
  • Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
    Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker
    Cancer Research.2023; 83(18): 3145.     CrossRef
  • In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
    Salman Alamery, Anfal AlAjmi, Tanveer A. Wani, Seema Zargar
    Medicina.2023; 59(11): 1923.     CrossRef
  • Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
    María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, Maximino Redondo, Teresa Téllez
    Cancers.2023; 15(23): 5499.     CrossRef
  • Novel HER-2 Targeted Therapies in Breast Cancer
    Catarina Lopes Fernandes, Diogo J. Silva, Alexandra Mesquita
    Cancers.2023; 16(1): 87.     CrossRef
  • Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer
    Jiyun Lee, Yeon Hee Park
    Future Oncology.2022; 18(1): 7.     CrossRef
  • Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
    Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski
    Journal of Clinical Oncology.2022; 40(7): 710.     CrossRef
  • HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
    Xin Yu, Xianxiu Ji, Chunxia Su
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
    Cancer Cell.2022; 40(7): 754.     CrossRef
  • Tailoring antiHer2 treatment strategies in breast cancer and beyond
    Palma Fedele, Valeria Sanna, Anna Natalizia Santoro, Maria Laura Iaia, Alessandro Fancellu
    Current Problems in Cancer.2022; 46(5): 100892.     CrossRef
  • HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
    Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
    Biomarker Research.2022;[Epub]     CrossRef
  • Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
    Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman
    Journal of Personalized Medicine.2022; 12(10): 1651.     CrossRef
  • An ultra-performance LC–MS/MS method for determination of JRF103 in human plasma: application in first in-patient study
    Ying Jin, Xiangjie Di, Lisha Fu, Mengyu Zhang, Neng Qiu, Runhan Liu, Fangqun Li, Xiaohui Qi, Xiaoxu Wang, Yongsheng Wang, Zhenlei Wang
    Bioanalysis.2022; 14(17): 1165.     CrossRef
  • Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
    Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
    Critical Reviews in Oncology/Hematology.2021; 160: 103299.     CrossRef
  • Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
    Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Dapeng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou
    Pharmaceutical Biology.2021; 59(1): 455.     CrossRef
  • Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
    Lara Ulrich, Alicia FC Okines
    Breast Cancer: Targets and Therapy.2021; Volume 13: 361.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
    Barbara Melosky, Paul Wheatley-Price, Rosalyn A. Juergens, Adrian Sacher, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B. Card, Quincy Chu
    Lung Cancer.2021; 160: 136.     CrossRef
  • Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
    Chia-Jung Li, Yen-Dun Tony Tzeng, Yi-Han Chiu, Hung-Yu Lin, Ming-Feng Hou, Pei-Yi Chu
    Cancers.2021; 13(12): 2978.     CrossRef
  • Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
    Debasis Das, Jingbing Wang, Jian Hong
    ChemMedChem.2021; 16(16): 2459.     CrossRef
  • Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors
    Seyed-Omar Zaraei, Rawan M. Sbenati, Nour N. Alach, Hanan S. Anbar, Randa El-Gamal, Hamadeh Tarazi, Mahmoud K. Shehata, Mohammed S. Abdel-Maksoud, Chang-Hyun Oh, Mohammed I. El-Gamal
    European Journal of Medicinal Chemistry.2021; 224: 113674.     CrossRef
  • Breast Cancer Treatments: Updates and New Challenges
    Anna Burguin, Caroline Diorio, Francine Durocher
    Journal of Personalized Medicine.2021; 11(8): 808.     CrossRef
  • Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
    M. Riudavets, I. Sullivan, P. Abdayem, D. Planchard
    ESMO Open.2021; 6(5): 100260.     CrossRef
  • A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
    Cancer Medicine.2021; 10(20): 7012.     CrossRef
  • In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
    Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuro Uchida, Tetsuya Mitsudomi
    Lung Cancer.2021; 162: 79.     CrossRef
  • HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
    Ioannis A. Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N. Syrigos
    Pharmaceuticals.2021; 14(12): 1300.     CrossRef
  • Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
    Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang
    Journal of Thoracic Oncology.2020; 15(6): 962.     CrossRef
  • Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
    Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu
    Pharmacology & Therapeutics.2020; 206: 107438.     CrossRef
  • Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
    Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
    Critical Reviews in Oncology/Hematology.2020; 148: 102906.     CrossRef
  • Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
    Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang, Xiaoyan Ma, Minghui Wang, Wenjing Wang, Songhui Zhao, Kai Wang, Song Gao, Li Zhang
    The Oncologist.2020; 25(3): e545.     CrossRef
  • Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
    Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel
    Clinical Lung Cancer.2020; 21(5): 428.     CrossRef
  • HER2-positive advanced breast cancer treatment in 2020
    Marcelle G. Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja
    Cancer Treatment Reviews.2020; 88: 102033.     CrossRef
  • New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
    Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, Anthony Gonçalves
    Cancers.2020; 12(6): 1573.     CrossRef
  • HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
    Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
    Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
    Breast Cancer Research and Treatment.2020; 184(3): 743.     CrossRef
  • EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
    Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse
    Cancer Treatment Reviews.2020; 90: 102105.     CrossRef
  • Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
    Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni
    Critical Reviews in Oncology/Hematology.2020; 156: 103119.     CrossRef
  • Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
    Xue Yang, Dapeng Wu, Shengli Yuan
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
    Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
    Cancers.2020; 12(11): 3249.     CrossRef
  • Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
    Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo
    Gastrointestinal Disorders.2020; 3(1): 1.     CrossRef
  • Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
    Apurva Pandey, Adam M. Brufsky
    Clinical Breast Cancer.2019; 19(1): e7.     CrossRef
  • Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
    Debasis Das, Jian Hong
    European Journal of Medicinal Chemistry.2019; 170: 55.     CrossRef
  • Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Wei Jiang, Meiju Ji
    Seminars in Cancer Biology.2019; 59: 3.     CrossRef
  • A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
    Tae-Yong Kim, Hye Sook Han, Keun-Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin-Soo Kim, Kyung-Hun Lee, Se Hoon Park, Eun-Kee Song, Soo-A Jung, NaMi Lee, Yeul Hong Kim, Jae Yong Cho, Yung-Jue Bang
    Gastric Cancer.2019; 22(6): 1206.     CrossRef
  • Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
    Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown
    Cancers.2019; 11(6): 737.     CrossRef
  • Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positi
    Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim, Ki Hyeong Lee, Seock‐Ah Im, Yeon Hee Park
    International Journal of Cancer.2019; 145(6): 1669.     CrossRef
  • Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
    Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha
    The Oncologist.2019; 24(12): e1303.     CrossRef
  • Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
    Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Makoto Suzuki, Pasi A. Jänne, Tetsuya Mitsudomi
    Lung Cancer.2018; 126: 72.     CrossRef
  • A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial
    Yeon Hee Park, Kyung‐Hun Lee, Joo Hyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee‐Hyun Kim, Ki Hyeong Lee, Jin Seok Ahn, Tae‐Yong Kim, Gun Min Kim, In Hae Park, Sung‐Bae Kim, Se Hyun Kim, Hye Sook Han, Young‐Hyuck Im, Jin‐Hee Ahn, Jung‐Yong Kim, Jahoon Kang
    International Journal of Cancer.2018; 143(12): 3240.     CrossRef
  • EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
    Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
    Clinical Cancer Research.2018; 24(24): 6548.     CrossRef
  • 13,251 View
  • 685 Download
  • 59 Web of Science
  • 56 Crossref
Close layer
Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function
Yeonjung Ha, Daejung Kim, Seungbong Han, Young Eun Chon, Yun Bin Lee, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
Cancer Res Treat. 2018;50(3):843-851.   Published online September 4, 2017
DOI: https://doi.org/10.4143/crt.2017.232
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to demonstrate the prognostic significance of changes in body composition in patients with newly diagnosed hepatocellular carcinoma (HCC).
Materials and Methods
Patients (n=178) newly diagnosed with HCC participated in the study between 2007 and 2012. Areas of skeletal muscle and abdominal fat were directly measured using a three-dimensional workstation. Cox proportional-hazards modes were used to estimate the effect of baseline variables on overall survival. The inverse probability of treatmentweighting (IPTW) method was used to minimize confounding bias.
Results
Cutoff values for sarcopenia, obtained from receiver-operating characteristic curves, were defined as skeletal muscle index at the third lumbar vertebra of ≤ 45.8 cm/m2 for males and ≤ 43.0 cm/m2 for females. Sarcopenia patients were older, more likely to be female, and had lower body mass index. Univariable analysis showed that the presence of sarcopenia and visceral to subcutaneous fat area ratio (VSR) were significantly associatedwith prognosis. The multivariable analyses revealed that VSR was predictive of overall survival. However, in the multivariable Cox model adjusted by IPTW, sarcopenia, not VSR, were associated with overall survival.
Conclusion
The presence of sarcopenia at HCC diagnosis is independently associated with survival.

Citations

Citations to this article as recorded by  
  • Sarcopenia Affects Liver Regeneration and Long-Term Survival Rate After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma
    Mei-Yun Wu, Cheng-Hsi Yeh, Chien-Chang Liao, Chao-Long Chen, Chih-Chi Wang, Chih-Che Lin, Wan- Ching Chang, Yu-Fan Cheng, Hsin-You Ou
    Transplantation Proceedings.2024; 56(3): 573.     CrossRef
  • Effect of Sarcopenia on the Prognosis of Clinical Outcomes in Patients With Hepatocellular Carcinoma After Hepatic Resection
    Thanatchawan Polvieng, Sermsak Hongjinda, Anuparp Thienhiran, Pipit Burasakarn, Pusit Fuengfoo
    The American Surgeon™.2024; 90(6): 1447.     CrossRef
  • Hepatocellular carcinoma and musculoskeletal system: A narrative literature review
    Jelena Jadzic, Danijela Djonic
    World Journal of Gastroenterology.2024; 30(15): 2109.     CrossRef
  • Apolipoprotein A-1 downregulation promotes basal-like breast cancer cell proliferation and migration associated with DNA methylation
    Cong Wang, Shiliang Chen, Ranran Zhang, Mengqing Chen, Xiaoxiao Yang, Yibo He, Zuifei Shangguan, Qifen Mao, Zhezhong Zhang, Sunke Ying
    Oncology Letters.2024;[Epub]     CrossRef
  • Association between visceral obesity and tumor recurrence in hepatocellular carcinoma recipients undergoing liver transplantation
    Ji-Hoon Sim, Kyung-Won Kim, YouSun Ko, Young-Jin Moon, Hye-Mee Kwon, In-Gu Jun, Sung-Hoon Kim, Kyoung-Sun Kim, Jun-Gol Song, Gyu-Sam Hwang
    International Journal of Obesity.2023; 47(12): 1214.     CrossRef
  • Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis
    Yusheng Guo, Yanqiao Ren, Licheng Zhu, Lian Yang, Chuansheng Zheng
    Scientific Reports.2023;[Epub]     CrossRef
  • Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives
    Riccardo Casciola, Laura Leoni, Biagio Cuffari, Maddalena Pecchini, Renata Menozzi, Antonio Colecchia, Federico Ravaioli
    Nutrients.2023; 15(4): 863.     CrossRef
  • Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment
    Anne-Laure Couderc, Evelyne Liuu, Pascaline Boudou-Rouquette, Johanne Poisson, Maxime Frelaut, Coline Montégut, Soraya Mebarki, Romain Geiss, Zoé ap Thomas, Aurélien Noret, Monica Pierro, Capucine Baldini, Elena Paillaud, Frédéric Pamoukdjian
    Nutrients.2023; 15(5): 1193.     CrossRef
  • Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
    Alexey Surov, Maximilian Thormann, Mattes Hinnerichs, Max Seidensticker, Ricarda Seidensticker, Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Iren
    Hepatology Communications.2023;[Epub]     CrossRef
  • Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta‑analysis
    Jiye Liu, Hanyong Luo, Letian Huang, Jiahe Wang
    Oncology Letters.2023;[Epub]     CrossRef
  • Adipose distribution patterns as prognostic factors in patients with HCC: A systematic review and meta-analysis
    Shuo Shi, Haiyan Yi, Yi Zheng, Yuxuan Zhao, Dexin Yu
    European Journal of Radiology.2023; 167: 111025.     CrossRef
  • Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis
    Xuanmei Li, Xue Huang, Lifu Lei, Shiwen Tong
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol
    Patrik Nasr, Mikael Forsgren, Wile Balkhed, Cecilia Jönsson, Nils Dahlström, Christian Simonsson, Shan Cai, Anna Cederborg, Martin Henriksson, Henrik Stjernman, Martin Rejler, Daniel Sjögren, Gunnar Cedersund, Wolf Bartholomä, Ingvar Rydén, Peter Lundberg
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Sarcopenia as a prognostic indicator of liver cirrhosis
    Sung‐Eun Kim, Dong Joon Kim
    Journal of Cachexia, Sarcopenia and Muscle.2022; 13(1): 8.     CrossRef
  • Comparison of frailty metrics and the Charlson Comorbidity Index for predicting adverse outcomes in patients undergoing surgery for spine metastases
    Andrew M. Hersh, Zach Pennington, Bethany Hung, Jaimin Patel, Earl Goldsborough, Andrew Schilling, James Feghali, Albert Antar, Siddhartha Srivastava, David Botros, Aladine A. Elsamadicy, Sheng-Fu Larry Lo, Daniel M. Sciubba
    Journal of Neurosurgery: Spine.2022; 36(5): 849.     CrossRef
  • Sarcopenia of Cirrhosis and the Therapeutic Potential of Transjugular Intrahepatic Portosystemic Shunt Creation
    Barry Schlansky, Khashayar Farsad
    Digestive Disease Interventions.2022; 06(02): 148.     CrossRef
  • Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions
    Abhilash Perisetti, Hemant Goyal, Rachana Yendala, Saurabh Chandan, Benjamin Tharian, Ragesh Babu Thandassery
    World Journal of Gastroenterology.2022; 28(4): 432.     CrossRef
  • The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
    Yasser Fouad, Gamal Esmat, Reda Elwakil, Serag Zakaria, Ayman Yosry, Imam Waked, Maissa El-Razky, Wahid Doss, Magdy El-Serafy, Ebraheem Mostafa, Mahmood Anees, Mohamed A. Sakr, Nadia AbdelAty, Ashraf Omar, Samy Zaki, Amgad Al-zahaby, Hamdy Mahfouz, Maysaa
    Saudi Journal of Gastroenterology.2022; 28(1): 3.     CrossRef
  • Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis
    Christine March, Jazan Omari, Maximilian Thormann, Maciej Pech, Andreas Wienke, Alexey Surov
    Clinical Nutrition ESPEN.2022; 49: 103.     CrossRef
  • Adiposity and cancer survival: a systematic review and meta-analysis
    En Cheng, Jocelyn Kirley, Elizabeth M. Cespedes Feliciano, Bette J. Caan
    Cancer Causes & Control.2022; 33(10): 1219.     CrossRef
  • Preoperative computed tomography-determined sarcopenia is a reliable prognostic factor in patients with gastric cancer after radical gastrectomy: A sex-specific analysis
    Ting Liu, Xiaoping Yi, Jie Ge, Jinwei Zhang, Fengbo Tan, Kun Song, Heli Liu, Mimi Tang
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • The psoas muscle depletion index is related to the degree of cirrhosis and skeletal muscle loss in patients with end-stage liver disease
    J.C. Hou, Y.M. Zhang, Z Qiang, L.Y. Zhu, H Zheng, Z.Y. Shen
    Acta Gastro Enterologica Belgica.2022; 85(3): 453.     CrossRef
  • Imaging based body composition profiling and outcomes after oncologic liver surgery
    Lorenzo Bernardi, Raffaello Roesel, Filippo Vagelli, Pietro Majno-Hurst, Alessandra Cristaudi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis
    Chuan Jiang, Yanyan Wang, Wei Fu, Guozhuan Zhang, Xiaoshan Feng, Xing Wang, Fang Wang, Le Zhang, Yang Deng
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • MRI-Derived Sarcopenia Associated with Increased Mortality Following Yttrium-90 Radioembolization of Hepatocellular Carcinoma
    Phillip L. Guichet, Bedros Taslakian, Chenyang Zhan, Eric Aaltonen, Sean Farquharson, Ryan Hickey, Cash J. Horn, Jonathan S. Gross
    CardioVascular and Interventional Radiology.2021; 44(10): 1561.     CrossRef
  • The prevalence and the impact of sarcopenia in digestive cancers. A systematic review
    Carmen Haiducu, Adrian Buzea, Liliana Elena Mirea, Gheorghe Andrei Dan
    Romanian Journal of Internal Medicine.2021; 59(4): 328.     CrossRef
  • Impact of body fat distribution and sarcopenia on the overall survival in patients with spinal metastases receiving radiotherapy treatment: a prospective cohort study
    B. J. Pielkenrood, P. R. van Urk, J. M. van der Velden, N. Kasperts, J. J. C. Verhoeff, G. H. Bol, H. M. Verkooijen, J. J. Verlaan
    Acta Oncologica.2020; 59(3): 291.     CrossRef
  • Visceral Adipose Tissue Radiodensity Is Linked to Prognosis in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy
    Maryam Ebadi, Carlos Moctezuma-Velazquez, Judith Meza-Junco, Vickie E. Baracos, Abha R. DunichandHoedl, Sunita Ghosh, Philippe Sarlieve, Richard J. Owen, Norman Kneteman, Aldo J. Montano-Loza
    Cancers.2020; 12(2): 356.     CrossRef
  • Review article: prognostic significance of body composition abnormalities in patients with cirrhosis
    Maryam Ebadi, Rahima A. Bhanji, Puneeta Tandon, Vera Mazurak, Vickie E. Baracos, Aldo J. Montano‐Loza
    Alimentary Pharmacology & Therapeutics.2020; 52(4): 600.     CrossRef
  • The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
    Mohammed Eslam, Shiv K. Sarin, Vincent Wai-Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming-Hua Zheng, Gamal Shiha, Yusuf Yilmaz, Rino Gani, Shahinul Alam, Yock Young Dan, Jia-Horng Kao, Saeed Hamid, Ian Homer Cua, Wah-Kheong Chan, Diana Paya
    Hepatology International.2020; 14(6): 889.     CrossRef
  • Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma
    Sooyeon Oh, Jooho Lee
    Clinical and Molecular Hepatology.2020; 26(4): 476.     CrossRef
  • The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?
    Felix Hahn, Lukas Müller, Fabian Stöhr, Aline Mähringer‐Kunz, Sebastian Schotten, Christoph Düber, Fabian Bartsch, Hauke Lang, Peter R Galle, Arndt Weinmann, Roman Kloeckner
    Liver International.2019; 39(7): 1307.     CrossRef
  • Safety and Prognosis of Transarterial Chemoembolization for Octogenarians with Hepatocellular Carcinoma
    Hua-Ming Cheng, Toshihiro Tanaka, Hideyuki Nishiofuku, Yuto Chanoki, Katsutoshi Horiuchi, Tetsuya Masada, Shota Tatsumoto, Takeshi Matsumoto, Nagaaki Marugami, Kimihiko Kichikawa
    CardioVascular and Interventional Radiology.2019; 42(10): 1413.     CrossRef
  • Visceral Fat Volume From Standard Preoperative CT is an Independent Predictor of Short-term Survival in Patients Undergoing Surgery for Metastatic Spine Disease
    Zach Pennington, Bart Pielkenrood, A. Karim Ahmed, C. Rory Goodwin, Jorrit-Jan Verlaan, Daniel M. Sciubba
    Clinical Spine Surgery: A Spine Publication.2019; 32(6): E303.     CrossRef
  • Sarcopenia in cirrhosis: from pathogenesis to interventions
    Maryam Ebadi, Rahima A. Bhanji, Vera C. Mazurak, Aldo J. Montano-Loza
    Journal of Gastroenterology.2019; 54(10): 845.     CrossRef
  • “Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”
    Yan Mardian, Yoshihiko Yano, Neneng Ratnasari, Lina Choridah, Widya Wasityastuti, Nurhuda Hendra Setyawan, Yoshitake Hayashi
    BMC Gastroenterology.2019;[Epub]     CrossRef
  • Controversies in Diagnosing Sarcopenia in Cirrhosis—Moving from Research to Clinical Practice
    Marie Sinclair
    Nutrients.2019; 11(10): 2454.     CrossRef
  • Sarcopenia in cirrhosis: a systematic review
    Ovidiu Paul Calapod, Andreea Maria Marin, Laura Carina Tribus, Carmen Fierbinţeanu-Braticevici
    Romanian Journal of Orthopaedic Surgery and Traumatology.2019; 2(2): 125.     CrossRef
  • The Adverse Impact of Sarcopenia and Visceral Fat Deposition on the Course of Hepatocellular Carcinoma and the Role of Nutritional Interventions
    Adam McCulloch, Hardip Malhi, Amritpal Dhaliwal, Sheldon Cooper, Tahir Shah
    European Medical Journal.2018; : 126.     CrossRef
  • 9,451 View
  • 350 Download
  • 44 Web of Science
  • 39 Crossref
Close layer
Impact of Body Mass Index on the Quality of Life after Total Gastrectomy for Gastric Cancer
Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Oh Kyoung Kwon, Ho Young Chung, Wansik Yu
Cancer Res Treat. 2018;50(3):852-860.   Published online September 13, 2017
DOI: https://doi.org/10.4143/crt.2017.080
AbstractAbstract PDFPubReaderePub
Purpose
We evaluated the impact of postoperative body mass index (BMI) shifts on the quality of life (QoL) following total gastrectomy in patients with gastric cancer.
Materials and Methods
QoL data collected from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and QLQ-STO22 questionnaires were obtained from 417 patients preoperatively and 1 year after surgery. Patients were divided into two groups based on changes in BMI: group 1 comprised patientswhose BMIrange category dropped, and group 2 included patients who maintained or rose to a higher category compared to their preoperative BMI category.
Results
There were 276 patients in group 1 and 141 in group 2. QoLs with respect to the global health status and functional scales were not significantly different between the groups 1 year after surgery. However, there were significantly greater decreases in QoL in group 1 due to gastrointestinal symptoms, such as nausea and vomiting (p=0.008), appetite loss (p=0.001), and constipation (p=0.038). Of the QLQ-STO22 parameters, dysphagia (p=0.013), pain (p=0.012), reflux symptoms (p=0.017), eating restrictions (p=0.007), taste (p=0.009), and body image (p=0.009) were associated with significantly worse QoL in group 1 than in group 2 1 year after surgery.
Conclusion
Patients have significantly different QoLs depending on the BMI shift after total gastrectomy. Efforts to reduce the gap in QoL should include intensive nutritional support and restoration of dietary behaviors. Appropriate clinical and institutional approaches, plus active medical interventions, are required for maintaining patients’ BMIs after surgery.

Citations

Citations to this article as recorded by  
  • Nutritional Experiences of Patients Undergoing Total Gastrectomy Surgery
    Derya Şayır, Kevser Karacabay
    Gastroenterology Nursing.2024; 47(3): 203.     CrossRef
  • Exploring the Association between Health-Related Physical Fitness and Quality of Life in Patients with Cancer: A Cross-Sectional Study
    Anita Borsati, Diana Giannarelli, Lorenzo Belluomini, Christian Ciurnelli, Alessio Colonna, Irene D’Amico, Arianna Daniele, Nicole Del Bianco, Linda Toniolo, Ilaria Trestini, Daniela Tregnago, Jessica Insolda, Marco Sposito, Massimo Lanza, Michele Milella
    Healthcare.2024; 12(16): 1643.     CrossRef
  • Research Progress on the Relationship between Nutritional Support and Postoperative Quality of Life in Patients with Gastric Cancer
    思孟 张
    Advances in Clinical Medicine.2024; 14(09): 765.     CrossRef
  • U-shaped association between body mass index and health-related quality of life impairment in Korean cancer survivors: a nationwide representative cross-sectional survey
    Jong Eun Park, Kyoung Eun Yeob, So Young Kim, Chul-Woung Kim, Hye Sook Han, Jong Hyock Park
    Journal of Cancer Survivorship.2023; 17(5): 1522.     CrossRef
  • The Predictive Value of a New Inflammatory-Nutritional Score for Quality of Life after Laparoscopic Distal Gastrectomy for Gastric Cancer
    Simeng Zhang, Ruiqing Liu, Maoshen Zhang, JiLin Hu, Shuai Xiang, Zinian Jiang, Dongsheng Wang
    Nutrition and Cancer.2023; 75(4): 1165.     CrossRef
  • Quality of Life in Patients Undergoing Surgery for Upper GI Malignancies
    Grigorios Christodoulidis, Marina-Nektaria Kouliou, Konstantinos-Eleftherios Koumarelas, Dimitris Giakoustidis, Thanos Athanasiou
    Life.2023; 13(9): 1910.     CrossRef
  • The effect of body mass index on quality of life in modified single stoma cutaneous ureterostomy or ileal conduit after radical cystectomy
    Wan‐Jin Zhang, Xu‐Yun Huang, Bin Lin, Wen‐Cai Zheng, Zhi‐Bin Ke, Xiao‐Dan Lin, Jia‐Yin Chen, Hai Cai, Yun‐Zhi Lin, Ye‐Hui Chen, Qing‐Shui Zheng, Yong Wei, Xue‐Yi Xue, Xiao‐Dong Li, Ning Xu
    Cancer Medicine.2023; 12(22): 20930.     CrossRef
  • Long-term health-related quality of life in patients with gastric cancer after total or distal gastrectomy: A propensity score-matched cohort study
    Jianhong Yu, Zaozao Wang, Hong Yang, Chenghai Zhang, Jiadi Xing, Ming Cui, Hui Liu, Yu Wu, Xiangqian Su
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Factors connected with anxiety and other neuropsychiatric symptoms in advanced gastric cancer
    Pawel Bryniarski, Magdalena Bryniarska, Maciej Jezioro, Daniel Andrysiak, Iwona Filipczak-Bryniarska
    Acta Neuropsychiatrica.2022; 34(1): 10.     CrossRef
  • Relationship Between Symptom Distress and Fatigue Characteristics in Patients with Gastric Cancer During 1 Month after Gastrectomy
    Hui-Ying Yang, Yun-Hsiang Lee, Jin-Ming Wu, I-Rue Lai, Shiow-Ching Shun
    Clinical Nursing Research.2022; 31(3): 463.     CrossRef
  • Risk of fracture following gastric surgery for benign and malignant conditions: A study level pooled analysis of population-based cohort studies
    Qiuping Zou, Chao Wei, Zhuo Shao, Hao Wang, Zhihong Xiao, Lixing Cao, Zubing Mei, Wei Zhao, Zhi Jiang, Zhiqiang Chen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Health-related quality of life after gastric cancer treatment in Brazil: Narrative review and reflections
    Rodrigo Nascimento Pinheiro, Samantha Mucci, Renato Morato Zanatto, Olavo Magalhães Picanço Junior, Alexandre Ferreira Oliveira, Gaspar de Jesus Lopes Filho
    World Journal of Clinical Cases.2021; 9(17): 4123.     CrossRef
  • Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer—A Systematic Review
    Sophia Kristina Rupp, Andreas Stengel
    Frontiers in Psychiatry.2021;[Epub]     CrossRef
  • Nutritional status, sarcopenia, gastrointestinal symptoms and quality of life after gastrectomy for cancer – A cross-sectional pilot study
    Sedegheh Gharagozlian, Tom Mala, Hilde Kristin Brekke, Lisa C. Kolbjørnsen, Åslaug A. Ullerud, Egil Johnson
    Clinical Nutrition ESPEN.2020; 37: 195.     CrossRef
  • Advantages of Distal Subtotal Gastrectomy over Total Gastrectomy in the Quality of Life of Long-Term Gastric Cancer Survivors
    Oh Kyoung Kwon, Byunghyuk Yu, Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung
    Journal of Gastric Cancer.2020; 20(2): 176.     CrossRef
  • Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer
    Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
    Annals of Surgical Treatment and Research.2020; 98(5): 262.     CrossRef
  • Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis
    Héctor G. van den Boorn, Charlotte I. Stroes, Aeilko H. Zwinderman, Wietse J. Eshuis, Maarten C.C.M. Hulshof, Faridi S. van Etten-Jamaludin, Mirjam A.G. Sprangers, Hanneke W.M. van Laarhoven
    Critical Reviews in Oncology/Hematology.2020; 154: 103069.     CrossRef
  • Impact of body mass index on quality of life after distal gastrectomy for gastric cancer
    Ki Bum Park, Byunghyuk Yu, Ji Yeon Park, Oh Kyoung Kwon, Wansik Yu
    Annals of Surgical Treatment and Research.2019; 96(5): 250.     CrossRef
  • 9,450 View
  • 322 Download
  • 20 Web of Science
  • 18 Crossref
Close layer
Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study
Qiu-Yan Chen, Shao-Yan Guo, Lin-Quan Tang, Tong-Yu Lu, Bo-Lin Chen, Qi-Yu Zhong, Meng-Sha Zou, Qing-Nan Tang, Wen-Hui Chen, Shan-Shan Guo, Li-Ting Liu, Yang Li, Ling Guo, Hao-Yuan Mo, Rui Sun, Dong-Hua Luo, Chong Zhao, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Mu-Sheng Zeng, Hai-Qiang Mai
Cancer Res Treat. 2018;50(3):861-871.   Published online September 13, 2017
DOI: https://doi.org/10.4143/crt.2017.237
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Little is known about combination of the circulating Epstein-Barr viral (EBV) DNA and tumor volume in prognosis of stage II nasopharyngeal carcinoma (NPC) patients in the intensity modulated radiotherapy (IMRT) era. We conducted this cohort study to evaluate the prognostic values of combining these two factors.
Materials and Methods
By Kaplan-Meier, we compare the differences of survival curves between 385 patients with different EBV DNA or tumor volume levels, or with the combination of two biomarkers mentioned above.
Results
Gross tumor volume of cervical lymph nodes (GTVnd, p < 0.001) and total tumor volume (GTVtotal, p < 0.001) were both closely related to pretreatment EBV DNA, while gross tumor volume of nasopharynx (GTVnx, p=0.047) was weakly related to EBV DNA. EBV DNA was significantly correlated with progress-free survival (PFS, p=0.005), locoregional-free survival (LRFS, p=0.039), and distant metastasis-free survival (DMFS, p=0.017), while GTVtotal, regardless of GTVnx and GTVnd, had a significant correlation with PFS and LRFS. The p-values of GTVtotal for PFS and LRFS were 0.008 and 0.001, respectively. According to GTVtotal and pretreatment EBV DNA level, patients were divided into a low-risk group (EBV DNA 0 copy/mL, GTVtotal < 30 cm3; EBV DNA 0 copy/mL, GTVtotal ≥ 30 cm3; or EBV DNA > 0 copy/mL, GTVtotal < 30 cm3) and a high-risk group (EBV DNA > 0 copy/mL, GTVtotal ≥ 30 cm3). When patients in the low-risk group were compared with those in the high-risk group, 3-year PFS (p=0.003), LRFS (p=0.010), and DMFS (p=0.031) rates were statistically significant.
Conclusion
Pretreatment plasma EBV DNA and tumor volume were both closely correlated with prognosis of stage II NPC patients in the IMRT era. Combination of EBV DNA and tumor volume can refine prognosis and indicate for clinical therapy.

Citations

Citations to this article as recorded by  
  • Risk stratification of LA‐NPC during chemoradiotherapy based on clinical classification and TVRR
    Qianlong Tang, Chaorong Mei, Bei Huang, Rui Huang, Le Kang, Ailin Chen, Na lei, Pengcheng Deng, Shouyan Ying, Peng Zhang, Yuan Qin
    Cancer Medicine.2024;[Epub]     CrossRef
  • A radiogenomic clinical decision support system to inform individualized treatment in advanced nasopharyngeal carcinoma
    Xue-Liang Fang, Lian-Zhen Zhong, Wei Jiang, Cheng-Long Huang, Yuan Lei, Si-Qi Tang, Qing-Jie Li, Li-Zhi Liu, Li Tian, Ying-Qin Li, Yu-Pei Chen, Li Lin, Rui Guo, Wen-Fei Li, Jie Tian, Na Liu, Di Dong, Jun Ma, Ling-Long Tang
    iScience.2024; 27(8): 110431.     CrossRef
  • Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma
    Zhong‐zheng Xiang, Tao He, Yuan‐yuan Zeng, Fang Liu, Bian‐fei Shao, Tian Yang, Jia‐chun Ma, Xi‐ran Wang, Si‐ting Yu, Lei Liu
    Cancer Medicine.2023; 12(2): 1102.     CrossRef
  • A prognostic nomogram incorporating tumor size and lymph node size for patients with nasopharyngeal carcinoma
    Qi Yi, Jiazuo Cai, Yunen Lin, Zimei Hu, Jie Lin, Zhong Huang, Wei Liu, Ronghui Zheng, YaWei Yuan, Chengcong Chen
    American Journal of Otolaryngology.2023; 44(2): 103717.     CrossRef
  • Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma
    Qian Chen, Liangfang Shen, Shan Li
    European Archives of Oto-Rhino-Laryngology.2023; 280(5): 2497.     CrossRef
  • High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
    Xiaotian Xu, Fangze Wei, Lin Xiao, Runye Wu, Baojun Wei, Shengkai Huang, Junlin Yi, Wei Cui
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • MRI-based deep learning model predicts distant metastasis and chemotherapy benefit in stage II nasopharyngeal carcinoma
    Yu-Jun Hu, Lin Zhang, You-Ping Xiao, Tian-Zhu Lu, Qiao-Juan Guo, Shao-Jun Lin, Lan Liu, Yun-Bin Chen, Zi-Lu Huang, Ya Liu, Yong Su, Li-Zhi Liu, Xiao-Chang Gong, Jian-Ji Pan, Jin-Gao Li, Yun-Fei Xia
    iScience.2023; 26(6): 106932.     CrossRef
  • The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas
    Julie Kjems, Katrin Elisabet Håkansson, Claus Andrup Kristensen, Jesper Grau Eriksen, Morten Horsholt Kristensen, Anne Ivalu Sander Holm, Jens Overgaard, Christian Rønn Hansen, Ruta Zukauskaite, Jørgen Johansen, Ivan Richter Vogelius, Jeppe Friborg
    Radiotherapy and Oncology.2023; 186: 109771.     CrossRef
  • The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma
    Gaoyuan Wang, Zhe Dong, Chenglong Huang, Xiaojing Du, Lin Chen, Kunpeng Li, Rui Guo, Linglong Tang, Jun Ma
    Oral Oncology.2023; 145: 106500.     CrossRef
  • Clinical Significance of Baseline Epstein–Barr Virus DNA for Recurrent or Metastatic Primary Pulmonary Lymphoepithelioma-Like Carcinoma
    Qihua Zou, Kongjia Luo, Liping Kang, Caiwen Huang, Jianliang Mai, Yongbin Lin, Ying Liang
    Future Oncology.2023; 19(37): 2481.     CrossRef
  • Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin
    Li Hua, Shaojun Chen, Mengzhuan Wei, Yongqi Shen, Jianxin Long, Zhan Lin, Yiliang Meng, Chengxian Guo, Haixin Huang, Xiaoning Tu, Min Yao
    Cancer Biotherapy and Radiopharmaceuticals.2022; 37(1): 2.     CrossRef
  • Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era
    Shan‐Shan Yang, Ya‐Jun Pang, Zhi‐Qiang Wang, Bao‐Yu Zhang, Zhi‐Qiao Liu, En‐Ni Chen, Pu‐Yun OuYang, Fang‐Yun Xie
    Cancer Medicine.2022; 11(4): 1109.     CrossRef
  • Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma
    Xiaoyu Li, Xingchen Peng, Sha Zhao, Hong Zhang, Yong Jiang, Fei Liu, Ping Ai
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma
    Huiyun Yang, Rongjun Zhang, Ruyun Zhang, Bin Zhang, Yuan Xie, Guanjie Qin, Yunyan Mo, Xiaolan Ruan, Wei Jiang
    Strahlentherapie und Onkologie.2022; 198(9): 828.     CrossRef
  • Survival among subgroups of patients with stage II nasopharyngeal carcinoma
    Shi-Ting Huang, Dan-Ke Su
    Scientific Reports.2022;[Epub]     CrossRef
  • Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers
    Santiago Cabezas-Camarero, Pedro Pérez-Segura
    Cancers.2022; 14(12): 2858.     CrossRef
  • Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
    Laura Keller, Yassine Belloum, Harriet Wikman, Klaus Pantel
    British Journal of Cancer.2021; 124(2): 345.     CrossRef
  • Treatment Deescalation Strategies for Nasopharyngeal Cancer
    Anna Lee, James C. H. Chow, Nancy Y. Lee
    JAMA Oncology.2021; 7(3): 445.     CrossRef
  • Clinical and survival analysis of nasopharyngeal carcinoma with consistently negative Epstein–Barr virus DNA
    Zhi‐Gong Wei, Xiao‐Lin Hu, Yan He, Hui Guan, Jing‐Jing Wang, Ling He, Xiao‐Li Mu, Zhe‐Ran Liu, Rui‐Dan Li, Xing‐Chen Peng
    Head & Neck.2021; 43(5): 1465.     CrossRef
  • Accumulation of LOX-1+ PMN-MDSCs in nasopharyngeal carcinoma survivors with chronic hepatitis B might permit immune tolerance to epstein–barr virus and relate to tumor recurrence
    Xing Li, Jin-Long Li, Nan Jiang, Jie Chen, Zi-Ming Liang, Zhen-Lin Zhao, Yan-Fang Xing
    Aging.2021; 13(1): 437.     CrossRef
  • A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
    Anne W.M. Lee, Victor H.F. Lee, Wai-Tong Ng, Primož Strojan, Nabil F. Saba, Alessandra Rinaldo, Stefan M. Willems, Juan P. Rodrigo, Arlene A. Forastiere, Alfio Ferlito
    European Journal of Cancer.2021; 153: 109.     CrossRef
  • Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load
    Yu-Ting Jiang, Kai-Hua Chen, Jie Yang, Zhong-Guo Liang, Song Qu, Ling Li, Xiao-Dong Zhu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Metastasis of nasopharyngeal carcinoma: What we know and do not know
    Ling-Ling Guo, Hai-Yun Wang, Li-Sheng Zheng, Ming-Dian Wang, Yun Cao, Yang Li, Zhi-Jie Liu, Li-Xia Peng, Bi-Jun Huang, Jian-Yong Shao, Chao-Nan Qian
    Visualized Cancer Medicine.2021; 2: 4.     CrossRef
  • Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature
    Chi Leung Chiang, Qiaojuan Guo, Wai Tong Ng, Shaojun Lin, Tiffany Sze Wai Ma, Zhiyuan Xu, Youping Xiao, Jishi Li, Tianzhu Lu, Horace Cheuk Wai Choi, Wenqi Chen, Eric Sze Chun Chau, Peter Ho Yin Luk, Shao Hui Huang, Brian O’Sullivan, Jianji Pan, Anne Wing
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma
    Pui-Lam Yip, Shing-Fung Lee, Cheuk-Wai Horace Choi, Po-Chung Sunny Chan, Ka-Wai Alice Cheung, Chung-Hang James Chow, Ka-Man Cheung, Wing-Yu Jessica Lai, Ho-Fun Victor Lee, Ka-On Lam, Chi-Leung Chiang, Chun-Yin Edwin Wong, Ming-Chun Darren Poon, Macy Tong,
    Cancers.2021; 13(17): 4286.     CrossRef
  • The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma
    Xin-Bin Pan, Ling Li, Song Qu, Long Chen, Shi-Xiong Liang, Xiao-Dong Zhu
    Oral Oncology.2020; 101: 104520.     CrossRef
  • Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients
    Natalia Samolyk-Kogaczewska, Ewa Sierko, Dorota Dziemianczyk-Pakiela, Klaudia Beata Nowaszewska, Malgorzata Lukasik, Joanna Reszec
    Cancers.2020; 12(2): 511.     CrossRef
  • Prognostic efficacy of extensive invasion of primary tumor volume for T3-4 nasopharyngeal carcinoma receiving intensity-modulated radiotherapy
    Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
    Oral Oncology.2020; 100: 104478.     CrossRef
  • Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up
    Xue-Song Sun, Xiao-Yun Li, Bei-Bei Xiao, Sai-Lan Liu, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
    Oral Oncology.2020; 100: 104490.     CrossRef
  • Metastatic disease in head & neck oncology
    Paolo Pisani, Mario Airoldi, Anastasia Allais, Paolo Aluffi Valletti, Mariapina Battista, Marco Benazzo, Roberto Briatore, Salvatore Cacciola, Salvatore Cocuzza, Andrea Colombo, Bice Conti, Alberto Costanzo, Laura della Vecchia, Nerina Denaro, Cesare Fant
    Acta Otorhinolaryngologica Italica.2020; 40(SUPPL. 1): S1.     CrossRef
  • BHRF1 Enhances EBV Mediated Nasopharyngeal Carcinoma Tumorigenesis through Modulating Mitophagy Associated with Mitochondrial Membrane Permeabilization Transition
    Shujie Song, Zhiying Jiang, David Ethan Spezia-Lindner, Ting Liang, Chang Xu, Haifeng Wang, Ye Tian, Yidong Bai
    Cells.2020; 9(5): 1158.     CrossRef
  • Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area
    E. Muraro, E. Vaccher, C. Furlan, E. Fratta, G. Fanetti, D. A. Fae’, D. Martorelli, M. Cangemi, J. Polesel, F. Navarria, C. Gobitti, E. Comaro, C. Scaini, C. Pratesi, S. Zanussi, V. Lupato, G. Grando, V. Giacomarra, S. Sulfaro, L. Barzan, R. Dolcetti, A.
    Pathology & Oncology Research.2020; 26(4): 2459.     CrossRef
  • Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein–Barr Virus–Positive Nasopharyngeal Carcinoma
    Bin Hu, Ming Sun, Zijin Wang, Yanping Zheng, Weifeng Cai, Helen Hsiao-Hsing Shi, Yanzhen Zhuang, Qin Lin
    Clinical Chemistry.2020; 66(9): 1219.     CrossRef
  • Molecular Prognostic Value of Circulating Epstein–Barr Viral DNA in Nasopharyngeal Carcinoma: A Meta-Analysis of 27,235 Cases in the Endemic Area of Southeast Asia
    Xulin Xie, Yupei Ren, Kun Wang, Bin Yi
    Genetic Testing and Molecular Biomarkers.2019; 23(7): 448.     CrossRef
  • Dynamic changes in plasma Epstein–Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study
    Sha‐Sha He, Yan Wang, Yong Bao, Xiu‐Yu Cai, Xing‐Li Yang, Dan‐Ming Chen, Yong Chen, Li‐Xia Lu
    Cancer Medicine.2018; 7(4): 1110.     CrossRef
  • Impact of paranasal sinus invasion on advanced nasopharyngeal carcinoma treated with intensity‐modulated radiation therapy: the validity of advanced T stage of AJCC/UICC eighth edition staging system
    Ying Wang, Jie Zhao, Yajie Zhao, Zhen Yang, Mingjun Lei, Zhanzhan Li, Rui Wei, Dengming Chen, Yuxiang He, Liangfang Shen
    Cancer Medicine.2018; 7(7): 2826.     CrossRef
  • Impact of age on survival of locoregional nasopharyngeal carcinoma: An analysis of the Surveillance, Epidemiology, and End Results program database, 2004‐2013
    S.‐J. Huang, Y.‐Y. Tang, H.‐M. Liu, G.‐X. Tan, X. Wang, H. Zhang, F. Yang, S. Yang
    Clinical Otolaryngology.2018; 43(5): 1209.     CrossRef
  • Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation
    Liang Peng, Yi Yang, Rui Guo, Yan‐Ping Mao, Cheng Xu, Yu‐Pei Chen, Ying Sun, Jun Ma, Ling‐Long Tang
    Cancer Medicine.2018; 7(12): 5988.     CrossRef
  • 8,944 View
  • 294 Download
  • 38 Web of Science
  • 38 Crossref
Close layer
NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia
Eun Sang Yi, Young Bae Choi, Rihwa Choi, Na Hee Lee, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Soo-Youn Lee, Hong Hoe Koo
Cancer Res Treat. 2018;50(3):872-882.   Published online September 13, 2017
DOI: https://doi.org/10.4143/crt.2017.283
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to identify the impact of NUDT15 variants on thiopurine intolerance and 6-thioguanine nucleotide (6-TGN) levels in Korean children with acute lymphoblastic leukemia (ALL).
Materials and Methods
Genotyping of NUDT15 was tested in 258 patients with ALL registered at Samsung Medical Center. Patients were classified into normal-activity (wild-type), intermediate-activity (heterozygous variant), and low-activity groups (homozygous or compound heterozygous variant). Clinical and laboratory features during the first year of maintenance therapy were investigated.
Results
A total of 182 patients were included in the final analysis. There were five (2.7%), 46 (25.3%), and 131 (72.0%) patients in low-, intermediate-, and normal-activity groups, respectively. The lowest 6-mercaptopurine (6-MP) dose (mg/m2/day) was administered to the low-activity group (low-activity group 7.5 vs. intermediate-activity group 24.4 vs. normalactivity group 31.1, p < 0.01) from three months to a year after beginning maintenance therapy. The low-activity group experienced the longest duration of therapy interruption during the first year (low-activity group 169 days vs. intermediate-activity group 30 days vs. normal-activity group 16 days, p < 0.01). They also showed the lowest blood cell counts and had a longer duration of leukopenia (low-activity group 131 days vs. intermediate-activity group 92 days vs. normal-activity group 59 days, p < 0.01). 6-TGN level and its ratio to 6-MP dose were lowest in the low-activity group.
Conclusion
NUDT15 variants cause hematopoietic toxicity with low 6-TGN levels. NUDT15 genotyping should be conducted before administering thiopurine, and dose adjustments require caution regardless of 6-TGN levels.

Citations

Citations to this article as recorded by  
  • The frequency of NUDT15 rs116855232 and its impact on mercaptopurine-induced toxicity in Syrian children with acute lymphoblastic leukemia
    Muhammad Muhammad, Maher Saifo, Majd Aljamali, Mousa Alali, Khaled M. Ghanem
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Editorial Response to the Letter Relating to our Article “Predicting Adverse Events to Thiopurines in IBD: Are We a Step Closer?”
    Mohmmed Tauseef Sharip, Miles Parkes, Sreedhar Subramanian
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant
    Navya Gupta, Latha Sneha Magatha, Dhaarani Jayaraman, Julius Xavier Scott, Sharon Benita Antony, Teena Koshy
    Journal of Oncology Pharmacy Practice.2023; 29(4): 999.     CrossRef
  • Density functional study of transition metal (Fe,Co,Ni)‐doped C60 fullerenes as 6‐thioguanine delivery system
    ShiQuan Wu, Li Li, QiQi Liang, HuaXu Gao, DeYuan Hu, TianYu Tang, Yanlin Tang
    Applied Organometallic Chemistry.2023;[Epub]     CrossRef
  • The influence of NUDT15 variants on 6-mercaptopurine-induced neutropenia in Vietnamese pediatric acute lymphoblastic leukemia
    Mai-Lan Nguyen, Anh Vu Hoang, Bich Tram Duong, Nguyen The Nguyen Phung
    Human Genetics and Genomics Advances.2023; 4(2): 100183.     CrossRef
  • NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China
    XiaoXia Wei, Jing Zhuang, Na Li, Bin Zheng, Hong Sun, JiaQin Cai, Xuhui Huang, Guifeng Zhang, Jie Zhuang
    International Journal of Hematology.2022; 115(2): 278.     CrossRef
  • NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine
    Kanyarat Khaeso, Patcharee Komvilaisak, Su-on Chainansamit, Nontaya Nakkam, Kunanya Suwannaying, Pitchayanan Kuwatjanakul, Keiko Hikino, Areerat Dornsena, Sirimas Kanjanawart, Napat Laoaroon, Suda Vannaprasaht, Takeshi Taketani, Wichittra Tassaneeyakul
    Drug Metabolism and Pharmacokinetics.2022; 43: 100436.     CrossRef
  • NUDT15 Genetic Variants in Chinese Han, Uighur, Kirghiz, and Dai Nationalities
    Fang Zhang, Gulbanur Amat, Yanjing Tang, Ru Chen, Xin Tian, Wenting Hu, Changcheng Chen, Shuhong Shen, Yangyang Xie
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population
    Kok-Siong Poon, Izz Irfan B. Imran, Silvester Kheng-Han Chew, Patrice Tan, Karen Mei-Ling Tan
    BMC Research Notes.2022;[Epub]     CrossRef
  • NUDT15Genotyping in Thiopurine Drug Therapy
    Jong Kwon Lee, Rihwa Choi, Soo-Youn Lee
    Laboratory Medicine Online.2022; 12(4): 217.     CrossRef
  • The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia
    Jae Min Lee, Ye Jee Shim, Do-Hoon Kim, Nani Jung, Jung-Sook Ha
    Children.2021; 8(3): 224.     CrossRef
  • Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy
    Abdelbaset A. Elzagallaai, Bruce C. Carleton, Michael J. Rieder
    Annual Review of Pharmacology and Toxicology.2021; 61(1): 679.     CrossRef
  • DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes
    Hee Young Ju, Ji Won Lee, Hee Won Cho, Ju Kyung Hyun, Youngeun Ma, Eun Sang Yi, Keon Hee Yoo, Ki Woong Sung, Rihwa Choi, Hong Hoe Koo, Soo-Youn Lee, A. M. Abd El-Aty
    PLOS ONE.2021; 16(1): e0245667.     CrossRef
  • NUDT15: A bench to bedside success story
    Ann M. Moyer
    Clinical Biochemistry.2021; 92: 1.     CrossRef
  • Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study
    Zhao-Yang Chen, Yang-Hui Zhu, Ling-Yan Zhou, Wei-Qiao Shi, Zhou Qin, Bin Wu, Yu Yan, Yu-Wen Pei, Ning-Ning Chao, Rui Zhang, Mi-Ye Wang, Ze-Hao Su, Xiao-Jun Lu, Zhi-Yao He, Ting Xu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China
    Gangling Pu, Yali Wang, Shaoqin Duan, Jingpei Chen, Chunhui Yang, Tingting Cui, Chunlian Fang, Yan Zhou, Han Zhang, Xin Tian
    Pediatrics International.2021; 63(7): 790.     CrossRef
  • Significance of TPMT and NUDT15 variants in 6-mercaptopurine metabolism in acute lymphoblastic leukaemia/lymphoma patients
    E. S. Kotova, O. A. Gavrilina, A. B. Sudarikov
    Russian journal of hematology and transfusiology.2021; 66(2): 253.     CrossRef
  • NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy
    Aswin Anand Pai, Ajith Mohan, Esther Sathya Bama Benjamin, Raveen Stephen Stallon Illangeswaran, Infencia Xavier Raj, Nancy Beryl Janet, Arun Kumar Arunachalam, ML Kavitha, Uday Kulkarni, Anup J Devasia, NA Fouzia, Aby Abraham, Alok Srivastava, Biju Georg
    Pharmacogenomics and Personalized Medicine.2021; Volume 14: 1303.     CrossRef
  • Reducing risk in thiopurine therapy
    Anthony M. Marinaki, Monica Arenas-Hernandez
    Xenobiotica.2020; 50(1): 101.     CrossRef
  • Precision therapy of 6‐mercaptopurine in Chinese children with acute lymphoblastic leukaemia
    Yue Zhou, Li Wang, Xiao‐Ying Zhai, Li Wen, Fang Tang, Fan Yang, Xi‐Ting Liu, Lei Dong, Li‐Juan Zhi, Hai‐Yan Shi, Guo‐Xiang Hao, Yi Zheng, Evelyne Jacqz‐Aigrain, Tian‐You Wang, Wei Zhao
    British Journal of Clinical Pharmacology.2020; 86(8): 1519.     CrossRef
  • NUDT15 Genetic Variants are Related to Thiopurine-Induced Neutropenia in Thai Children with Acute Lymphoblastic Leukemia
    Apichaya Puangpetch, Rawiporn Tiyasirichokchai, Samart Pakakasama, Supaporn Wiwattanakul, Usanarat Anurathapan, Suradej Hongeng, Chonlaphat Sukasem
    Pharmacogenomics.2020; 21(6): 403.     CrossRef
  • Association of NUDT15 c.415C>T and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia
    Sunitha Kodidela, Patchava Dorababu, Dimpal N. Thakkar, Biswajit Dubashi, Rajan Sundaram, Niveditha Muralidharan, Ravi Prasad Nidanapu, Anil Aribandi, Suresh Chandra Pradhan, Chakradhara Rao Satyanarayana Uppugunduri
    Genes.2020; 11(6): 594.     CrossRef
  • Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia
    Shaik Mohammad Naushad, Patchava Dorababu, Yedluri Rupasree, Addepalli Pavani, Digumarti Raghunadharao, Tajamul Hussain, Salman A. Alrokayan, Vijay Kumar Kutala
    Cancer Chemotherapy and Pharmacology.2019; 83(5): 875.     CrossRef
  • Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia
    Rihwa Choi, Insuk Sohn, Min‐Ji Kim, Hye In Woo, Ji Won Lee, Youngeun Ma, Eun Sang Yi, Hong Hoe Koo, Soo‐Youn Lee
    British Journal of Clinical Pharmacology.2019; 85(7): 1585.     CrossRef
  • Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients
    Xia Zhu, Kang Chao, Miao Li, Wen Xie, Hong Zheng, Jin-Xin Zhang, Pin-Jin Hu, Min Huang, Xiang Gao, Xue-Ding Wang
    World Journal of Gastroenterology.2019; 25(38): 5850.     CrossRef
  • Homozygous mutation in NUDT15 in childhood acute lymphoblastic leukemia with increased susceptibility to mercaptopurine toxicity: A case report
    Juan Cheng, Hao Zhang, Hai‑Zhen Ma, Juan Li
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping
    Yoichi Kakuta, Yoshitaka Kinouchi, Tooru Shimosegawa
    Journal of Gastroenterology.2018; 53(2): 172.     CrossRef
  • 10,316 View
  • 389 Download
  • 29 Web of Science
  • 27 Crossref
Close layer
Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer
Jun Hwa Lee, Yun Hwan Kim, Kyung-Hee Kim, Jae Youl Cho, Sang Myung Woo, Byong Chul Yoo, Seung Cheol Kim
Cancer Res Treat. 2018;50(3):883-893.   Published online September 18, 2017
DOI: https://doi.org/10.4143/crt.2017.275
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We sought to develop a matrix assisted laser desorption ionization-time of flight (MALDI-TOF)-based, ovarian cancer (OVC), low-mass-ion discriminant equation (LOME) and to evaluate a possible supportive role for triple-TOF mass analysis in identifying metabolic biomarkers.
Materials and Methods
A total of 114 serum samples from patients with OVC and benign ovarian tumors were subjected to MALDI-TOF analysis and a total of 137 serum samples from healthy female individuals and patients with OVC, colorectal cancer, hepatobiliary cancer, and pancreatic cancer were subjected to triple-TOF analysis. An OVC LOME was constructed by reference to the peak intensity ratios of discriminatory low-mass ion (LMI) pairs. Triple-TOF analysiswas used to select and identify metabolic biomarkers for OVC screening.
Results
Three OVC LOMEs were finally constructed using discriminatory LMI pairs (137.1690 and 84.4119 m/z; 496.5022 and 709.7642 m/z; and 524.5614 and 709.7642 m/z); all afforded accuracies of > 90%. The LMIs at 496.5022 m/z and 524.5614 m/z were those of lysophosphatidylcholine (LPC) 16:0 and LPC 18:0. Triple-TOF analysis selected seven discriminative LMIs; each LMI had a specificity > 90%. Of the seven LMIs, fourwith a 137.0455 m/z ion atretention times of 2.04-3.14 minuteswere upregulated in sera from OVC patients; the ion was identified as that derived from hypoxanthine.
Conclusion
MALDI-TOF–based OVC LOMEs combined with triple-TOF–based OVC metabolic biomarkers allow reliable OVC screening; the techniques are mutually complementary both quantitatively and qualitatively.

Citations

Citations to this article as recorded by  
  • Preliminary Metabolomics Study Suggests Favorable Metabolic Changes in the Plasma of Breast Cancer Patients after Surgery and Adjuvant Treatment
    Andrea Jiménez-Franco, Juan Manuel Jiménez-Aguilar, Marta Canela-Capdevila, Raquel García-Pablo, Helena Castañé, Cristian Martínez-Navidad, Pablo Araguas, Bárbara Malavé, Rocío Benavides-Villarreal, Johana C. Acosta, Alina Iuliana Onoiu, Navita Somaiah, J
    Biomedicines.2024; 12(10): 2196.     CrossRef
  • Circulating proteins as predictive and prognostic biomarkers in breast cancer
    Hugo Veyssière, Yannick Bidet, Frederique Penault-Llorca, Nina Radosevic-Robin, Xavier Durando
    Clinical Proteomics.2022;[Epub]     CrossRef
  • Applications of MALDI-MS/MS-Based Proteomics in Biomedical Research
    Laura Darie-Ion, Danielle Whitham, Madhuri Jayathirtha, Yashveen Rai, Anca-Narcisa Neagu, Costel C. Darie, Brînduşa Alina Petre
    Molecules.2022; 27(19): 6196.     CrossRef
  • Methylglyoxal Adducts Levels in Blood Measured on Dried Spot by Portable Near-Infrared Spectroscopy
    Giuseppe Bonapace, Francesco Gentile, Nicola Coppedé, Maria Laura Coluccio, Virginia Garo, Marco Flavio Michele Vismara, Patrizio Candeloro, Giuseppe Donato, Natalia Malara
    Nanomaterials.2021; 11(9): 2432.     CrossRef
  • Identification of New Peptide Biomarkers for Bacterial Bloodstream Infection
    Yating Ma, Xinyu Wen, Yi Kong, Chen Chen, Ming Yang, Shang He, Jianan Wang, Chengbin Wang
    PROTEOMICS – Clinical Applications.2020;[Epub]     CrossRef
  • Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis
    Kexin Li, Yuqing Pei, Yue Wu, Yi Guo, Wei Cui
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • Comparative cerebrospinal fluid metabolites profiling in glioma patients to predict malignant transformation and leptomeningeal metastasis with a potential for preventive personalized medicine
    Ji Hye Im, Byong Chul Yoo, Jun Hwa Lee, Kyung-Hee Kim, Tae Hoon Kim, Kyue-Yim Lee, Jong Heon Kim, Jong Bae Park, Ji-Woong Kwon, Sang Hoon Shin, Heon Yoo, Ho-Shin Gwak
    EPMA Journal.2020; 11(3): 469.     CrossRef
  • Exploring Serum Metabolic Markers for the Discrimination of Ccrcc From Renal Angiomyolipoma By Metabolomics
    Mingfeng Xiang, Feng Du, Jing Dai, Ling Chen, Ruijin Geng, Huiming Huang, Baogang Xie
    Biomarkers in Medicine.2020; 14(8): 675.     CrossRef
  • Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?
    Igor Govorov , Stanislav Sitkin , Tatyana Pervunina , Alexey Moskvin , Denis Baranenko , Eduard Komlichenko
    Current Medicinal Chemistry.2020; 27(22): 3611.     CrossRef
  • 11,151 View
  • 247 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Participation of CCL1 in Snail-Positive Fibroblasts in Colorectal Cancer Contribute to 5-Fluorouracil/Paclitaxel Chemoresistance
Ziqian Li, Kaying Chan, Yifei Qi, Linlin Lu, Fen Ning, Mengling Wu, Haifang Wang, Yuan Wang, Shaohui Cai, Jun Du
Cancer Res Treat. 2018;50(3):894-907.   Published online September 18, 2017
DOI: https://doi.org/10.4143/crt.2017.356
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Cancer-associated fibroblasts (CAFs) activated by cancer cells has a central role in development and malignant biological behavior in colorectal cancer (CRC). Adult fibroblasts do not express Snail, but Snail-positive fibroblasts are discovered in the stroma of malignant CRC and reported to be the key role to chemoresistance. However, the reciprocal effect of CAFs expressed Snail to chemoresistance on CRC cells and the underlying molecular mechanisms are not fully characterized.
Materials and Methods
Snail-overexpressed 3T3 stable cell lines were generated by lipidosome and CT26 mixed with 3T3-Snail subcutaneous transplanted CRC models were established by subcutaneous injection. Cell Counting Kit-8, flow cytometry and western blotting assays were performed, and immunohistochemistry staining was studied. The cytokines participated in chemoresistance was validated with reverse transcriptase-polymerase chain reaction and heatmap.
Results
Snail-expression fibroblasts are discovered in human and mouse spontaneous CRCs. Overexpression of Snail induces 3T3 fibroblasts transdifferentiation to CAFs. CT26 co-cultured with 3T3-Snail resisted the impairment from 5-fluorouracil and paclitaxel in vitro. The subcutaneous transplanted tumor models included 3T3-Snail cells develop without restrictions even after treating with 5-fluorouracil or paclitaxel. Moreover, these chemoresistant processes may be mediated by CCL1 secreted by Snail-expression fibroblasts via transforming growth factor β/nuclear factor-κB signaling pathways.
Conclusion
Taken together, Snail-expressing 3T3 fibroblasts display CAFs properties that support 5-fluorouracil and paclitaxel chemoresistance in CRC via participation of CCL1 and suggest that inhibition of the Snail-expression fibroblasts in tumor may be a useful strategy to limit chemoresistance.

Citations

Citations to this article as recorded by  
  • Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
    Sumel Ashique, Mithun Bhowmick, Radheshyam Pal, Heya Khatoon, Prashant Kumar, Himanshu Sharma, Ashish Garg, Shubneesh Kumar, Ushasi Das
    Advances in Cancer Biology - Metastasis.2024; 10: 100114.     CrossRef
  • Reduced chemokine C‐C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites
    Miku Iwata, Ryuma Haraguchi, Riko Kitazawa, Chihiro Ito, Kohei Ogawa, Yasutsugu Takada, Sohei Kitazawa
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Sensing antibody functions with a novel CCR8-responsive engineered cell
    Jianyu Hao, Yitong Lv, Xufeng Xiao, Lidan Li, Changyuan Yu
    Acta Biochimica Polonica.2024;[Epub]     CrossRef
  • Advances in targeting cancer-associated fibroblasts through single-cell spatial transcriptomic sequencing
    Pin Lyu, Xiaoming Gu, Fuqi Wang, Haifeng Sun, Quanbo Zhou, Shuaixi Yang, Weitang Yuan
    Biomarker Research.2024;[Epub]     CrossRef
  • Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer
    Samaneh Tokhanbigli, Mehra Haghi, Kamal Dua, Brian Gregory George Oliver
    Cancer Drug Resistance.2024;[Epub]     CrossRef
  • Drug resistance and tumor immune microenvironment: An overview of current understandings (Review)
    Yan Liu, Jun Liang, Yanping Zhang, Qie Guo
    International Journal of Oncology.2024;[Epub]     CrossRef
  • Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
    Zengli Fang, Qingcai Meng, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Chen Liang, Jie Hua, Yingjun Zhao, Xianjun Yu, Si Shi
    Cancer Communications.2023; 43(1): 3.     CrossRef
  • Faeces from malnourished colorectal cancer patients accelerate cancer progression
    Xu Chao, Zhang Lei, Liu Hongqin, Wang Ziwei, Li Dechuan, Du Weidong, Xu Lu, Chen Haitao, Zhang Bo, Ju Haixing, Yao Qinghua
    Clinical Nutrition.2022; 41(3): 632.     CrossRef
  • Chemokines and chemokine receptors in colorectal cancer; multifarious roles and clinical impact
    Maria Braoudaki, Mohammed Saqif Ahmad, Denis Mustafov, Sara Seriah, Mohammad Naseem Siddiqui, Shoib Sarwar Siddiqui
    Seminars in Cancer Biology.2022; 86: 436.     CrossRef
  • Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
    Qianyu Wang, Xiaofei Shen, Gang Chen, Junfeng Du
    Cancers.2022; 14(12): 2928.     CrossRef
  • Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting
    Sonia Aristin Revilla, Onno Kranenburg, Paul J. Coffer
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer
    Qian Zou, Xue Lei, Aijing Xu, Ziqi Li, Qinglian He, Xiujuan Huang, Guangxian Xu, Faqing Tian, Yuanlin Ding, Wei Zhu
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Cancer-Associated Fibroblasts: The Origin, Biological Characteristics and Role in Cancer—A Glance on Colorectal Cancer
    Charalampos Fotsitzoudis, Asimina Koulouridi, Ippokratis Messaritakis, Theocharis Konstantinidis, Nikolaos Gouvas, John Tsiaoussis, John Souglakos
    Cancers.2022; 14(18): 4394.     CrossRef
  • Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
    Luciana Mosca, Andrea Ilari, Francesco Fazi, Yehuda G. Assaraf, Gianni Colotti
    Drug Resistance Updates.2021; 54: 100742.     CrossRef
  • Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway
    Masataka Fujikawa, Yu-ichiro Koma, Masayoshi Hosono, Naoki Urakawa, Kohei Tanigawa, Masaki Shimizu, Takayuki Kodama, Hiroki Sakamoto, Mari Nishio, Manabu Shigeoka, Yoshihiro Kakeji, Hiroshi Yokozaki
    The American Journal of Pathology.2021; 191(4): 686.     CrossRef
  • Development of Anti-Mouse CC Chemokine Receptor 8 Monoclonal Antibodies for Flow Cytometry
    Tomohiro Tanaka, Ren Nanamiya, Junko Takei, Takuro Nakamura, Miyuki Yanaka, Hideki Hosono, Masato Sano, Teizo Asano, Mika K. Kaneko, Yukinari Kato
    Monoclonal Antibodies in Immunodiagnosis and Immunotherapy.2021; 40(2): 65.     CrossRef
  • The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
    Yanghong Ni, Xiaoting Zhou, Jia Yang, Houhui Shi, Hongyi Li, Xia Zhao, Xuelei Ma
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • The Versatile Roles of Cancer-Associated Fibroblasts in Colorectal Cancer and Therapeutic Implications
    Longfei Deng, Nianfen Jiang, Jun Zeng, Yi Wang, Hongjuan Cui
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers
    Xiaoqun Lv, Guoxiong Xu
    World Journal of Gastrointestinal Oncology.2021; 13(11): 1648.     CrossRef
  • Guanylate‐binding protein‐2 inhibits colorectal cancer cell growth and increases the sensitivity to paclitaxel of paclitaxel‐resistant colorectal cancer cells by interfering Wnt signaling
    Jing Wang, Hui Min, Bin Hu, Xiaorong Xue, Yufan Liu
    Journal of Cellular Biochemistry.2020; 121(2): 1250.     CrossRef
  • Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
    Nuray Erin, Jelena Grahovac, Anamaria Brozovic, Thomas Efferth
    Drug Resistance Updates.2020; 53: 100715.     CrossRef
  • Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor–A Literature Review
    Jan Korbecki, Klaudyna Kojder, Katarzyna Barczak, Donata Simińska, Izabela Gutowska, Dariusz Chlubek, Irena Baranowska-Bosiacka
    International Journal of Molecular Sciences.2020; 21(16): 5647.     CrossRef
  • 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes
    Sabrina Blondy, Valentin David, Mireille Verdier, Muriel Mathonnet, Aurélie Perraud, Niki Christou
    Cancer Science.2020; 111(9): 3142.     CrossRef
  • Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment
    Jose J.G. Marin, Rocio I.R. Macias, Maria J. Monte, Elisa Herraez, Ana Peleteiro-Vigil, Beatriz Sanchez de Blas, Paula Sanchon-Sanchez, Alvaro G. Temprano, Ricardo A. Espinosa-Escudero, Elisa Lozano, Oscar Briz, Marta R. Romero
    Cancers.2020; 12(9): 2605.     CrossRef
  • CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands
    Jan Korbecki, Szymon Grochans, Izabela Gutowska, Katarzyna Barczak, Irena Baranowska-Bosiacka
    International Journal of Molecular Sciences.2020; 21(20): 7619.     CrossRef

  • Human Adipose-Derived Mesenchymal Stem Cells-Derived Exosomal microRNA-19b Promotes the Healing of Skin Wounds Through Modulation of the CCL1/TGF-β Signaling Axis


    Guoxiu Cao, Bei Chen, Xian Zhang, Hongyun Chen
    Clinical, Cosmetic and Investigational Dermatology.2020; Volume 13: 957.     CrossRef
  • Cancer‐associated fibroblasts promote PD‐L1 expression in mice cancer cells via secreting CXCL5
    Ziqian Li, Jiawang Zhou, Junjie Zhang, Shiying Li, Hongsheng Wang, Jun Du
    International Journal of Cancer.2019; 145(7): 1946.     CrossRef
  • Nodal Facilitates Differentiation of Fibroblasts to Cancer-Associated Fibroblasts that Support Tumor Growth in Melanoma and Colorectal Cancer
    Ziqian Li, Junjie Zhang, Jiawang Zhou, Linlin Lu, Hongsheng Wang, Ge Zhang, Guohui Wan, Shaohui Cai, Jun Du
    Cells.2019; 8(6): 538.     CrossRef
  • The multi-factorial nature of clinical multidrug resistance in cancer
    Yehuda G. Assaraf, Anamaria Brozovic, Ana Cristina Gonçalves, Dana Jurkovicova, Aija Linē, Miguel Machuqueiro, Simona Saponara, Ana Bela Sarmento-Ribeiro, Cristina P.R. Xavier, M. Helena Vasconcelos
    Drug Resistance Updates.2019; 46: 100645.     CrossRef
  • The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective
    Silvia Batista, Ana C. Gregório, Andreia Hanada Otake, Nuno Couto, Bruno Costa-Silva
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • 10,675 View
  • 297 Download
  • 32 Web of Science
  • 30 Crossref
Close layer
EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
Cancer Res Treat. 2018;50(3):908-916.   Published online September 19, 2017
DOI: https://doi.org/10.4143/crt.2017.378
AbstractAbstract PDFPubReaderePub
Purpose
Malignant pleural effusions (MPEs) are often observed in lung cancer, particularly adenocarcinoma. The aim of this study was to investigate epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma-associated MPEs (LA-MPEs) and its correlation with efficacy of EGFR tyrosine kinase inhibitor (TKI) therapy.
Materials and Methods
Samples comprised 40 cell blocks of pathologically-confirmed LA-MPEs collected before the start of EGFR TKI therapy. EGFR mutation status was re-evaluated by peptide nucleic acid clamping and the clinical outcomes of EGFR TKI‒treated patients were analyzed retrospectively.
Results
EGFR mutations were detected in 72.5% of LA-MPE cell blocks (29/40). The median progression-free survival for patients with EGFR mutations in LA-MPEs was better than that for patients with wild-type EGFR (7.33 months vs. 2.07 months; hazard ratio, 0.486; 95% confidence interval, 0.206 to 1.144; p=0.032). The objective response rate (ORR) of 26 patients with EGFR mutations in LA-MPEs among the 36 patients with measurable lesions was 80.8%, while the ORR of the 10 patients with wild-type EGFR in LA-MPEs was 10% (p < 0.001). Among the 26 patients with EGFR mutations in LA-MPEs, the ORR of target lesions and LA-MPEs were 88.5% and 61.5%, respectively (p=0.026).
Conclusion
EGFR mutation status in cell blocks of LA-MPEs confirmed by pathologic diagnosis is highly predictive of EGFR TKI efficacy. For patients with EGFR mutations in LA-MPEs, the response to EGFR TKIs seems to be worse for pleural effusions than for solid tumors.

Citations

Citations to this article as recorded by  
  • Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis
    Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu
    MedComm.2024;[Epub]     CrossRef
  • Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
    Melissa Wang, Kaitlin Sparrow, Chrystal Chan, Ashley Gillson, Daniel Stollery, Pen Li
    Respiratory Medicine.2023; 206: 107093.     CrossRef
  • Malignant pleural effusion diagnosis and therapy
    Liangliang Yang, Yue Wang
    Open Life Sciences.2023;[Epub]     CrossRef
  • Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
    Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study
    Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Haijie Jin, Huiqin Li, Bing Lu
    Cancer Medicine.2023; 12(14): 14949.     CrossRef
  • EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
    Toshiya Fujiwara, Kazuhiko Shien, Motoki Matsuura, Junichi Soh, Hiromasa Yamamoto, Soshi Takao, Yuho Maki, Tsuyoshi Ueno, Ryujiro Sugimoto, Ken Suzawa, Mikio Okazaki, Hiroyuki Tao, Makio Hayama, Masafumi Kataoka, Yoshifumi Sano, Hidetoshi Inokawa, Motohir
    Annals of Surgical Oncology.2023; 30(11): 6697.     CrossRef
  • Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
    Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
    Scientific Reports.2023;[Epub]     CrossRef
  • Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
    Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
    Thoracic Cancer.2022; 13(9): 1289.     CrossRef
  • Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer
    Wei Zhang, Wenjuan Han, Bo Yu, Xin Zhao, Gaojun Lu, Wendy Wu, Yi Zhang
    Thoracic Cancer.2022; 13(11): 1642.     CrossRef
  • Management of Malignant Pleural Effusion: Where Are We Now?
    Julien Guinde, Hervé Dutau, Philippe Astoul
    Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 559.     CrossRef
  • Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment
    Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
    Cancer Management and Research.2022; Volume 14: 3347.     CrossRef
  • The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
    Xinyi Li, Cong Huang, Xiaohui Xie, Ziyang Wu, Xia Tian, Yibo Wu, Xin Du, Luwen Shi
    Journal of Clinical Pharmacy and Therapeutics.2021; 46(2): 256.     CrossRef
  • Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
    Audra J. Schwalk, David E. Ost, Sahara N. Saltijeral, Henriette De La Garza, Roberto F. Casal, Carlos A. Jimenez, Georgie A. Eapen, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Yasir Elamin, Jianjun Zhang, Jack A. Roth, Stephen S
    Chest.2021; 159(3): 1256.     CrossRef
  • Advances in pleural infection and malignancy
    Eihab O. Bedawi, Julien Guinde, Najiib M. Rahman, Philippe Astoul
    European Respiratory Review.2021; 30(159): 200002.     CrossRef
  • Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
    Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
    Cancers.2021; 13(11): 2798.     CrossRef
  • Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer
    Tetsuo Tani, Ichiro Nakachi, Shinnosuke Ikemura, Shigenari Nukaga, Keiko Ohgino, Aoi Kuroda, Hideki Terai, Keita Masuzawa, Taro Shinozaki, Kota Ishioka, Yohei Funatsu, Hidefumi Koh, Koichi Fukunaga, Kenzo Soejima
    Cancer Management and Research.2021; Volume 13: 7497.     CrossRef
  • LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
    Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
    Archivos de Bronconeumología.2020; 56(7): 465.     CrossRef
  • Current applications of molecular testing on body cavity fluids
    Daniel Pinto, Fernando Schmitt
    Diagnostic Cytopathology.2020; 48(9): 840.     CrossRef
  • Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
    Jianqiang Li, Xingliang Li, Wenxian Wang, Yang Shao, Yiping Zhang, Zhengbo Song
    Translational Oncology.2020; 13(8): 100784.     CrossRef
  • Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
    Ning Liu, Min Yu, Tao Yin, Yong Jiang, Xuelian Liao, Jie Tang, Yanying Li, Diyuan Qin, Dan Li, Yongsheng Wang
    Signal Transduction and Targeted Therapy.2020;[Epub]     CrossRef
  • LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
    Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
    Archivos de Bronconeumología (English Edition).2020; 56(7): 465.     CrossRef
  • Recent Developments in the Management of Malignant Pleural Effusions: a Narrative Review
    Clifford E. Coile, Jessie G. Harvey, Michal Senitko
    Current Pulmonology Reports.2020; 9(4): 164.     CrossRef
  • Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
    Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li, Zhongliang Zheng, Bin Xu, Yingge Li, Yi Dong
    Thoracic Cancer.2019; 10(2): 193.     CrossRef
  • Making cold malignant pleural effusions hot: driving novel immunotherapies
    Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
    OncoImmunology.2019; 8(4): e1554969.     CrossRef
  • Novel insights into the systemic treatment of lung cancer malignant pleural effusion
    Claire Tissot, Pierre Gay, Clément Brun, Marios E. Froudarakis
    The Clinical Respiratory Journal.2019; 13(3): 131.     CrossRef
  • Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma
    Momin T. Siddiqui, Fernando Schmitt, Andrew Churg
    Journal of the American Society of Cytopathology.2019; 8(6): 352.     CrossRef
  • 10,010 View
  • 279 Download
  • 35 Web of Science
  • 26 Crossref
Close layer
Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2
Kyung Jin Eoh, Ji Eun Kim, Hyung Seok Park, Seung-Tae Lee, Ji Soo Park, Jung Woo Han, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Jae Hoon Kim, Young Tae Kim, Eun Ji Nam
Cancer Res Treat. 2018;50(3):917-925.   Published online September 27, 2017
DOI: https://doi.org/10.4143/crt.2017.220
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Next-generation sequencing (NGS) allows simultaneous sequencing of multiple cancer susceptibility genes and may represent a more efficient and less expensive approach than sequential testing. We assessed the frequency of germline mutations in individuals with epithelial ovarian cancer (EOC), using multi-gene panels and NGS.
Materials and Methods
Patients with EOC (n=117) with/without a family history of breast or ovarian cancer were recruited consecutively, from March 2016 toDecember 2016.GermlineDNAwas sequenced using 35-gene NGS panel, in order to identify mutations. Upon the detection of a genetic alteration using the panel, results were cross-validated using direct sequencing.
Results
Thirty-eight patients (32.5%) had 39 pathogenic or likely pathogenic mutations in eight genes, including BRCA1 (n=21), BRCA2 (n=10), BRIP1 (n=1), CHEK2 (n=2), MSH2 (n=1), POLE (n=1), RAD51C (n=2), and RAD51D (n=2). Among 64 patients with a family history of cancer, 27 (42.2%) had 27 pathogenic or likely pathogenic mutations, and six (9.3%) had mutations in genes other than BRCA1/2, such as CHECK2, MSH2, POLE, and RAD51C. Fifty-five patients (47.0%) were identified to carry only variants of uncertain significance.
Conclusion
Using the multi-gene panel test, we found that, of all patients included in our study, 32.5% had germline cancer-predisposing mutations. NGS was confirmed to substantially improve the detection rates of a wide spectrum of mutations in EOC patients compared with those obtained with the BRCA1/2 testing alone.

Citations

Citations to this article as recorded by  
  • Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand
    Chalermkiat Kansuttiviwat, Pongtawat Lertwilaiwittaya, Ekkapong Roothumnong, Panee Nakthong, Peerawat Dungort, Chutima Meesamarnpong, Warisara Tansa-Nga, Khontawan Pongsuktavorn, Supakit Wiboonthanasarn, Warunya Tititumjariya, Nannipa Phuphuripan, Chittap
    npj Genomic Medicine.2024;[Epub]     CrossRef
  • Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer
    Zheng Feng, Siyu Chen, Na An, Zhihui Xiu, Xingzhu Ju, Xiaojun Chen, Rui Bi, Jie Wang, Shida Zhu, Xiaohua Wu, Hao Wen
    JCO Global Oncology.2024;[Epub]     CrossRef
  • Germline Genetic Testing for Hereditary Breast and Ovarian Cancer: Current Concepts in Risk Evaluation
    Siddhartha Yadav, Fergus J. Couch, Susan M. Domchek
    Cold Spring Harbor Perspectives in Medicine.2024; 14(8): a041318.     CrossRef
  • Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families
    Ava Kwong, Cecilia Yuen Sze Ho, Chun Hang Au, Sze Keong Tey, Edmond Shiu Kwan Ma
    Journal of Personalized Medicine.2024; 14(8): 866.     CrossRef
  • Clinical Significance of PALB2 Pathogenic Germline Variant
    Min-Chae Kang, R.N., Jong Eun Park, Mi-Ae Jang, Dongju Won, Boyoung Park, Seeyoun Lee, Dong Ock Lee, Kum Hei Ryu, Yoon-Jung Chang, Sun-Young Kong
    Laboratory Medicine Online.2024; 14(4): 311.     CrossRef
  • Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma
    Angel Chao, Chen-Yang Huang, Willie Yu, Chiao-Yun Lin, Hao Lin, An-Shine Chao, Cheng-Tao Lin, Hung-Hsueh Chou, Kuang-Gen Huang, Huei-Jean Huang, Ting-Chang Chang, Steven G. Rozen, Ren-Chin Wu, Chyong-Huey Lai
    BMC Cancer.2024;[Epub]     CrossRef
  • The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study
    Dinh-Toi Chu, Mai Vu Ngoc Suong, Hue Vu Thi, Thuy-Duong Vu, Manh-Hung Nguyen, Vijai Singh
    Expert Review of Molecular Diagnostics.2023; 23(1): 53.     CrossRef
  • Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2
    Nandana D. Rao, Brian H. Shirts, Alvaro Galli
    PLOS ONE.2023; 18(2): e0278010.     CrossRef
  • Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review
    Serena Bertozzi, Ambrogio Londero, Anjeza Xholli, Guglielmo Azioni, Roberta Di Vora, Michele Paudice, Ines Bucimazza, Carla Cedolini, Angelo Cagnacci
    Journal of Clinical Medicine.2023; 12(4): 1422.     CrossRef
  • Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence
    Roopak Murali, Vaishnavi Balasubramaniam, Satish Srinivas, Sandhya Sundaram, Ganesh Venkatraman, Sudha Warrier, Arun Dharmarajan, Rajesh Kumar Gandhirajan
    Metabolites.2023; 13(4): 560.     CrossRef
  • Factors predictingBRCA1/2pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis
    Giovanni Innella, Lea Godino, Giulia Erini, Antonio De Leo, Donatella Santini, Anna Myriam Perrone, Pierandrea De Iaco, Claudio Zamagni, Daniela Turchetti
    Journal of Clinical Pathology.2023; 76(8): 510.     CrossRef
  • Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
    Priyanka Narayan, Muhammad Danyal Ahsan, Emily M. Webster, Luiza Perez, Sarah R. Levi, Benedict Harvey, Isabel Wolfe, Shanice Beaumont, Jesse T. Brewer, Drew Siegel, Charlene Thomas, Paul Christos, Andy Hickner, Eloise Chapman-Davis, Evelyn Cantillo, Kevi
    Gynecologic Oncology.2023; 177: 72.     CrossRef
  • Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?
    Klara Horackova, Marketa Janatova, Petra Kleiblova, Zdenek Kleibl, Jana Soukupova
    International Journal of Molecular Sciences.2023; 24(23): 17020.     CrossRef
  • Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study
    Phuong L. Mai, Austin Miller, Amanda Black, Roni T. Falk, John F. Boggess, Katherine Tucker, Ashley R. Stuckey, Gustavo C. Rodriguez, Cheung Wong, Thomas T. Amatruda, Kelly J. Wilkinson, Susan C. Modesitt, S. Diane Yamada, Kristin L. Bixel, Gretchen E. Gl
    American Journal of Obstetrics and Gynecology.2022; 227(1): 61.e1.     CrossRef
  • Hereditary gynecologic tumors and precision cancer medicine
    Chikako Ogawa, Akira Hirasawa, Naoyuki Ida, Keiichiro Nakamura, Hisashi Masuyama
    Journal of Obstetrics and Gynaecology Research.2022; 48(5): 1076.     CrossRef
  • Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
    Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim
    Cancer Genetics.2022; 266-267: 19.     CrossRef
  • Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
    Sidrah Shah, Alison Cheung, Mikolaj Kutka, Matin Sheriff, Stergios Boussios
    International Journal of Environmental Research and Public Health.2022; 19(13): 8113.     CrossRef
  • Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome
    Tomoko Yoshihama, Akira Hirasawa, Kokichi Sugano, Teruhiko Yoshida, Mineko Ushiama, Arisa Ueki, Tomoko Akahane, Yoshiko Nanki, Kensuke Sakai, Takeshi Makabe, Wataru Yamagami, Nobuyuki Susumu, Kaori Kameyama, Kenjiro Kosaki, Daisuke Aoki
    International Cancer Conference Journal.2021; 10(1): 6.     CrossRef
  • Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers
    Yoon Young Choi, Su-Jin Shin, Jae Eun Lee, Lisa Madlensky, Seung-Tae Lee, Ji Soo Park, Jeong-Hyeon Jo, Hyunki Kim, Daniela Nachmanson, Xiaojun Xu, Sung Hoon Noh, Jae-Ho Cheong, Olivier Harismendy
    Scientific Reports.2021;[Epub]     CrossRef
  • Retroperitoneal leiomyosarcoma in a female patient with a germline splicing variant RAD51D c.904-2A > T: a case report
    Mashu Futagawa, Hideki Yamamoto, Mariko Kochi, Yusaku Urakawa, Reimi Sogawa, Fumino Kato, Mika Okazawa-Sakai, Daisuke Ennishi, Katsunori Shinozaki, Hirofumi Inoue, Hiroyuki Yanai, Akira Hirasawa
    Hereditary Cancer in Clinical Practice.2021;[Epub]     CrossRef
  • A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect
    Lesa M. Dawson, Kerri N. Smith, Salem Werdyani, Robyn Ndikumana, Cindy Penney, Louisa L. Wiede, Kendra L. Smith, Justin A. Pater, Andrée MacMillan, Jane Green, Sheila Drover, Terry‐Lynn Young, Darren D. O’Rielly
    Molecular Genetics & Genomic Medicine.2020;[Epub]     CrossRef
  • Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
    Yan You, Lei Li, Junliang Lu, Huanwen Wu, Jing Wang, Jie Gao, Ming Wu, Zhiyong Liang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases
    Malwina Suszynska, Magdalena Ratajska, Piotr Kozlowski
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations
    Malwina Suszynska, Piotr Kozlowski
    Genes.2020; 11(7): 798.     CrossRef
  • Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer
    Jin‐Sun Ryu, Hye‐Young Lee, Eun Hae Cho, Kyong‐Ah Yoon, Min‐Kyeong Kim, Jungnam Joo, Eun‐Sook Lee, Han‐Sung Kang, Seeyoun Lee, Dong Ock Lee, Myong Cheol Lim, Sun‐Young Kong
    Cancer Science.2020; 111(10): 3912.     CrossRef
  • RAD51C and RAD51D in the hereditary breast and ovarian cancer syndrome
    Ana Isabel Sánchez Bermúdez, M.ª Desamparados Sarabia Meseguer, Verónica Guardiola Castillo, Francisco Ruiz Espejo, José Antonio Noguera Velasco
    Revista de Medicina de Laboratorio.2020;[Epub]     CrossRef
  • Diagnostic yield and clinical utility of a comprehensive gene panel for hereditary tumor syndromes
    Jonas Henn, Isabel Spier, Ronja S. Adam, Stefanie Holzapfel, Siegfried Uhlhaas, Katrin Kayser, Guido Plotz, Sophia Peters, Stefan Aretz
    Hereditary Cancer in Clinical Practice.2019;[Epub]     CrossRef
  • Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes — Providing evidence of cancer predisposition genes
    Malwina Suszynska, Katarzyna Klonowska, Anna J. Jasinska, Piotr Kozlowski
    Gynecologic Oncology.2019; 153(2): 452.     CrossRef
  • Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma
    Yu-Fa Su, Eing-Mei Tsai, Chih-Chieh Chen, Chun-Chieh Wu, Tze-Kiong Er
    Clinica Chimica Acta.2019; 494: 1.     CrossRef
  • Hereditary ovarian cancers: state of the art
    Angela Toss, Eleonora Molinaro, Margaret Sammarini, Maria C. Del Savio, Laura Cortesi, Fabio Facchinetti, Giovanni Grandi
    Minerva Medica.2019;[Epub]     CrossRef
  • BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study
    Claudia Marchetti, Rossella De Leo, Angela Musella, Marco D’Indinosante, Ettore Capoluongo, Angelo Minucci, Pierluigi Benedetti Panici, Giovanni Scambia, Anna Fagotti
    Annals of Surgical Oncology.2018; 25(12): 3701.     CrossRef
  • Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients
    Magdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, Alina Kuzniacka, Izabela Brozek, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Wojciech Biernat, Piotr Kozlowski, Janusz Limon, Bartosz Wasag, Magdalena Ratajska
    Cancers.2018; 10(11): 442.     CrossRef
  • Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap
    Jeanna M McCuaig, Tracy L Stockley, Patricia Shaw, Michael Fung-Kee-Fung, Alon D Altman, James Bentley, Marcus Q Bernardini, Beatrice Cormier, Hal Hirte, Katharina Kieser, Andree MacMillan, Wendy S Meschino, Karen Panabaker, Renee Perrier, Diane Provenche
    Journal of Medical Genetics.2018; 55(9): 571.     CrossRef
  • 16,015 View
  • 803 Download
  • 34 Web of Science
  • 33 Crossref
Close layer
Clinical Risk Factors Influencing Dental Developmental Disturbances in Childhood Cancer Survivors
Chung-Min Kang, Seung Min Hahn, Hyo Sun Kim, Chuhl Joo Lyu, Jae-Ho Lee, Jinae Lee, Jung Woo Han
Cancer Res Treat. 2018;50(3):926-935.   Published online October 10, 2017
DOI: https://doi.org/10.4143/crt.2017.296
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although studies regarding dental developmental disturbances after childhood cancer treatment have increased, they have many limitations. Studies analyzing the significance of independent clinical risk factors with regard to the dental health status are also rare. We aimed to investigate the risk factors for dental developmental disturbances, particularly severe disturbances, in childhood cancer survivors (CCS).
Materials and Methods
Oral examinations and retrospective reviews of medical and panoramic radiographs were performed for 196 CCS (mean age, 15.6 years). Cancer type, age at diagnosis, treatment modality, type and accumulated dose of administered drugs, and dose and site of radiation were recorded. Dental developmental disturbances were diagnosed using panoramic radiographs and graded for severity according to the Modified Dental Defect Index (MDDI). Descriptive statistics and multivariate analyseswere performed to determine the association between dental abnormalities and clinical factors.
Results
In total, 109 CCS (55.6%) exhibited at least one dental anomaly, and the median value of MDDI was 2.5. Microdontia (30.6%) was the most prevalent anomaly, followed by tooth agenesis (20.4%), V-shaped roots (14.8%), and taurodontism (10.2%). Multivariate analysis revealed that a young age at diagnosis (≤ 3 years), a history of hematopoietic stem cell transplantation, the use of multiple classes of chemotherapeutic agents (≥ 4 classes), and the use of heavy metal agents were significant risk factors for severe dental disturbances.
Conclusion
CCS with any of the above risk factors for severe developmental disturbances should be comprehensively followed up to minimize adverse consequences to their dental development and preserve their future dental health.

Citations

Citations to this article as recorded by  
  • Prevalence of, and risk factors for, dental sequelae in adolescents who underwent cancer therapy during childhood
    Judit Rabassa‐Blanco, Lluís Brunet‐Llobet, Paula Marcote‐Sinclair, Sol Balsells‐Mejía, María Genoveva Correa‐Llano, Jaume Miranda‐Rius
    Oral Diseases.2024; 30(2): 604.     CrossRef
  • Bone age and dental late effects in childhood cancer survivors: Radiographic findings in a Brazilian sample
    Híttalo Carlos Rodrigues De Almeida, Cleomar Donizeth Rodrigues, Luiz Pedro Mendes De Azevedo, Aronita Rosenblatt, Márcia Maria Fonseca Da Silveira, Ana Paula Veras Sobral
    International Journal of Paediatric Dentistry.2024;[Epub]     CrossRef
  • A Narrative Review of the Association between Dental Abnormalities and Chemotherapy
    Tatsuya Akitomo, Yasuko Tsuge, Chieko Mitsuhata, Ryota Nomura
    Journal of Clinical Medicine.2024; 13(16): 4942.     CrossRef
  • Parental awareness and dental health behavior of children with congenital heart disease, with diabetes mellitus, or undergoing anti-cancer treatment, compared to healthy children
    Elinor Halperson, Hanan Badarneh, Ella Zion, Helly Kruchenezki, Gal Goldstein, Sagui Gavri, David Zangen, Avia Fux-Noy
    Frontiers in Oral Health.2024;[Epub]     CrossRef
  • Dental dysplasia in childhood cancer survivors: a case series of permanent tooth abnormalities
    Yumi Muraki, Atsushi Shioyasono, Mika Nishii, Daisuke Takeda, Junya Kusumoto, Masaya Akashi
    Oral and Maxillofacial Surgery.2024;[Epub]     CrossRef
  • Dental caries and dental developmental defects as adverse effects of antineoplastic treatment in childhood cancer survivors
    K. Seremidi, K. Kavvadia, A. Kattamis, A. Polychronopoulou
    European Archives of Paediatric Dentistry.2023; 24(3): 357.     CrossRef
  • Tooth Abnormalities and Their Age-Dependent Occurrence in Leukemia Survivors
    Anna Jodłowska, Lidia Postek-Stefańska
    Cancers.2023; 15(22): 5420.     CrossRef
  • Assessment of Risk Factors for Dental Developmental Disorders in Pediatric Cancer Survivors
    Jihyun Lee, Hyung-Jun Choi, Jaeho Lee, Je Seon Song, Chung-Min Kang
    THE JOURNAL OF THE KOREAN ACADEMY OF PEDTATRIC DENTISTRY.2023; 50(4): 421.     CrossRef
  • An ex vivo organ culture screening model revealed that low temperature conditions prevent side effects of anticancer drugs
    Tian Tian, Kanako Miyazaki, Yuta Chiba, Keita Funada, Tomomi Yuta, Kanji Mizuta, Yao Fu, Jumpei Kawahara, Xue Han, Yuna Ando, Ami Funada, Aya Yamada, Tsutomu Iwamoto, Seiji Nakamura, Ichiro Takahashi, Satoshi Fukumoto, Keigo Yoshizaki
    Scientific Reports.2022;[Epub]     CrossRef
  • The prevalence of dental developmental anomalies among childhood cancer survivors according to types of anticancer treatment
    Elinor Halperson, Vered Matalon, Gal Goldstein, Shirly Saieg Spilberg, Karin Herzog, Avia Fux-Noy, Aviv Shmueli, Diana Ram, Moti Moskovitz
    Scientific Reports.2022;[Epub]     CrossRef
  • Systemic Anticancer Therapy Details and Dental Adverse Effects in Children
    Anna Jodłowska, Lidia Postek-Stefańska
    International Journal of Environmental Research and Public Health.2022; 19(11): 6936.     CrossRef
  • Oligomicrodontia in a Pediatric Cancer Survivor after Chemotherapy: A Case Report
    Ana Zulijani, Martina Žigante, Luka Morelato, Berislav Perić, Ana Milardović
    Healthcare.2022; 10(8): 1521.     CrossRef
  • Oral and dental late effects in long-term survivors of childhood embryonal brain tumors
    Kristine Eidal Tanem, Einar Stensvold, Petter Wilberg, Anne B. Skaare, Petter Brandal, Bente Brokstad Herlofson
    Supportive Care in Cancer.2022; 30(12): 10233.     CrossRef
  • Dental developmental complications in pediatric hematopoietic stem cell transplantation patients: A study using CMC clinical data warehouse
    Jaehyun Kim, Hee Jin Lim, Ja Hyeong Ku, Yoon-Ah Kook, Nack-Gyun Chung, Yoonji Kim, Nazmul Haque
    PLOS ONE.2022; 17(12): e0279579.     CrossRef
  • The Broad Variability in Dental Age Observed among Childhood Survivors Is Cancer Specific
    Patrycja Proc, Joanna Szczepańska, Małgorzata Zubowska, Beata Zalewska-Szewczyk, Wojciech Młynarski
    Cancer Research and Treatment.2021; 53(1): 252.     CrossRef
  • Dental late effects of antineoplastic treatment on childhood cancer survivors: Radiographic findings
    Kyriaki Seremidi, Katerina Kavvadia, Antonis Kattamis, Argyro Polychronopoulou
    International Journal of Paediatric Dentistry.2021; 31(6): 742.     CrossRef
  • Late adverse effects of childhood acute lymphoblastic leukemia treatment on developing dentition
    Egle Immonen, Atte Nikkilä, Timo Peltomäki, Liisa Aine, Olli Lohi
    Pediatric Blood & Cancer.2021;[Epub]     CrossRef
  • Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study
    Juliette Stolze, Kim C. E. Vlaanderen, Frederique C. E. D. Holtbach, Jop C. Teepen, Leontien C. M. Kremer, Jacqueline J. Loonen, Eline van Dulmen-den Broeder, Marry M. van den Heuvel-Eibrink, Helena J. H. van der Pal, Birgitta Versluys, Margriet van der H
    Cancers.2021; 13(21): 5264.     CrossRef
  • Dental management of a childhood cancer survivor with malformed primary teeth
    Ryo Kameoka, Tomomi Kawakami, Miho Maeda, Tsukasa Hori, Ayako Yanagisawa, Toshiomi Shirase
    Pediatric Dental Journal.2020; 30(1): 45.     CrossRef
  • Oral and dental considerations in pediatric cancers
    Priyanshi Ritwik, Tammuella E. Chrisentery-Singleton
    Cancer and Metastasis Reviews.2020; 39(1): 43.     CrossRef
  • Late effects of chemo and radiation treatment on dental structures of childhood cancer survivors. A systematic review and meta‐analysis
    Kyriaki Seremidi, Dimitrios Kloukos, Argy Polychronopoulou, Antonis Kattamis, Katerina Kavvadia
    Head & Neck.2019; 41(9): 3422.     CrossRef
  • Caring for survivors of childhood cancer: it takes a village
    Ailin Song, Jonathan D. Fish
    Current Opinion in Pediatrics.2018; 30(6): 864.     CrossRef
  • 10,024 View
  • 332 Download
  • 25 Web of Science
  • 22 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP